ticlopidine has been researched along with Arteriosclerosis, Coronary in 881 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antiplatelet response to clopidogrel and its influence upon the risk of cardiovascular adverse events among patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) has not been investigated fully." | 9.24 | Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. ( Gawrońska-Szklarz, B; Gorący, J; Jastrzębska, M; Kiedrowicz, R; Kornacewicz-Jach, Z; Olędzki, S; Safranow, K, 2017) |
| "Ticagrelor has been demonstrated to provide a more rapid and powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients." | 9.22 | One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. ( Dong, X; Han, Y; He, M; Li, M; Li, Y; Liu, B; Lu, S; Pan, Y; Shi, J; Sun, D; Zhao, S; Zheng, W, 2016) |
| " The aim of this study was to investigate the pharmacodynamic response to clopidogrel in patients with IGT and insulin resistance (IR)." | 9.20 | Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease. ( Angiolillo, DJ; Fujita, K; Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Suga, T; Ueno, M; Yamaji, K; Yamamoto, H, 2015) |
| "A total of 53 consecutive Japanese patients with stable coronary artery disease (CAD) who received aspirin and clopidogrel were enrolled." | 9.20 | Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease. ( Ariyoshi, N; Fujimoto, Y; Hanaoka, H; Kobayashi, Y; Koshizaka, M; Nakayama, T; Nishi, T; Sugimoto, K; Takahara, M; Wakabayashi, S, 2015) |
| " Ticagrelor demonstrated a more rapid onset and greater magnitude of platelet inhibition than clopidogrel in Hispanic patients with stable coronary artery disease (CAD)." | 9.20 | Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. ( Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R, 2015) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 9.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| " We proposed that clopidogrel therapy in patients with stable coronary artery disease imparts a pleiotropic effect that extends beyond antiplatelet aggregation to other atheroprotective processes." | 9.19 | Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. ( Binongo, JN; Dhawan, SS; Ghazzal, ZB; Pohlel, FK; Quyyumi, AA; Ramadan, R; Syed, H, 2014) |
| " We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT." | 9.19 | Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. ( Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 9.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "Diabetes mellitus (DM) is the most important predictor of chronic kidney disease (CKD), and pharmacodynamic (PD) studies have shown that DM patients with impaired renal function are characterized by reduced clopidogrel response." | 9.17 | Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Kodali, MK; Patel, R; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2013) |
| "The balance between platelet MP release and EPC mobilization seems influenced by clopidogrel plasma levels, suggesting a protective mechanism on coronary artery disease." | 9.16 | Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. ( Barbosa, SP; Bianco, HT; Brunialti, MK; de Nucci, G; Fonseca, FA; França, CN; Izar, MC; Kasmas, SH; Pinheiro, LF; Salomão, R, 2012) |
| " The present study was conducted in healthy individuals (n = 50) and in outpatients with coronary artery disease (CAD) at a distance from the acute ischemic episode (aspirin group, n = 71; aspirin/clopidogrel group, n = 106)." | 9.16 | Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry. ( Baccouche, H; Bandi, A; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Mossialos, L; Sassi, M; Tsinopoulos, G; Zarifis, J, 2012) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 9.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "Recently we have demonstrated a dose-dependent improvement of endothelial function after administration of a single loading dose of clopidogrel in patients with coronary artery disease (CAD)." | 9.15 | Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. ( Munzel, T; Nick, E; Ostad, MA; Paixao-Gatinho, V; Schiewe, R; Schnorbus, B; Tschentscher, P; Warnholtz, A, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 9.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| " One hundred and seventy-two coronary artery disease patients who had taken aspirin only or combinations with aspirin and clopidogrel for over 7 days were included." | 9.14 | Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. ( Cha, KS; Goh, RY; Han, JY; Kim, KE; Kim, MH; Quan, ML; Woo, KS, 2010) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 9.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days." | 9.14 | Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. ( Akers, WS; Campbell, CL; Charnigo, R; Dunn, SP; Holt, J; Oestreich, JH; Smyth, SS; Steinhubl, SR, 2009) |
| "We studied patients with stable coronary artery disease on chronic aspirin therapy randomised to addition of clopidogrel 75 mg/d (n = 30) or continuation of aspirin 100 mg/d (n = 30) for 4 weeks." | 9.14 | Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. ( Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009) |
| "In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery disease who were taking aspirin therapy (75 to 100 mg/d) received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks." | 9.14 | Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. ( Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V, 2009) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 9.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "The aim of this study was to evaluate the relationship between reticulated platelets (RPs), platelet size, and platelet function in patients with stable coronary artery disease (CAD) taking aspirin and clopidogrel." | 9.13 | Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. ( Alviar, CL; Arikan, M; DeLao, T; Dong, JF; Granada, JF; Guthikonda, S; Kleiman, NS; Lev, EI; Tellez, A; Vaduganathan, M, 2008) |
| " One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and 33 patients on aspirin only were screened for platelet ADP-induced signalling by conventional aggregometry, platelet P-selectin expression and the platelet reactivity index (PRI)." | 9.13 | ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. ( Bauersachs, J; Eigenthaler, M; Ertl, G; Flierl, U; Schäfer, A; Störk, S; Walter, U; Weinberger, S, 2008) |
| " One hundred ten aspirin-treated patients with stable coronary artery disease were randomized to a loading dose (LD, day 1)/ maintenance dose (MD, days 2-29) of prasugrel 60 mg/10 mg or clopidogrel 600 mg/75 mg." | 9.13 | Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. ( Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| " Aspirin-treated subjects with coronary artery disease were randomized to double-blind treatment with clopidogrel 600 mg loading dose (LD) followed by daily 75 mg maintenance dose (MD) or prasugrel 60 mg LD and daily 10 mg MD for 28 days." | 9.13 | Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite." | 9.13 | Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. ( Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD)." | 9.12 | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ, 2006) |
| "Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects." | 9.12 | Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. ( Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P, 2006) |
| " Platelet inhibitors are widely used in coronary artery disease (CAD), and we hypothesized that the platelet inhibitor clopidogrel could modify chemokines in CAD patients." | 9.12 | Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. ( Andreassen, AK; Aukrust, P; Brosstad, F; Damås, JK; Frøland, SS; Gjertsen, E; Gullestad, L; Hansteen, V; Pedersen, TM; Semb, AG; Solum, NO; Ueland, T; Waehre, T; Yndestad, A, 2006) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 9.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "We searched for additional anti-platelet effects of clopidogrel in coronary artery disease (CAD) patients treated with aspirin." | 9.12 | The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. ( Biernat, M; Dropinski, J; Dziedzina, S; Jakiela, B; Plutecka, H; Sanak, M; Szczeklik, A; Wegrzyn, W, 2007) |
| " We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD)." | 9.12 | Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. ( Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH, 2007) |
| "Clopidogrel, especially when combined with aspirin, reduces the rate of ischaemic events in patients with coronary artery disease (CAD)." | 9.11 | Inter-individual variability in response to clopidogrel in patients with coronary artery disease. ( Dubiel, JS; Dudek, D; Dziewierz, A; Heba, G; Mielecki, W; Rakowski, T, 2005) |
| "Investigate the association between P2Y12 Purinoceptor (P2RY12) polymorphisms and adverse clinical events in coronary artery disease (CAD) patients treated with clopidogrel." | 8.98 | Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis. ( Chen, J; Fu, Y; Li, JL; Liang, GK; Liu, J; Lu, Y; Nie, XY; Qin, SB; Shao, H; Shi, LW, 2018) |
| "The results of the meta-analysis suggest that ABCB1 C3435T polymorphism may increase the risk of bleeding in Asian patients treated with clopidogrel." | 8.95 | Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. ( Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y, 2017) |
| "The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding." | 8.91 | Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. ( Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY, 2015) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 8.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "To perform a meta-analysis of the association between CYP2C19 loss- and gain-of-function variants and cardiovascular outcomes and bleeding in patients with coronary artery disease treated with clopidogrel, and to explore the causes of heterogeneity between studies." | 8.88 | Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. ( Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M, 2012) |
| "Concomitant use of PPIs and clopidogrel in patients with coronary artery disease is associated with an increased risk of MACE or acute coronary syndrome, but there is insufficient evidence to conclude that there is an interaction between individual PPIs and clopidogrel." | 8.88 | Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. ( Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Yao, H, 2012) |
| "Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been hypothesized to be associated with lesser degrees of platelet inhibition and increased risk for recurrent ischemic events in patients with coronary artery disease on clopidogrel therapy; however, studies from Western countries have yielded mixed results." | 8.88 | Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. ( Cho, KI; Jang, JS; Je, HG; Jeong, YH; Jin, HY; Kim, BH; Kim, DI; Kim, DK; Kim, DS; Lee, SW; Park, YH; Seo, JS; Seol, SH; Yang, TH, 2012) |
| "For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i." | 8.88 | Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 8.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| " In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk." | 8.84 | Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008) |
| "When used as an alternative to or in addition to aspirin, clopidogrel has been demonstrated by some but not all randomized controlled trials to be effective in secondary prevention of cardiovascular (CV) events in patients with (1) coronary artery disease (CAD), (2) acute coronary syndrome (ACS), and (3) coronary stent placement." | 8.84 | Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. ( Cheng, JW, 2007) |
| " In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease." | 8.84 | Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007) |
| "Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment." | 8.31 | Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease. ( Chen, X; Hu, X; Li, H; Li, M; Ma, Q; Peng, L; Song, P; Tang, J; Zhang, Y; Zhou, G, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease." | 8.12 | Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. ( Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S, 2022) |
| "Dual antiplatelet therapy (DAPT) of clopidogrel and aspirin is crucial for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI)." | 7.88 | Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients. ( Abdul Kader, MASK; Amin, AM; Ibrahim, B; Kah Hay, Y; Mohamed Noor, DA; Mostafa, H; Sheau Chin, L; Teh, CH, 2018) |
| "To investigate the potential correlation between miR-223 level in leukocytes and platelet responses to clopidogrel in patients with coronary artery disease." | 7.88 | Leukocyte miR-223-3p is not associated with altered platelet responses to clopidogrel in patients with coronary artery disease. ( Chen, S; Li, S; Xie, W; Yin, Q; Zhang, M, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is a recommended treatment for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) to reduce the rate of ischemic events and stent thrombosis." | 7.88 | CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. ( Chen, XP; Hu, XL; Li, H; Li, MP; Ma, QL; Peng, LM; Song, PY; Wang, JY; Zhang, YJ, 2018) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 7.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| " Rates of discharge clopidogrel use were described for patients with no angiography, angiography without obstructive coronary artery disease (CAD; ≥50% stenosis in ≥1 vessel), and angiography with obstructive CAD." | 7.83 | Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. ( Hellkamp, AS; Hess, CN; Peng, SA; Peterson, ED; Roe, MT; Scirica, BM; Thomas, L; Wang, TY, 2016) |
| "To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease." | 7.83 | [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016) |
| "Dual antiplatelet therapy with clopidogrel and aspirin is the current standard of care in the management of patients with coronary artery disease (CAD) and acute coronary syndrome (ACS)." | 7.81 | Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( Arya, V; Bhargava, M; Mahajan, P; Mohanty, A; Saraf, A; Sawhney, JP, 2015) |
| "The aim of this analysis was to determine the effect of prolonging clopidogrel therapy >12 months versus ≤12 months after PCI on very late outcomes in patients with diabetes mellitus (DM)." | 7.81 | Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. ( Agrawal, K; Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Prince, L; Smoot, KJ; Sokolovskaya, G; Temiyasathit, S; Thukkani, AK, 2015) |
| "This study aimed to analyze the impact of body mass index (BMI) and the metabolic syndrome (MS) on responses to clopidogrel or prasugrel and bleeding risk after acute coronary syndrome." | 7.80 | Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. ( Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V, 2014) |
| "Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled." | 7.80 | Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients." | 7.80 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. ( Hunnangkul, S; Kamkaew, R; Likidlilid, A; Poldee, S; Suktitipat, B; Tassaneetrithep, B; Tresukosol, D, 2014) |
| " To assess the efficacy and safety of aspirin desensitisation in Chinese patients with coronary artery disease." | 7.79 | Aspirin desensitisation for Chinese patients with coronary artery disease. ( Chan, HL; Chan, KK; Chau, CH; Cheung, CY; Cheung, GS; Choi, MC; Lee, JK; Li, SK; Tsui, KL; Wu, KL, 2013) |
| "The prospective study comprised 152 patients with coronary artery disease (CAD) on the therapy of clopidogrel." | 7.79 | [Clopidogrel resistance of patients with coronary artery disease and its correlation with platelet count and mean platelet volume]. ( Gao, W; Han, JL; Li, HY; Li, L; Qiao, R; Yu, HY; Zhang, J, 2013) |
| "This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 7.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
| "To characterize the clinical presentation of a cohort of patients with coronary artery disease (CAD) and aspirin reactions." | 7.79 | Characterization of aspirin allergies in patients with coronary artery disease. ( Feng, CH; Stevenson, DD; White, AA, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 7.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| "To compare the effects of clopidogrel combined with dihydropyridine calcium-channel blockers (CCBs) or non-dihydropyridine CCBs on coronary artery disease (CAD) in elderly patients." | 7.78 | [Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study]. ( Cao, J; Fan, L; Gao, Y; Liu, X; Lu, X; Ma, C, 2012) |
| "To compare the effects of clopidogrel with or without combined with CYP3A4-metabolized statin in treating coronary artery disease (CAD) among the elderly patients." | 7.78 | [Comparison on the effects of clopidogrel, statins combination in treating coronary artery disease among the elderly patients: a retrospective cohort study]. ( Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Ma, C, 2012) |
| "To assess the impact of cytochrome P450 (CYP) 2C19*17 allelic variant on platelet aggregation and bleeding risk in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI) and treated with clopidogrel." | 7.78 | Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. ( Chen, H; Dai, ZL; Wu, XY, 2012) |
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 7.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| "To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel." | 7.76 | Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010) |
| "The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI." | 7.76 | Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding." | 7.76 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)." | 7.76 | Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010) |
| "The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST)." | 7.75 | Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N, 2009) |
| " As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI)." | 7.75 | Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). ( Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW, 2009) |
| "The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent (DES) implantation." | 7.74 | Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. ( Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2008) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 7.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| " Therefore, we investigated the effects of these polymorphisms on platelet aggregation in aspirin-treated patients with coronary artery disease (CAD)." | 7.74 | P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. ( Bierend, A; Böger, RH; Maas, R; Rau, T; Schwedhelm, E, 2008) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 6.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| " Pharmacodynamic assessments were conducted using three assays (vasodilator-stimulated phosphoprotein, VerifyNow P2Y12, and light transmittance aggregometry, LTA) at baseline, 30 min, 2, 24 h, and 1 week." | 6.82 | A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. ( Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM, 2016) |
| "The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known." | 6.80 | A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. ( Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R, 2015) |
| " We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)." | 6.80 | Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. ( Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015) |
| " However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation." | 6.79 | Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014) |
| " We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel." | 6.79 | Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. ( Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014) |
| " At the end of the dosing interval on day 28, mean final-extent IPA was 10." | 6.79 | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. ( Emanuelsson, H; Hiasa, Y; Teng, R, 2014) |
| " Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and clopidogrel 75-mg using data from two PK/PD studies in stable coronary artery disease (CAD) patients (GENERATIONS and FEATHER)." | 6.79 | The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. ( Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ, 2014) |
| " The prevalence of adverse events was assessed at each visit through a direct interview." | 6.78 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013) |
| " In the ONSET-OFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD)." | 6.77 | Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ( Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C, 2012) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 6.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| " Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable." | 6.73 | Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. ( Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E, 2008) |
| " Whether platelet inhibition can be enhanced by increasing clopidogrel maintenance dosage in T2DM patients is unknown." | 6.73 | Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. ( Angiolillo, DJ; Bass, TA; Bernardo, E; Charlton, RK; Costa, MA; Desai, B; Guzman, LA; Shoemaker, SB; Yuan, H; Zenni, MM, 2007) |
| "In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS." | 5.51 | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022) |
| "Aspirin resistance was detected in 22 (16." | 5.40 | Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA, 2014) |
| "Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation." | 5.39 | Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013) |
| " If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown." | 5.38 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "Patients with more extensive coronary atherosclerosis have a higher rate of HPR, which might partly account for higher risk of periprocedural MI." | 5.36 | High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. ( Barbato, E; Bartunek, J; De Bruyne, B; Di Sciascio, G; Heyndrickx, G; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Wijns, W, 2010) |
| "Aspirin resistance was defined as an ARU (aspirin reaction units) > or =550, and clopidogrel resistance was defined as platelet inhibition <20%." | 5.35 | Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. ( Han, K; Jeon, HK; Kim, H; Lee, HK, 2009) |
| " Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly assigned (1:1) to 75-100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, or standard dual antiplatelet therapy with 75-100 mg aspirin daily plus either 75 mg clopidogrel daily (for patients with stable coronary artery disease) or 90 mg ticagrelor twice daily (for patients with acute coronary syndromes) for 12 months, followed by aspirin monotherapy for 12 months." | 5.27 | Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la ( Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A, 2018) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "Antiplatelet response to clopidogrel and its influence upon the risk of cardiovascular adverse events among patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI) has not been investigated fully." | 5.24 | Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. ( Gawrońska-Szklarz, B; Gorący, J; Jastrzębska, M; Kiedrowicz, R; Kornacewicz-Jach, Z; Olędzki, S; Safranow, K, 2017) |
| "The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents." | 5.24 | 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017) |
| "Ticagrelor has been demonstrated to provide a more rapid and powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients." | 5.22 | One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. ( Dong, X; Han, Y; He, M; Li, M; Li, Y; Liu, B; Lu, S; Pan, Y; Shi, J; Sun, D; Zhao, S; Zheng, W, 2016) |
| "We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled." | 5.20 | High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015) |
| "Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders." | 5.20 | 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015) |
| "Clopidogrel is indicated for the treatment and prevention of peripheral vascular, cerebrovascular, and coronary artery diseases." | 5.20 | Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial. ( Cho, DK; Kim, SH; Lee, HJ; Lee, HS; Lim, SW; Shin, J; Sung, JH, 2015) |
| " The aim of this study was to investigate the pharmacodynamic response to clopidogrel in patients with IGT and insulin resistance (IR)." | 5.20 | Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease. ( Angiolillo, DJ; Fujita, K; Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Suga, T; Ueno, M; Yamaji, K; Yamamoto, H, 2015) |
| "The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin." | 5.20 | Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015) |
| "A total of 53 consecutive Japanese patients with stable coronary artery disease (CAD) who received aspirin and clopidogrel were enrolled." | 5.20 | Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease. ( Ariyoshi, N; Fujimoto, Y; Hanaoka, H; Kobayashi, Y; Koshizaka, M; Nakayama, T; Nishi, T; Sugimoto, K; Takahara, M; Wakabayashi, S, 2015) |
| "Platelet function studies (light transmission aggregometry, VerifyNow, and flow cytometry) were performed on blood from patients with stable coronary artery disease who were taking aspirin when a loading dose of clopidogrel (600 mg) was given during a cangrelor infusion (0." | 5.20 | Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation. ( Agarwal, Z; Gogo, P; Schneider, DJ; Seecheran, N, 2015) |
| " Ticagrelor demonstrated a more rapid onset and greater magnitude of platelet inhibition than clopidogrel in Hispanic patients with stable coronary artery disease (CAD)." | 5.20 | Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. ( Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, LC; Maya, J; Price, MJ; Teng, R, 2015) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 5.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| " The antiplatelet effect and safety of prasugrel was compared to that of double-dose clopidogrel in patients with stable coronary artery disease or acute coronary syndrome (ACS) exhibiting HTPR on clopidogrel and treated with PCI, using multiple electrode aggregometry (MEA) to assess platelet reactivity." | 5.19 | Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. ( Clemmensen, P; Dridi, NP; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K; Stissing, T, 2014) |
| " We proposed that clopidogrel therapy in patients with stable coronary artery disease imparts a pleiotropic effect that extends beyond antiplatelet aggregation to other atheroprotective processes." | 5.19 | Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. ( Binongo, JN; Dhawan, SS; Ghazzal, ZB; Pohlel, FK; Quyyumi, AA; Ramadan, R; Syed, H, 2014) |
| " We verified if the pharmacodynamic effects of CYP3A4-metabolized statins (atorvastatin) and non-CYP3A4-metabolized statins (pitavastatin) differ in patients with coronary artery disease (CAD) treated with DAPT." | 5.19 | Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. ( Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C, 2014) |
| " Subjects with coronary artery disease treated with aspirin were randomly assigned to clopidogrel 75 mg daily or prasugrel 10 mg daily for 7 days." | 5.19 | Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ, 2014) |
| "In a randomized study with a factorial design, 82 stable coronary artery disease patients treated with 75 mg clopidogrel MD and aspirin were assigned to receive in a double blind fashion lansoprazole (30 mg/day) or placebo and to receive in an open fashion 150 mg clopidogrel MD or 10 mg prasugrel MD." | 5.19 | Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. ( Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ, 2014) |
| "The ELEVATE-TIMI 56 (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56) investigators genotyped 333 patients with coronary artery disease and randomized them to various clopidogrel regimens." | 5.19 | Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. ( Angiolillo, DJ; Berg, DD; Cyr, JF; Frelinger, AL; Hochholzer, W; Lei, L; Mattimore, JF; Mega, JL; Mesa, RA; Michelson, AD; O'Donoghue, ML; Ruff, CT; Sabatine, MS, 2014) |
| "The goal of this study was to investigate the impact of high-dose atorvastatin on the pharmacodynamic (PD) effects of double-dose clopidogrel in statin-naive patients with stable coronary artery disease (CAD) and high-on-treatment platelet reactivity (HTPR) while on standard-dose clopidogrel before percutaneous coronary intervention (PCI)." | 5.17 | High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. ( Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A, 2013) |
| "PARADOX was a prospective, randomized, double-blind, double-dummy, placebo-controlled, crossover study of objectively assessed nonsmokers (n = 56) and smokers (n = 54) with stable coronary artery disease receiving aspirin therapy." | 5.17 | The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. ( Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A, 2013) |
| "We examined PD and active metabolite pharmacokinetics (PKs) with prasugrel 5 and 10 mg and clopidogrel 75 mg in a 3-period (12 days each) blinded, crossover study in VE (n = 73; mean: 79 ± 3 years of age) or (n = 82) nonelderly (NE) (≥45 to <65 years of age; mean: 56 ± 5 years of age) stable coronary artery disease (CAD) patients receiving background aspirin." | 5.17 | Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. ( Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 5.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "Diabetes mellitus (DM) is the most important predictor of chronic kidney disease (CKD), and pharmacodynamic (PD) studies have shown that DM patients with impaired renal function are characterized by reduced clopidogrel response." | 5.17 | Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Kodali, MK; Patel, R; Rollini, F; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2013) |
| "The balance between platelet MP release and EPC mobilization seems influenced by clopidogrel plasma levels, suggesting a protective mechanism on coronary artery disease." | 5.16 | Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. ( Barbosa, SP; Bianco, HT; Brunialti, MK; de Nucci, G; Fonseca, FA; França, CN; Izar, MC; Kasmas, SH; Pinheiro, LF; Salomão, R, 2012) |
| " The present study was conducted in healthy individuals (n = 50) and in outpatients with coronary artery disease (CAD) at a distance from the acute ischemic episode (aspirin group, n = 71; aspirin/clopidogrel group, n = 106)." | 5.16 | Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry. ( Baccouche, H; Bandi, A; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Mossialos, L; Sassi, M; Tsinopoulos, G; Zarifis, J, 2012) |
| "Stable coronary artery disease (CAD) patients with HTPR (>208 P2Y(12) reaction units [PRU] by the VerifyNow test) after elective PCI with at least 1 drug-eluting stent (DES) were randomly assigned to either prasugrel 10 mg daily or clopidogrel 75 mg daily." | 5.16 | A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity ( Angiolillo, DJ; Gawaz, M; Jakubowski, JA; Kastrati, A; Müller, U; Neumann, FJ; Richardt, G; Stone, GW; Trenk, D, 2012) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 5.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "Recently we have demonstrated a dose-dependent improvement of endothelial function after administration of a single loading dose of clopidogrel in patients with coronary artery disease (CAD)." | 5.15 | Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. ( Munzel, T; Nick, E; Ostad, MA; Paixao-Gatinho, V; Schiewe, R; Schnorbus, B; Tschentscher, P; Warnholtz, A, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "The goal of this study was to investigate whether omega-3 polyunsaturated fatty acids (n-3 PUFA) are able to alter plasma fibrin clot properties and reduce thrombin formation in stable coronary artery disease patients undergoing percutaneous coronary intervention (PCI)." | 5.15 | Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). ( Gajos, G; Nessler, J; Piwowarska, W; Rostoff, P; Undas, A; Zalewski, J, 2011) |
| " clopidogrel in stable coronary artery disease (CAD) patients with high levels of platelet inhibition (HPI) during the ONSET/OFFSET study." | 5.15 | Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Storey, RF; Tantry, U; Wei, C, 2011) |
| "To investigate, in the prospective CESSATION study, the effect of clopidogrel withdrawal at 1 year after DES implantation on (i) arachidonic acid (AA)- and adenosine diphosphate (ADP)-induced platelet aggregation, and (ii) biomarkers of vascular inflammation, including soluble CD40 ligand (sCD40L), high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL-6)." | 5.15 | Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. ( Calver, A; Corbett, S; Curzen, N; Dent, H; Englyst, N; Gray, H; Leadbeater, P; Morgan, J; Roderick, P; Sambu, N; Simpson, I; Warner, TD, 2011) |
| "Adjunctive treatment with pentoxifylline is not associated with increased platelet inhibitory effects in DM patients with coronary artery disease receiving DAPT." | 5.15 | Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011) |
| " One hundred and seventy-two coronary artery disease patients who had taken aspirin only or combinations with aspirin and clopidogrel for over 7 days were included." | 5.14 | Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients. ( Cha, KS; Goh, RY; Han, JY; Kim, KE; Kim, MH; Quan, ML; Woo, KS, 2010) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 5.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days." | 5.14 | Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. ( Akers, WS; Campbell, CL; Charnigo, R; Dunn, SP; Holt, J; Oestreich, JH; Smyth, SS; Steinhubl, SR, 2009) |
| "One hundred and twenty stable coronary artery disease patients requiring a diagnostic angiography were recruited prior to pre-treatment with clopidogrel." | 5.14 | Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E, 2009) |
| "This multicenter registry documents satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent when used with 6 months of dual antiplatelet therapy in a "real-world" setting." | 5.14 | Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. ( Chen, X; Gao, R; Han, Y; Jiang, T; Jing, Q; Li, H; Li, Y; Li, Z; Liu, H; Liu, Y; Qiu, J; Shang, X; Xu, B; Yang, L; Zhang, H, 2009) |
| "We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease." | 5.14 | Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009) |
| "The study aimed to assess the impact of nine polymorphisms of genes encoding platelet receptors, enzymes, and hemostatic factors on clopidogrel efficacy to inhibit platelet reactivity in patients with stable coronary artery disease undergoing elective coronary angiography either with or without ad hoc percutaneous coronary intervention." | 5.14 | High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. ( Bilkova, D; Hajkova, J; Kala, P; Kvasnicka, J; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "Patients with coronary artery disease participating in a double-blind study comparing lipid-lowering effects of atorvastatin (20-80 mg OD; n = 22) and rosuvastatin (10-40 mg OD; n = 24) were studied before and after 2 weeks treatment with clopidogrel 75 mg OD after completed statin dose titration." | 5.14 | Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. ( Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J, 2009) |
| "We studied patients with stable coronary artery disease on chronic aspirin therapy randomised to addition of clopidogrel 75 mg/d (n = 30) or continuation of aspirin 100 mg/d (n = 30) for 4 weeks." | 5.14 | Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. ( Branicka, A; Stepień, E; Tracz, W; Undas, A; Wołkow, P; Zmudka, K, 2009) |
| "In a multicenter, randomized, double-blind study, 123 patients with stable coronary artery disease who were taking aspirin therapy (75 to 100 mg/d) received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks." | 5.14 | Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. ( Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V, 2009) |
| "Patients with stable coronary artery disease on aspirin therapy received a 300-mg clopidogrel load; nonresponders were identified by light transmittance aggregometry." | 5.14 | Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. ( Antonino, MJ; Bliden, KP; Butler, K; Eikelboom, JW; Gurbel, PA; Henderson, D; Husted, S; Kereiakes, DJ; Nielsen, T; Patel, DV; Rasmussen, L; Sabe-Affaki, G; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "CYP2C19 (*1, *2, *3, *4, *5, *6, *7, *8, *17) genotyping was performed in patients with coronary artery disease treated with ticagrelor (180-mg load, 90 mg BID) (n=92) or clopidogrel (600-mg load, 75 mg/d) (n=82)." | 5.14 | First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. ( Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 5.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "The effects of therapy with aspirin 300 mg/day and with combined aspirin 100 mg/day plus clopidogrel 75 mg/day on platelet function were compared in patients with diabetes mellitus and coronary artery disease and impaired antiplatelet responses to aspirin 100 mg/day." | 5.13 | Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. ( Aygul, N; Duzenli, MA; Ozdemir, K; Soylu, A; Tokac, M, 2008) |
| "The aim of this study was to evaluate the relationship between reticulated platelets (RPs), platelet size, and platelet function in patients with stable coronary artery disease (CAD) taking aspirin and clopidogrel." | 5.13 | Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. ( Alviar, CL; Arikan, M; DeLao, T; Dong, JF; Granada, JF; Guthikonda, S; Kleiman, NS; Lev, EI; Tellez, A; Vaduganathan, M, 2008) |
| "To investigate an association of responsiveness to clopidogrel loading dose with genotypes of cytochrome P450 (CYP) 2C19, other CYP isozymes and nongenetic factors in patients with coronary artery disease." | 5.13 | CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. ( Bischofs, C; Buse, V; Dippon, J; Gawaz, M; Geisler, T; Moerike, K; Schaeffeler, E; Schwab, M; Winter, S; Zuern, C, 2008) |
| " One hundred consecutive patients with coronary artery disease (CAD) on combined acetylsalicylic acid and clopidogrel treatment (75 mg/d) and 33 patients on aspirin only were screened for platelet ADP-induced signalling by conventional aggregometry, platelet P-selectin expression and the platelet reactivity index (PRI)." | 5.13 | ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. ( Bauersachs, J; Eigenthaler, M; Ertl, G; Flierl, U; Schäfer, A; Störk, S; Walter, U; Weinberger, S, 2008) |
| " One hundred ten aspirin-treated patients with stable coronary artery disease were randomized to a loading dose (LD, day 1)/ maintenance dose (MD, days 2-29) of prasugrel 60 mg/10 mg or clopidogrel 600 mg/75 mg." | 5.13 | Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. ( Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| " Aspirin-treated subjects with coronary artery disease were randomized to double-blind treatment with clopidogrel 600 mg loading dose (LD) followed by daily 75 mg maintenance dose (MD) or prasugrel 60 mg LD and daily 10 mg MD for 28 days." | 5.13 | Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE, 2008) |
| "We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes." | 5.13 | Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. ( Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk." | 5.13 | Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J, 2008) |
| "1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study." | 5.13 | Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. ( Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2008) |
| "In aspirin-treated subjects with coronary artery disease, prasugrel 60/10 mg provides faster onset and greater inhibition of P2Y(12) receptor-mediated platelet aggregation than clopidogrel 600/75 mg, because of greater and more efficient generation of the active metabolite." | 5.13 | Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. ( Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "We evaluated the safety, tolerability, and pharmacodynamic profile of REG1 in a randomized, double-blind, placebo-controlled study, assigning 50 subjects with coronary artery disease taking aspirin and/or clopidogrel to 4 dose levels of RB006 (15, 30, 50, and 75 mg) and RB007 (30, 60, 100, and 150 mg)." | 5.13 | Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. ( Aberle, LG; Alexander, JH; Becker, RC; Chan, MY; Chronos, N; Cohen, MG; Dyke, CK; Gilchrist, IC; Harrington, RA; Kleiman, NS; Lin, M; Melloni, C; Myles, SK; Rusconi, CP; Steinhubl, SR; Tonkens, RM; Vorchheimer, DA; Walder, J, 2008) |
| "This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD)." | 5.12 | Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. ( Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ, 2006) |
| "Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects." | 5.12 | Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. ( Baldus, S; Böger, R; Heitzer, T; Karstens, M; Meinertz, T; Ortak, M; Rudolph, V; Schwedhelm, E; Sydow, K; Tschentscher, P, 2006) |
| " Platelet inhibitors are widely used in coronary artery disease (CAD), and we hypothesized that the platelet inhibitor clopidogrel could modify chemokines in CAD patients." | 5.12 | Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. ( Andreassen, AK; Aukrust, P; Brosstad, F; Damås, JK; Frøland, SS; Gjertsen, E; Gullestad, L; Hansteen, V; Pedersen, TM; Semb, AG; Solum, NO; Ueland, T; Waehre, T; Yndestad, A, 2006) |
| "Aspirin resistance may increase up to more then threefold the risk of major cardiovascular events (MACE) in patients with stable coronary artery disease." | 5.12 | The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Ozcan, M; Pamukcu, B; Umman, B, 2006) |
| "The aim of our prospective multicenter Clopidogrel Registry was to evaluate the efficacy and safety of a 300-mg loading dose of clopidogrel at the time of ad hoc stenting in patients with suspected coronary artery disease who were not pretreated with clopidogrel for any reason, and to compare the 30-day clinical event rates with the outcome of patients pretreated with a loading dose of clopidogrel 6 to 24 hours before stenting." | 5.12 | Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. ( Domanovits, H; Edes, I; Edes, IF; Facskó, A; Farhan, S; Glogar, D; Gyöngyösi, M; Homorodi, N; Huber, K; Király, C; Kristóf, E; Maurer, G; Pavo, N; Sodeck, G; Strehblow, C; Szük, T, 2007) |
| "Aspirin resistance may increase the risk of major adverse cardiac events (MACE) more than threefold in patients with stable coronary artery disease (CAD)." | 5.12 | Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). ( Mercanoglu, F; Meric, M; Nisanci, Y; Oflaz, H; Oncul, A; Onur, I; Ozcan, M; Pamukcu, B; Umman, B, 2007) |
| "We searched for additional anti-platelet effects of clopidogrel in coronary artery disease (CAD) patients treated with aspirin." | 5.12 | The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. ( Biernat, M; Dropinski, J; Dziedzina, S; Jakiela, B; Plutecka, H; Sanak, M; Szczeklik, A; Wegrzyn, W, 2007) |
| " We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD)." | 5.12 | Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. ( Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH, 2007) |
| "This study (Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics [ISAR-SWEET] Study) enrolled 701 diabetic patients with coronary artery disease who underwent an elective percutaneous coronary intervention after pretreatment with a 600-mg dose of clopidogrel >2 hours before the procedure: 351 patients were randomly assigned to abciximab and 350 patients to placebo." | 5.11 | Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. ( Berger, PP; Bollwein, H; Dibra, A; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Pache, J; Schömig, A; Schühlen, H; von Beckerath, N, 2004) |
| "Clopidogrel, especially when combined with aspirin, reduces the rate of ischaemic events in patients with coronary artery disease (CAD)." | 5.11 | Inter-individual variability in response to clopidogrel in patients with coronary artery disease. ( Dubiel, JS; Dudek, D; Dziewierz, A; Heba, G; Mielecki, W; Rakowski, T, 2005) |
| "Investigate the association between P2Y12 Purinoceptor (P2RY12) polymorphisms and adverse clinical events in coronary artery disease (CAD) patients treated with clopidogrel." | 4.98 | Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis. ( Chen, J; Fu, Y; Li, JL; Liang, GK; Liu, J; Lu, Y; Nie, XY; Qin, SB; Shao, H; Shi, LW, 2018) |
| "P2Y12 inhibitors, including clopidogrel have become an integral part of treatment for patients receiving coronary stent placement as a result of stable coronary artery disease or acute coronary syndromes (ACS) and also for medically managed ACS patients." | 4.98 | Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful? ( Bella, J; Krim, N; Zeb, I, 2018) |
| "The results of the meta-analysis suggest that ABCB1 C3435T polymorphism may increase the risk of bleeding in Asian patients treated with clopidogrel." | 4.95 | Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. ( Dong, Y; He, H; Lu, J; Ma, X; Meng, T; Xie, J; Zhai, Y, 2017) |
| "Pretreatment with oral P2Y12 inhibitors occurs each time clopidogrel, prasugrel, ticagrelor are given to patients with suspected coronary artery disease before definition of the coronary anatomy." | 4.93 | Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. ( Angiolillo, DJ; Capodanno, D, 2016) |
| "The use of prasugrel in patients with coronary artery disease (CAD) has been associated with decreased major adverse cardiac events (MACEs) compared with clopidogrel but with an increased risk of bleeding." | 4.91 | Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. ( Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY, 2015) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 4.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| " Patients with indications for antithrombotic therapy often will have coexisting vascular disease, such as coronary artery disease, requiring concomitant antiplatelet therapy with aspirin alone or more commonly with a dual antiplatelet regimen, aspirin and clopidogrel, or prasugrel or ticagrelor." | 4.90 | Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits? ( Alpert, JS; Asencio, LA; Huang, JJ, 2014) |
| "Pharmacogenomics has been implicated in the response variability of antiplatelet drugs in coronary artery disease (CAD), particularly for aspirin and clopidogrel." | 4.90 | Pharmacogenomics of oral antiplatelet drugs. ( de Boer, A; Deneer, VH; Klungel, OH; Yasmina, A, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| "Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients." | 4.89 | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013) |
| "To perform a meta-analysis of the association between CYP2C19 loss- and gain-of-function variants and cardiovascular outcomes and bleeding in patients with coronary artery disease treated with clopidogrel, and to explore the causes of heterogeneity between studies." | 4.88 | Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. ( Brugada, R; Elosua, R; Lluis-Ganella, C; Lucas, G; Marrugat, J; Masiá, R; Sala, J; Subirana, I; Tomás, M; Zabalza, M, 2012) |
| "Contrary to the findings of post hoc analyses of randomized trials, observational studies showed that recent exposure to clopidogrel before coronary artery bypass grafting is associated with increased risk of postoperative death, reoperations for bleeding, blood loss, and need of blood transfusions." | 4.88 | Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. ( Airaksinen, KE; Biancari, F; Lip, GY, 2012) |
| "Concomitant use of PPIs and clopidogrel in patients with coronary artery disease is associated with an increased risk of MACE or acute coronary syndrome, but there is insufficient evidence to conclude that there is an interaction between individual PPIs and clopidogrel." | 4.88 | Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. ( Huang, B; Huang, H; Huang, Y; Jing, X; Li, J; Li, Y; Yao, H, 2012) |
| "Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been hypothesized to be associated with lesser degrees of platelet inhibition and increased risk for recurrent ischemic events in patients with coronary artery disease on clopidogrel therapy; however, studies from Western countries have yielded mixed results." | 4.88 | Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. ( Cho, KI; Jang, JS; Je, HG; Jeong, YH; Jin, HY; Kim, BH; Kim, DI; Kim, DK; Kim, DS; Lee, SW; Park, YH; Seo, JS; Seol, SH; Yang, TH, 2012) |
| "For many years clopidogrel was the 'gold standard' ADP receptor antagonist in patients with coronary artery disease in combination with acetylsalicylic acid, i." | 4.88 | Clopidogrel in coronary artery disease: update 2012. ( Huber, K, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 4.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| "This article concentrates on individual genetic differences responsible for variations of action of clopidogrel, which have been found to be partially responsible for increased cardiovascular events in patients with coronary artery disease under dual antiplatelet therapy." | 4.87 | Genetic variability in response to clopidogrel therapy and its clinical implications. ( Freynhofer, MK; Huber, K; Schrör, K; Siller-Matula, J; Yukhanyan, L, 2011) |
| " Platelet dysfunction has been implicated as a central contributor to the increased risk of coronary artery disease in patients with DM, and it is not surprising that the anti-platelet agent, clopidogrel, has been shown to have efficacy in both short and long term outcomes in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention." | 4.87 | Variability of clopidogrel response in patients with type 2 diabetes mellitus. ( Banerjee, S; Hall, HM; McGuire, DK, 2011) |
| "We performed this meta-analysis to update the clinical evidences on the relation between clopidogrel non-responsiveness and clinical outcomes in patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention." | 4.86 | Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. ( Abbate, R; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Sofi, F, 2010) |
| "Standard double antiplatelet therapy (aspirin plus clopidogrel) used in patients with coronary artery disease during acute coronary syndromes (ACS) and/or in conjunction with percutaneous coronary interventions (PCI) has some limitations." | 4.86 | [Antiplatelet therapy in coronary heart disease. Some problems and achivements]. ( Gratsianskiĭ, NA, 2010) |
| " The long-term benefit of dual anti-platelet therapy with clopidogrel and aspirin is well established for patients with acute coronary syndrome and for secondary prophylaxis of coronary artery disease." | 4.86 | [Platelet inhibition with prasugrel]. ( Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM, 2010) |
| " Although monotherapy with either aspirin or clopidogrel has been validated in secondary prevention, for high-risk patients such as those with acute coronary syndromes or requiring percutaneous coronary intervention, dual antiplatelet therapy appears to be most beneficial." | 4.85 | Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. ( Bhatt, DL, 2009) |
| "This integrated analysis compared speed of onset, level of platelet inhibition, and response variability to prasugrel and clopidogrel in healthy subjects and in patients with stable coronary artery disease with data pooled from 24 clinical pharmacology studies." | 4.85 | Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. ( Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ, 2009) |
| "The present review focuses on the roles of thromboxane A2 (TxA2) in arterial thrombosis, atherogenesis, vascular stent-related ischemic events and renal proteinuria." | 4.85 | Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. ( Alberts, P; Bounameaux, H; Fontana, P; Mann, J; Sakariassen, KS; Sorensen, AS, 2009) |
| "Current guidelines support dual antiplatelet therapy with aspirin and clopidogrel (Plavix) in a number of clinical scenarios, ie, in ST-segment-elevation myocardial infarction (MI), non-ST-elevation MI, and percutaneous coronary intervention." | 4.85 | Dual antiplatelet therapy in coronary artery disease: a case-based approach. ( Menon, V; Raymond, C, 2009) |
| "The benefits of clopidogrel in the treatment and prevention of coronary artery disease are well established, however, not all individuals respond in the same way to clopidogrel; there are patients who suffer adverse events despite clopidogrel treatment." | 4.84 | Clinical implications of clopidogrel resistance. ( Badimón, JJ; De Miguel, A; Ibanez, B, 2008) |
| " In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk." | 4.84 | Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008) |
| "When used as an alternative to or in addition to aspirin, clopidogrel has been demonstrated by some but not all randomized controlled trials to be effective in secondary prevention of cardiovascular (CV) events in patients with (1) coronary artery disease (CAD), (2) acute coronary syndrome (ACS), and (3) coronary stent placement." | 4.84 | Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. ( Cheng, JW, 2007) |
| " In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease." | 4.84 | Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007) |
| "The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse." | 4.84 | Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. ( Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A, 2007) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| " On the contrary, the initial treatment with clopidogrel in addition to aspirin and anticoagulation led to a 20% relative risk reduction for an endpoint of death, myocardial infarction and stroke in the CURE trial." | 4.81 | [Modern therapy in acute coronary syndrome]. ( Blankenberg, S; Espinola-Klein, C; Meyer, J; Rupprecht, HJ, 2002) |
| "Clopidogrel combined with aspirin is widely used in coronary artery disease (CAD) patients, while some patients exhibit high platelet activity when receiving the combined treatment." | 4.31 | Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease. ( Chen, X; Hu, X; Li, H; Li, M; Ma, Q; Peng, L; Song, P; Tang, J; Zhang, Y; Zhou, G, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Inflammation increases the risk of thrombosis in coronary artery disease (CAD) patients and affects the antiplatelet efficacy of clopidogrel." | 4.12 | Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy. ( Han, K; Huang, X; Ma, M; Sun, T; Yang, S; Zhao, Z; Zhou, Y, 2022) |
| "Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease." | 4.12 | Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel. ( Ariyoshi, N; Kitahara, H; Kobayashi, Y; Nishi, T; Ohno, Y; Saito, Y; Wakabayashi, S, 2022) |
| "Background Dual antiplatelet therapy based on aspirin and P2Y12 receptor antagonists such as clopidogrel is currently the primary treatment for coronary artery disease (CAD)." | 4.02 | Influence of ( Chen, XP; Du, YX; Hu, XL; Li, H; Li, MP; Li, MY; Liu, YL; Ma, QL; Peng, LM; Song, MY; Song, PY, 2021) |
| "Dual antiplatelet therapy (DAPT) of clopidogrel and aspirin is crucial for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI)." | 3.88 | Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients. ( Abdul Kader, MASK; Amin, AM; Ibrahim, B; Kah Hay, Y; Mohamed Noor, DA; Mostafa, H; Sheau Chin, L; Teh, CH, 2018) |
| "To investigate the potential correlation between miR-223 level in leukocytes and platelet responses to clopidogrel in patients with coronary artery disease." | 3.88 | Leukocyte miR-223-3p is not associated with altered platelet responses to clopidogrel in patients with coronary artery disease. ( Chen, S; Li, S; Xie, W; Yin, Q; Zhang, M, 2018) |
| "The present study is an investigation of the association between high on-treatment platelet reactivity to clopidogrel (HTPRC) and hepatosteatosis in patients who had elective stent implantation due to coronary artery disease." | 3.88 | Association between high on-treatment platelet reactivity to clopidogrel and hepatosteatosis in patients undergoing elective stent implantation. ( Alper, AT; Barutca, H; Bora Şişman, S; Bozbeyoğlu, E; Çakıllı, Y; Çinier, G; Güzelburç, Ö; Şahin, S; Tekkeşin, Aİ; Velibey, Y; Yıldırımtürk, Ö, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is a recommended treatment for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) to reduce the rate of ischemic events and stent thrombosis." | 3.88 | CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. ( Chen, XP; Hu, XL; Li, H; Li, MP; Ma, QL; Peng, LM; Song, PY; Wang, JY; Zhang, YJ, 2018) |
| "Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial." | 3.85 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (n = 10,135), we analyzed outcomes in patients with coronary artery disease (n = 1827) according to treatment with triple antithrombotic therapy (defined as concurrent therapy with an oral anticoagulant, a thienopyridine, and aspirin) or dual antithrombotic therapy (comprising either an oral anticoagulant and one antiplatelet agent [OAC plus AA] or 2 antiplatelet drugs and no anticoagulant [DAP])." | 3.83 | Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. ( Ansell, J; Chang, P; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Rao, M; Simon, DN; Singer, DE; Thomas, L, 2016) |
| " Serum uric acid (SUA) has been largely addressed in the past as a possible risk factor for coronary artery disease, with a possible association with platelets hyperreactivity." | 3.83 | Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M, 2016) |
| " Rates of discharge clopidogrel use were described for patients with no angiography, angiography without obstructive coronary artery disease (CAD; ≥50% stenosis in ≥1 vessel), and angiography with obstructive CAD." | 3.83 | Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. ( Hellkamp, AS; Hess, CN; Peng, SA; Peterson, ED; Roe, MT; Scirica, BM; Thomas, L; Wang, TY, 2016) |
| "Within this retrospective observational spontaneous clinical study 44 patients (31 males and 13 females) all presenting stable coronary artery disease were evaluated; 25 subjects were treated with only acetylsalicylic acid and/or clopidogrel in association with statins (standard therapeutic protocol) while for the other 18 subjects the standard therapeutic protocol was integrated with Arnica comp." | 3.83 | Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease. ( Bianchi, M; Di Nardo, V; Fioranelli, M; Roccia, MG, 2016) |
| "In patients receiving dual antiplatelet therapy for coronary artery disease, higher PTH levels are associated with an increased ADP-mediated platelet reactivity and suboptimal response to clopidogrel, especially for values above 96." | 3.83 | Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease." | 3.83 | [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016) |
| " Vorapaxar, a novel platelet thrombin receptor (PAR-1/4) blocker, is currently approved for post-myocardial infarction and peripheral artery disease indications on top of clopidogrel or/and aspirin." | 3.83 | Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial. ( Bekbossynova, M; Cattaneo, M; Golukhova, E; Kim, MH; Marciniak, TA; Pya, Y; Serebruany, VL, 2016) |
| "New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits." | 3.83 | Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| " However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin." | 3.81 | Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report. ( Chyrchel, B; Chyrchel, M; Kołton-Wróż, M; Kruszelnicka, O; Mielecki, W; Surdacki, A; Totoń-Żurańska, J; Wołkow, P, 2015) |
| "Dual antiplatelet therapy with clopidogrel and aspirin is the current standard of care in the management of patients with coronary artery disease (CAD) and acute coronary syndrome (ACS)." | 3.81 | Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( Arya, V; Bhargava, M; Mahajan, P; Mohanty, A; Saraf, A; Sawhney, JP, 2015) |
| "The aim of this analysis was to determine the effect of prolonging clopidogrel therapy >12 months versus ≤12 months after PCI on very late outcomes in patients with diabetes mellitus (DM)." | 3.81 | Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. ( Agrawal, K; Cho, K; Dufour, AB; Faxon, DP; Gagnon, DR; Gaziano, JM; Kinlay, S; Ly, S; Prince, L; Smoot, KJ; Sokolovskaya, G; Temiyasathit, S; Thukkani, AK, 2015) |
| "This study aimed to analyze the impact of body mass index (BMI) and the metabolic syndrome (MS) on responses to clopidogrel or prasugrel and bleeding risk after acute coronary syndrome." | 3.80 | Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. ( Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V, 2014) |
| " Clopidrogel and aspirin are antiplatelet agents widely used in the treatment of peripheral vascular, cerebrovascular, and coronary artery disease." | 3.80 | Spontaneous chest wall hematoma with dual antiplatelet therapy. ( Bevan, P; Bunton, R; Menon, A, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "We studied the association of thrombin generation potential with platelet protease activated receptor (PAR)-1 regulation and platelet activation in 52 stable coronary artery disease patients on continuous therapy with aspirin and clopidogrel (n = 42) or prasugrel (n = 10)." | 3.80 | Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. ( Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F, 2014) |
| "We recruited 50 volunteers from the Oglala Sioux Tribe with coronary artery disease taking aspirin and clopidogrel." | 3.80 | Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. ( Best, LG; Dobesh, PP; Oestreich, JH, 2014) |
| "Increased incidence of coronary artery disease has led to the increased use of dual antiplatelet therapy composed of aspirin and clopidogrel." | 3.80 | [Clinical impact of dual antiplatelet therapy on peptic ulcer disease]. ( Ahn, DG; Kim, BJ; Kim, JG; Kim, JW, 2014) |
| "Patients (DM, n = 30; non-DM, n = 30) with stable coronary artery disease taking aspirin 81 mg/day and P2Y12 antagonist naive were enrolled." | 3.80 | Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Jakubowski, JA; Moser, BA; Rollini, F; Sugidachi, A; Tello-Montoliu, A; Ueno, M, 2014) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| "Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients." | 3.80 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. ( Hunnangkul, S; Kamkaew, R; Likidlilid, A; Poldee, S; Suktitipat, B; Tassaneetrithep, B; Tresukosol, D, 2014) |
| "Patients on aspirin therapy for 1 week or longer with known or suspected coronary artery disease undergoing nonurgent cardiac catheterization (n=1172), of whom 924 were on aspirin and clopidogrel therapy, were studied." | 3.80 | Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. ( Bliden, KP; Franzese, C; Gurbel, PA; Jeong, YH; Kang, K; Lev, EI; Pandya, S; Tantry, US, 2014) |
| "A total of 2141 patients with coronary artery disease treated exclusively with Cypher sirolimus-eluting stents (SES) or Endeavor zotarolimus-eluting stents (ZES) were considered for retrospective analysis." | 3.79 | Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents. ( Chen, F; Gao, Y; He, J; Luo, Y; Lv, S; Ren, X; Wu, C; Yu, X; Zhang, X; Zhang, Y, 2013) |
| "The aim of this study was to evaluate the association of PON1 genetic variants with the susceptibility to coronary artery disease (CAD) and with the clinical endpoints in aspirin and clopidogrel (dual antiplatelet therapy)-treated Han Chinese patients with CAD after percutaneous coronary intervention (PCI)." | 3.79 | Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. ( Chen, JY; Kang, YH; Lai, WH; Lao, HY; Li, XX; Wu, H; Yu, XY; Zhong, SL, 2013) |
| " To assess the efficacy and safety of aspirin desensitisation in Chinese patients with coronary artery disease." | 3.79 | Aspirin desensitisation for Chinese patients with coronary artery disease. ( Chan, HL; Chan, KK; Chau, CH; Cheung, CY; Cheung, GS; Choi, MC; Lee, JK; Li, SK; Tsui, KL; Wu, KL, 2013) |
| "The prospective study comprised 152 patients with coronary artery disease (CAD) on the therapy of clopidogrel." | 3.79 | [Clopidogrel resistance of patients with coronary artery disease and its correlation with platelet count and mean platelet volume]. ( Gao, W; Han, JL; Li, HY; Li, L; Qiao, R; Yu, HY; Zhang, J, 2013) |
| "Our study confirms that initial clinical presentation, especially ACS, is a strong predictor of clopidogrel low response; this suggests that the evolution of coronary artery disease for one patient influences the clopidogrel response over time." | 3.79 | Impact of initial clinical presentation on clopidogrel low response. ( Bauters, A; Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Landel, JB; Lemesle, G; Sudre, A; Susen, S, 2013) |
| "This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy." | 3.79 | Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013) |
| "Cytochrome P450 (CYP) 2C19 plays a key role in clopidogrel activation and thus impacts the clinical outcome of patients with coronary artery disease (CAD)." | 3.79 | The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease. ( Chai, H; Chen, M; Huang, DJ; Li, Q; Liu, W; Liu, XJ; Luo, XL; Peng, Y; Ren, X; Wang, XQ; Zhang, C; Zhao, ZG, 2013) |
| "To characterize the clinical presentation of a cohort of patients with coronary artery disease (CAD) and aspirin reactions." | 3.79 | Characterization of aspirin allergies in patients with coronary artery disease. ( Feng, CH; Stevenson, DD; White, AA, 2013) |
| "A 73-year-old woman was admitted to our hospital with anterior acute myocardial infarction due to subacute thrombosis after coronary stenting with a zotarolimus-eluting stent (ZES), which is a newly developed drug-eluting stent that has been widely used since May 2009 in Japan." | 3.78 | A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. ( Arima, M; Matsuda, A; Nitta, M; Shimizu, M; Yoshida, K, 2012) |
| "Clopidogrel use after drug-eluting stent (DES) coronary artery implantation is essential for the prevention of early in-stent thrombosis, but clopidogrel use among older DES recipients has not been widely studied." | 3.78 | Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent. ( Malenka, DJ; Morden, NE; Roth, GA; Skinner, J; Zhou, W, 2012) |
| " Phenotyping of platelet response to clopidogrel was a better predictor of stent thrombosis than genotyping." | 3.78 | Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. ( Delle-Karth, G; Grzybowski, T; Huber, K; Jilma, B; Kozinski, M; Kubica, J; Lang, IM; Linkowska, K; Maurer, G; Neunteufl, T; Siller-Matula, JM, 2012) |
| " We applied these new methods in examining the effect of an anti-platelet agent, clopidogrel, on subsequent events, including bleeding, myocardial infarction, and death after a drug-eluting stent was implanted into a coronary artery." | 3.78 | Extension of Kaplan-Meier methods in observational studies with time-varying treatment. ( Ho, PM; Magid, D; Powers, D; Raebel, MA; Shetterly, S; Tsai, TT; Xu, S, 2012) |
| "Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel." | 3.78 | Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. ( Ahrens, I; Bode, C; Brandt, C; Duerschmied, D; Mauler, M; Moser, M; Weidner, S, 2012) |
| "To compare the effects of clopidogrel combined with dihydropyridine calcium-channel blockers (CCBs) or non-dihydropyridine CCBs on coronary artery disease (CAD) in elderly patients." | 3.78 | [Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study]. ( Cao, J; Fan, L; Gao, Y; Liu, X; Lu, X; Ma, C, 2012) |
| "To compare the effects of clopidogrel with or without combined with CYP3A4-metabolized statin in treating coronary artery disease (CAD) among the elderly patients." | 3.78 | [Comparison on the effects of clopidogrel, statins combination in treating coronary artery disease among the elderly patients: a retrospective cohort study]. ( Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Ma, C, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "To assess the impact of cytochrome P450 (CYP) 2C19*17 allelic variant on platelet aggregation and bleeding risk in Chinese patients with blood stasis syndrome undergoing percutaneous coronary intervention (PCI) and treated with clopidogrel." | 3.78 | Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. ( Chen, H; Dai, ZL; Wu, XY, 2012) |
| " An objective causality assessment suggested that the liver hematoma was possibly related to the combination of clopidogrel and aspirin." | 3.78 | Dual antiplatelet agent-induced spontaneous liver hematoma. ( Darwish, OS; Iqbal, E, 2012) |
| "In this blinded, 3-period, crossover study in stable patients with coronary artery disease (CAD) taking aspirin, prasugrel 5 and 10 mg and clopidogrel 75 mg were administered to LBW (56." | 3.78 | Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. ( Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C, 2012) |
| "Among patients receiving clopidogrel for coronary artery disease, concomitant therapy with proton pump inhibitors (PPIs) has been associated with an increased risk for recurrent coronary events." | 3.77 | Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. ( Escudero, D; Monreal, M; Muñoz-Torrero, JF; Pascual, MT; Sanclemente, C; Suárez, C; Trujillo-Santos, J; Zamorano, J, 2011) |
| "Clopidogrel should be initiated as soon as possible in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) except those who urgently require coronary artery bypass grafting (CABG)." | 3.77 | An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. ( Ebina, T; Endo, M; Hibi, K; Ishikawa, T; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Okada, K; Umemura, S, 2011) |
| "Light transmission aggregation (LTA) is considered the reference method to identify residual platelet reactivity (RPR) in high-risk patients with coronary artery disease on clopidogrel treatment." | 3.77 | Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study. ( Abbate, R; Antonucci, E; Gori, AM; Maggini, N; Marcucci, R; Miranda, M; Paniccia, R; Prisco, D; Romano, E, 2011) |
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 3.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| " We determined the association of CYP2C19 loss-of-function (*2) and gain-of-function (*17) allele status with platelet reactivity in 118 stented patients on DAPT ≥2 weeks and in 143 patients with stable coronary artery disease on aspirin therapy alone." | 3.77 | The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. ( Bliden, KP; Gurbel, PA; Pakyz, RE; Ryan, K; Shuldiner, AR; Tantry, US, 2011) |
| "An increasing number of patients suffering from cardiovascular disease, especially coronary artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major adverse events." | 3.77 | Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on ( Cattaneo, M; Chassot, PG; Eichinger, S; Hofmann, N; Huber, K; Korte, W; Rickli, H; Spannagl, M; Verheugt, F; von Heymann, C; Ziegler, B, 2011) |
| "This study demonstrates that high on treatment platelet reactivity with aspirin and/or clopidogrel is common amongst patients who develop stent thrombosis." | 3.77 | High on treatment platelet reactivity and stent thrombosis. ( French, JK; Juergens, CP; Parikh, D; Rajendran, S; Shugman, I, 2011) |
| "We enrolled 202 consecutive patients with stable coronary artery disease (CAD) undergoing PCI and treated with clopidogrel." | 3.77 | Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. ( Abe, T; Deguchi, M; Hokimoto, S; Horio, E; Iwashita, S; Kaikita, K; Miyazaki, Y; Nakagawa, K; Nakamura, S; Ogawa, H; Ono, T; Sato, K; Sugiyama, S; Sumida, H; Tayama, S; Tsujita, K; Yamabe, H; Yamamoto, K, 2011) |
| "This case-control study identified 3 genes (CYP2C19, ABCB1, and ITGB3) and 2 clopidogrel-related factors (loading dose and proton pump inhibitors) that were independently associated with early stent thrombosis." | 3.77 | Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. ( Allanic, F; Barthélémy, O; Beygui, F; Cayla, G; Collet, JP; de la Briolle, A; Gruel, Y; Huerre, Y; Hulot, JS; Montalescot, G; O'Connor, SA; Pathak, A; Scott, SA; Silvain, J; Vignalou, JB, 2011) |
| "Increased baseline platelet reactivity as well as diabetes mellitus and acute coronary syndrome are associated with low aspirin response in the aged patients." | 3.77 | [Aspirin response and related factors in aged patients]. ( Fan, Y; Feng, XR; Liu, F; Liu, ML; Liu, QZ; Tian, QP, 2011) |
| "To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel." | 3.76 | Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. ( Atar, D; Donovan, JL; Goto, S; Kannan, AO; Makarov, L; Rao, SV; Serebruany, V; Silva, MA, 2010) |
| "Platelet hyperreactivity in MEA might be a better risk predictor for stent thrombosis than the assessment of the specific clopidogrel effect with the VASP phosphorylation assay." | 3.76 | Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. ( Christ, G; Delle-Karth, G; Huber, K; Jilma, B; Lang, IM; Siller-Matula, JM, 2010) |
| "The aim of the present study was to assess the impact of clopidogrel responsiveness on the risk of bleeding in clopidogrel-treated patients undergoing PCI." | 3.76 | Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Schulz, S; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding." | 3.76 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010) |
| "We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy." | 3.76 | Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010) |
| "We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)." | 3.76 | Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010) |
| " The study was performed in healthy subjects, patients with coronary artery disease, patients with end-stage renal disease, and patients with acute coronary syndrome after treatment with prasugrel or clopidogrel." | 3.76 | A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. ( Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ, 2010) |
| "To report a case of metastatic leiomyosarcoma, in which a patient developed chest pain accompanied by acute left bundle-branch block (LBBB) after gemcitabine infusion." | 3.75 | Gemcitabine-induced acute coronary syndrome: a case report. ( Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozdemir, M; Ozturk, B; Sahin, G; Tacoy, G; Topal, S; Yaman, E; Yildiz, R, 2009) |
| "One hundred and sixty-one coronary artery disease patients taking aspirin alone and 91 patients taking a combination of aspirin and clopidogrel were enrolled." | 3.75 | Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry. ( Diodati, JG; Lordkipanidzé, M; Palisaitis, DA; Pharand, C; Schampaert, E, 2009) |
| "The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST)." | 3.75 | Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. ( Braun, S; Kastrati, A; Mehilli, J; Morath, T; Schömig, A; Sibbing, D; Vogt, W; von Beckerath, N, 2009) |
| " As compared with the conventional 300-mg dose, pretreatment with a 600-mg loading dose of clopidogrel significantly reduced periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI)." | 3.75 | Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg). ( Byun, KH; Cho, JR; Choi, S; Jung, JH; Lee, N; Lee, SH; Min, PK; Sung, CW, 2009) |
| "In patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), identification of left main and/or 3-vessel disease (LM/3VD) is crucial for deciding whether to initiate early treatment with clopidogrel, which can increase the risk of surgical bleeding." | 3.75 | Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. ( Ebina, T; Hashiba, K; Hibi, K; Kimura, K; Kiyokuni, M; Komura, N; Kosuge, M; Morita, S; Nakayama, N; Umemura, S, 2009) |
| "This study sought to investigate the incidence of stent thrombosis (ST) in patients treated with drug-eluting stents (DES) and clearly defined short-term dual antiplatelet therapy (DAT) for three or six months for sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES), respectively." | 3.75 | Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. ( Hartenthaler, B; Hofmann, R; Hönig, S; Kammler, J; Kerschner, K; Kypta, A; Lambert, T; Leisch, F; Steinwender, C, 2009) |
| "We sought to correlate the inhibition of platelet aggregation (IPA) with plasma levels of unchanged clopidogrel (UC), active thiol metabolite (ATM), and inactive carboxyl metabolite (ICM) in a large cohort of patients with coronary artery disease and ischemic stroke treated with clopidogrel." | 3.75 | Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance". ( Atar, D; Booze, C; Cherala, G; Kuliczkowski, W; Serebruany, V; Surigin, S; Williams, C, 2009) |
| "Common variation in the P2RY12 gene is a significant determinant of the interindividual variability in residual on-clopidogrel platelet reactivity in patients with coronary artery disease." | 3.75 | Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. ( Bouman, HJ; de Maat, MP; Hackeng, CM; Kruit, A; Leebeek, FW; Rudez, G; Ruven, HJ; ten Berg, JM; van Werkum, JW, 2009) |
| "Clopidogrel as a sole anti-platelet treatment after coronary stenting resulted in a relatively high percentage of subacute stent thrombosis." | 3.75 | Coronary artery stenting in patients treated by clopidogrel without aspirin. ( Amit, G; Leibowitz, D; Rott, D; Weiss, AT; Zahger, D, 2009) |
| "The purpose of this study was to evaluate the risk of stent thrombosis (ST), clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent (DES) implantation." | 3.74 | Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. ( Cheong, SS; Hong, MK; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, DW; Park, SJ; Park, SW; Yun, SC, 2008) |
| "To assess the association between clopidogrel use and long-term clinical outcomes of patients receiving drug-eluting stents (DES) and bare-metal stents (BMS) for treatment of coronary artery disease." | 3.74 | Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. ( Anstrom, KJ; Califf, RM; Eisenstein, EL; Harrington, RA; Kandzari, DE; Kong, DF; Kramer, JM; Mark, DB; Matchar, DB; Peterson, ED; Schulman, KA; Shaw, LK; Tuttle, RH, 2007) |
| "Secondary post hoc analysis of an existing dataset consisting of 711 patients after coronary stenting (n = 601) and ischemic stroke (n = 110) treated previously with aspirin for at least 1 month, and then with aspirin + clopidogrel for at least 7 days was performed." | 3.74 | Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients. ( Atar, D; Malinin, AI; Serebruany, VL, 2007) |
| " We examined 66 healthy control individuals, 144 aspirin users with stable coronary artery disease (CAD), and 245 CAD patients treated with aspirin and clopidogrel." | 3.74 | Determination of aspirin responsiveness by use of whole blood platelet aggregometry. ( Giannitsis, E; Hohlfeld, T; Ivandic, BT; Katus, HA; Schlick, P; Staritz, P, 2007) |
| "Recent studies have suggested that low-dose aspirin has preserved benefit with less bleeding compared with standard-dose aspirin when given with or without clopidogrel in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACSs)." | 3.74 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. ( Cannon, CP; Gibler, WB; Milford-Beland, S; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Tickoo, S, 2007) |
| "Platelet function analyses, which included measures of platelet aggregation and activation, were performed in 173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel." | 3.74 | Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. ( Alfonso, F; Angiolillo, DJ; Bañuelos, C; Bass, TA; Bernardo, E; Costa, MA; Escaned, J; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Jimenez-Quevedo, P; Macaya, C; Moreno, R; Palazuelos, J; Sabaté, M, 2007) |
| " Therefore, we investigated the effects of these polymorphisms on platelet aggregation in aspirin-treated patients with coronary artery disease (CAD)." | 3.74 | P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease. ( Bierend, A; Böger, RH; Maas, R; Rau, T; Schwedhelm, E, 2008) |
| "In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days." | 3.74 | Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008) |
| "Thrombotic events still occur in aspirin-treated patients with coronary artery disease." | 3.73 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "Dabigatran is a direct acting (anti-II) oral anticoagulant which does not interfere with CYP and has favourable safety and efficacy profiles compared with VKAs." | 2.82 | Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. ( Ajjan, RA; Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Franchi, F; Guzman, LA; King, R; Phoenix, F; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2016) |
| " Pharmacodynamic assessments were conducted using three assays (vasodilator-stimulated phosphoprotein, VerifyNow P2Y12, and light transmittance aggregometry, LTA) at baseline, 30 min, 2, 24 h, and 1 week." | 2.82 | A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. ( Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Singh, K; Wilson, RE; Zenni, MM, 2016) |
| "Ticagrelor has been shown to have antiplatelet effects superior to those of clopidogrel, with subsequent reduced clinical ischemic events." | 2.82 | Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). ( Arbel, Y; Lev, EI; Mosseri, M; Musallam, A; Orvin, K; Perl, L; Roguin, A, 2016) |
| " Platelet activation markers were measured by flow cytometry on unstimulated or stimulated (adenosine diphosphate (ADP) 20 μM) platelets, before and after each dosing period." | 2.82 | Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. ( Borna, C; Brown, P; Erlinge, D; Gidlöf, O; Jakubowski, JA; Lood, C; Truedsson, L; Wagner, H; Winters, K; Zhou, C, 2016) |
| "The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known." | 2.80 | A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. ( Angiolillo, DJ; Caplan, R; Carlson, G; Clavijo, L; Maya, J; Price, MJ; Teng, R, 2015) |
| " We sought to evaluate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and the pharmacokinetic profile of ticagrelor and its metabolite AR-C124910XX, in black patients with stable CAD taking low-dose aspirin (acetylsalicylic acid)." | 2.80 | Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. ( Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R, 2015) |
| " However, the effects of EV-077 on pharmacodynamic (PD) profiles in patients with DM and coronary artery disease (CAD) while on antiplatelet therapy is poorly explored and represented the aim of this in vitro pilot investigation." | 2.79 | Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. ( Angiolillo, DJ; Bender, N; Darlington, A; Desai, B; Franchi, F; Muñiz-Lozano, A; Patel, R; Rollini, F; Sakariassen, KS; Tello-Montoliu, A; Wilson, RE, 2014) |
| " We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel." | 2.79 | Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. ( Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014) |
| " At the end of the dosing interval on day 28, mean final-extent IPA was 10." | 2.79 | Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. ( Emanuelsson, H; Hiasa, Y; Teng, R, 2014) |
| " Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and clopidogrel 75-mg using data from two PK/PD studies in stable coronary artery disease (CAD) patients (GENERATIONS and FEATHER)." | 2.79 | The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. ( Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ, 2014) |
| " Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation." | 2.79 | Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014) |
| "Aspirin was used in 94." | 2.78 | Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. ( Ardati, AK; Aronow, HD; Chetcuti, S; Grossman, PM; Gurm, HS; Moscucci, M; Pitt, B; Share, D; Smith, DE, 2013) |
| " The prevalence of adverse events was assessed at each visit through a direct interview." | 2.78 | Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial. ( Choi, DJ; Kang, HJ; Kim, HS; Kim, MA; Koo, BK; Lee, HY; Lee, S; Oh, BH; Park, KW, 2013) |
| " In the ONSET-OFFSET study (parallel group trial) and the RESPOND study (crossover trial), the pharmacodynamic effects of ticagrelor were compared with clopidogrel in patients with coronary artery disease (CAD)." | 2.77 | Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ( Bliden, K; Butler, K; Gurbel, PA; Husted, SE; Høimark, L; Storey, RF; Tantry, US; Teng, R; Wei, C, 2012) |
| "Cangrelor is an intravenous, potent, and reversible P2Y(12) inhibitor with fast onset and offset of action." | 2.77 | Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. ( Bhatt, DL; Dietrich, M; Gallup, D; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Liu, T; Mahaffey, KW; Price, MJ; Skerjanec, S; Steg, GW; Stone, GW; Todd, M; White, HD, 2012) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 2.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| " (2) Clopidogrel may be under dosed in obese patients." | 2.75 | Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010) |
| "Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y(12) inhibitor available in both intravenous and oral formulations." | 2.75 | Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous ( Bhatt, DL; Gibson, CM; Gretler, DD; Harrington, RA; Huber, K; Kochman, J; Leonardi, S; Madan, M; McClure, MW; Paynter, GE; Rao, SV; Roe, MT; Thompson, V; Welsh, RC; Zeymer, U, 2010) |
| " This study evaluated the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective PCI in a randomized, prospective, double-blind, and placebo-controlled design." | 2.74 | Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial. ( Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E; Turgeon, J, 2009) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| " A total of 119 patients undergoing PCI were blindly randomized in 2:1 fashion to receive clopidogrel loading 600 mg on the table immediately before PCI and 75 mg 2 times/day for 1 month (high-dose group) versus standard dosing (300 mg loading and 75 mg/day; low-dose group)." | 2.73 | Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents. ( Abuzahra, M; Bobek, J; Caldera, A; Dokainish, H; Gonzalez, R; Hartley, WB; Lakkis, N; Pillai, M, 2008) |
| " Decision to increase clopidogrel dosage may vary on the basis of the assay used, thus highlighting the need for unambiguous guidelines with respect to assay selection, as platelet function assays are not interchangeable." | 2.73 | Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. ( Diodati, JG; Lordkipanidzé, M; Nguyen, TA; Palisaitis, DA; Pharand, C; Schampaert, E, 2008) |
| " Whether platelet inhibition can be enhanced by increasing clopidogrel maintenance dosage in T2DM patients is unknown." | 2.73 | Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. ( Angiolillo, DJ; Bass, TA; Bernardo, E; Charlton, RK; Costa, MA; Desai, B; Guzman, LA; Shoemaker, SB; Yuan, H; Zenni, MM, 2007) |
| " The dose-dependent effect was confirmed by the absolute and relative increase in platelet aggregation after resuming standard dosing (p < 0." | 2.73 | Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Desai, B; Fernandez-Ortiz, A; Guzman, LA; Hernández-Antolin, R; Macaya, C; Palazuelos, J; Weisberg, I; Zenni, MZ, 2008) |
| " We tested the hypothesis that the intestinal efflux transporter P-glycoprotein (P-gp) limits the oral bioavailability of clopidogrel and that variance in the MDR1 gene encoding P-gp predicts absorption variability." | 2.72 | Impact of P-glycoprotein on clopidogrel absorption. ( Goeser, T; Grimberg, G; Jung, N; Kastrati, A; Lazar, A; Schömig, A; Schömig, E; Taubert, D; von Beckerath, N, 2006) |
| "Sarpogrelate treatment reduces restenosis after coronary stenting, which suggests that serotonin released from activated platelets may play an important role in stent restenosis." | 2.71 | Sarpogrelate treatment reduces restenosis after coronary stenting. ( Fujita, M; Ho, M; Ishii, K; Miki, O; Miwa, K; Miyamoto, A; Mizuno, K; Tsukahara, R, 2003) |
| "Probucol is a lipid-lowering drug that has an antioxidant effect." | 2.70 | Effect of antioxidant probucol for preventing stent restenosis. ( Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002) |
| "5 mg/kg intravenous (IV), and eptifibatide using the ESPIRIT dosing (180 g/kg bolus IV, immediately followed by a 2 g/kg/minute continuous IV infusion, and then a second 180 g/kg bolus IV ten minutes after the first bolus)." | 2.70 | Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. ( Bertolet, BD; Gupta, A; Miller, L, 2002) |
| "Ticlopidine therapy was discontinued in 1." | 2.68 | Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. ( Bauters, C; Bedossa, M; Bertrand, ME; Bonnet, JL; Danchin, N; Grollier, G; Lablanche, JM; Leclercq, C; McFadden, EP; Vahanian, A; Van Belle, E, 1996) |
| "Treatment with aspirin and new P2Y12 receptor blockers has further reduced the rate of cardiovascular death, myocardial infarction or stroke after ACS compared with aspirin and clopidogrel." | 2.52 | Dual antiplatelet therapy for coronary artery disease. ( Lee, CW, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| " There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0." | 2.48 | The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012) |
| " Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)." | 2.48 | Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. ( Angiolillo, DJ; Ferreiro, JL, 2012) |
| " This article provides an overview on antiplatelet drug response variability, an update on definitions, including the role of pharmacodynamic testing, underlying mechanisms - with emphasis on recent understandings on pharmacogenetics and drug-drug interactions - and current and future perspectives on individualized antiplatelet therapy." | 2.47 | Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. ( Angiolillo, DJ; Tello-Montoliu, A; Ueno, M, 2011) |
| " This article provides an overview of ADP P2Y₁₂ receptor-inhibiting strategies, including high clopidogrel dosing regimens and novel agents under advanced clinical development." | 2.46 | Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development. ( Angiolillo, DJ; Vivas, D, 2010) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Clopidogrel is an established alternative to ticlopidine in addition to aspirin after coronary stenting because of its safety, but its optimal initial dosing is unclear." | 2.44 | Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. ( Abbate, A; Agostoni, P; Biondi-Zoccai, GG; Lotrionte, M; Moretti, C; Sangiorgi, G; Sheiban, I; Valgimigli, M, 2007) |
| "Ticlopidine was subsequently discontinued due to severe diarrhea." | 2.44 | Clopidogrel desensitization: case report and review of published protocols. ( Garner, J; Hergott, L; Owen, P; Page, RL, 2008) |
| "Clopidogrel pretreatment before PCI is beneficial and safe regardless of whether a GPI is used at the time of PCI." | 2.44 | Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. ( Cannon, CP; Fox, KA; Hamdalla, HN; Mehta, SR; Sabatine, MS; Steinhubl, SR; Topol, EJ, 2008) |
| "Aspirin has been studied and used most extensively." | 2.42 | Role of antiplatelet drugs in the prevention of cardiovascular events. ( Tendera, M; Wojakowski, W, 2003) |
| "Setting Department for the Treatment of Acute Coronary Syndrome in tertiary teaching hospital, Serbia." | 1.48 | The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Marinkovic, V; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2018) |
| "Bleeding was the primary outcome." | 1.46 | Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017) |
| "The total thrombus-formation analysis system (T-TAS) was developed for quantitative analysis of platelet thrombus formation by the use of microchips with thrombogenic surfaces (collagen, platelet chip [PL-chip]; collagen plus tissue factor, atherome chip [AR-chip])." | 1.43 | Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. ( Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Kaikita, K; Kojima, S; Nakagawa, K; Ogawa, H; Oimatsu, Y; Sakamoto, K; Sueta, D; Tsujita, K, 2016) |
| "24." | 1.43 | Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy. ( Brodie, BR; Duffy, PL; Inaba, S; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Metzger, DC; Mintz, GS; Rinaldi, MJ; Shimizu, T; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Yun, KH, 2016) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "Aspirin is the key treatment in the secondary prevention of atherothrombosis." | 1.42 | Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. ( Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S, 2015) |
| "Aspirin resistance was detected in 22 (16." | 1.40 | Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( Akturk, IF; Caglar, FN; Caglar, IM; Erturk, M; Surgit, O; Tuncer, N; Uzun, F; Yalcın, AA, 2014) |
| "Patients with ESRD are at higher risk for coronary artery disease (CAD) and also their post-interventional outcome is worse compared to patients with normal renal function." | 1.40 | Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study. ( Bocksch, W; Fateh-Moghadam, S; Gawaz, M; Geisler, T; Htun, P; Kan, T; Mueller, E; Pohle, C; Schindler, R, 2014) |
| "Bleeding was assessed using the Bleeding Academic Research Consortium criteria." | 1.40 | Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. ( Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S, 2014) |
| "Aspirin PR was 3-33% and clopidogrel PR was 10-35% in visit-1." | 1.40 | Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. ( Barnard, J; Bhatt, DL; Kottke-Marchant, K; Murugesan, G; Timur, AA; Zhang, L, 2014) |
| "Hemodynamic significance of all coronary stenoses was assessed with Fractional Flow Reserve (FFR)." | 1.39 | The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease. ( de Groot, PG; Hillaert, MA; Pasterkamp, G; Pijls, NH; Roest, M; Rutten, B; Sels, JW; van Holten, TC; Waltenberger, J, 2013) |
| "Diabetes mellitus is an independent predictor of adverse clinical events after drug-eluting stent implantation." | 1.39 | Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. ( Chen, X; Han, Y; Jiang, T; Jing, Q; Li, Y; Liu, H; Ma, Y; Wang, G; Wang, S; Wang, X; Yan, G; Yang, L; Zhang, L; Zhu, G, 2013) |
| "Fibrinogen ≥345 mg/dl was significantly associated with both CK-MB-defined (p = 0." | 1.39 | Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. ( Ang, L; Ilapakurti, M; Lee, MS; Mahmud, E; Palakodeti, V; Thani, KB, 2013) |
| "Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions." | 1.38 | Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012) |
| " If cigarette smoking is associated with a dose-response effect on pharmacodynamic measures in clopidogrel-treated patients is unknown." | 1.38 | Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Charlton, RK; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2012) |
| "Omeprazole, a PPI, has been reported to weaken the antiplatelet effects of clopidogrel." | 1.38 | Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. ( Horiuchi, H; Ikeda, T; Imai, M; Jinnai, T; Kato, Y; Kimura, T; Makiyama, T; Shirakawa, R; Tada, T; Tazaki, J; Yamane, K, 2012) |
| " At 1-year follow-up, major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), acute coronary syndrome leading to hospitalization and nonfatal stroke, were recorded." | 1.37 | Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. ( Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O, 2011) |
| " The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement." | 1.37 | Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. ( Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D, 2011) |
| "Cardiogenic shock was present in 45%, and distal left main coronary artery disease was present in 71% of patients." | 1.37 | Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. ( El-Omar, M; Imola, F; Mamas, MA; Manzoli, A; Pappalardo, A; Prati, F; Ramazzotti, V, 2011) |
| "Coronary artery disease was associated with increased risk (OR=11." | 1.36 | Femoral artery complications after cardiac catheterization: a study of patient profile. ( Almaroof, B; Castillo-Sang, M; Cireddu, J; Engoren, M; Kasper, G; Sferra, J; Tsang, AW; Zelenock, GB, 2010) |
| " For pharmacokinetic analysis, blood was drawn at 0, 20, 40, 60, 90, 120, 180, 240 and 360 min after clopidogrel loading and peak plasma concentrations (C(max)) of the AMC were quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS)." | 1.36 | Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. ( Bouman, HJ; Breet, NJ; Hackeng, CM; Parlak, E; Taubert, D; ten Berg, JM; ten Cate, H; van Werkum, JW, 2010) |
| "Patients with more extensive coronary atherosclerosis have a higher rate of HPR, which might partly account for higher risk of periprocedural MI." | 1.36 | High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. ( Barbato, E; Bartunek, J; De Bruyne, B; Di Sciascio, G; Heyndrickx, G; Mangiacapra, F; Muller, O; Ntalianis, A; Trana, C; Wijns, W, 2010) |
| " Primary end point was the combined incidence of major adverse coronary events and major bleedings." | 1.36 | Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel. ( Di Sciascio, G; Irini, D; Pasceri, V; Patti, G; Pelliccia, F; Pristipino, C; Roncella, A; Speciale, G; Varveri, A, 2010) |
| "Nuisance bleeding is common in patients on prolonged DAPT post-DES implantation and can impact compliance." | 1.36 | Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. ( Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2010) |
| " Alternative dosing regimens might enhance platelet inhibition." | 1.36 | Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. ( Barker, CM; Kandzari, DE; Murray, SS; Price, MJ; Teirstein, PS; Topol, EJ, 2010) |
| "Aspirin resistance was defined as an ARU (aspirin reaction units) > or =550, and clopidogrel resistance was defined as platelet inhibition <20%." | 1.35 | Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. ( Han, K; Jeon, HK; Kim, H; Lee, HK, 2009) |
| " One hundred sixty-one patients on 100 mg of aspirin co-medication underwent elective coronary stenting and were given an initial dosage of 600 mg clopidogrel, followed by 75 mg clopidogrel daily." | 1.35 | How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. ( Engelhardt, A; Lask, S; Mügge, A; Neubauer, H, 2008) |
| "Most patients with PAD die of either heart attacks or strokes and they die of the former conditions far earlier than controls." | 1.32 | [Antiplatelet therapy in patients with peripheral arterial disease (PAD)]. ( Diehm, C; Huber, R; Lawall, H, 2004) |
| " No periprocedural major adverse cardiac events (death, Q wave infarction, urgent revascularisation) were observed." | 1.31 | [The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization]. ( Bartuś, S; Dubiel, JS; Dudek, D; Zymek, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (0.79) | 18.2507 |
| 2000's | 288 (32.69) | 29.6817 |
| 2010's | 573 (65.04) | 24.3611 |
| 2020's | 13 (1.48) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, YL | 1 |
| Hu, XL | 2 |
| Song, PY | 2 |
| Li, H | 4 |
| Li, MP | 2 |
| Du, YX | 1 |
| Li, MY | 1 |
| Ma, QL | 2 |
| Peng, LM | 2 |
| Song, MY | 1 |
| Chen, XP | 2 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 1 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 1 |
| Rodríguez-González, F | 1 |
| Tugores, A | 1 |
| Barry, HC | 1 |
| Viscusi, MM | 1 |
| Mangiacapra, F | 8 |
| Circhetta, S | 1 |
| Paolucci, L | 1 |
| De Luca, R | 1 |
| Nusca, A | 1 |
| Melfi, R | 1 |
| Ricottini, E | 4 |
| Ussia, GP | 2 |
| Grigioni, F | 1 |
| Redfors, B | 2 |
| Kirtane, AJ | 8 |
| Liu, M | 2 |
| Musikantow, DR | 1 |
| Witzenbichler, B | 9 |
| Rinaldi, MJ | 7 |
| Metzger, DC | 6 |
| Weisz, G | 8 |
| Stuckey, TD | 7 |
| Brodie, BR | 6 |
| Ben-Yehuda, O | 5 |
| Mehran, R | 9 |
| Stone, GW | 18 |
| Lee, YJ | 1 |
| Cho, JY | 1 |
| Yun, KH | 2 |
| Lee, SJ | 2 |
| Hong, SJ | 1 |
| Ahn, CM | 1 |
| Kim, BK | 3 |
| Ko, YG | 3 |
| Choi, D | 3 |
| Hong, MK | 8 |
| Jang, Y | 6 |
| Kim, JS | 4 |
| Komiyama, M | 1 |
| Agewall, S | 1 |
| Hasegawa, K | 1 |
| Seecheran, NA | 1 |
| Sukha, D | 1 |
| Grimaldos, K | 1 |
| Grimaldos, G | 1 |
| Richard, S | 1 |
| Ishmael, A | 1 |
| Gomes, C | 1 |
| Kampradi, L | 1 |
| Seecheran, R | 1 |
| Seecheran, V | 1 |
| Peram, L | 1 |
| Dookeeram, D | 1 |
| Giddings, S | 1 |
| Sandy, S | 1 |
| Ramlackhansingh, A | 1 |
| Raza, S | 1 |
| Umaharan, P | 1 |
| Tello-Montoliu, A | 15 |
| Schneider, D | 1 |
| Zhao, Z | 1 |
| Ma, M | 1 |
| Huang, X | 1 |
| Sun, T | 1 |
| Han, K | 2 |
| Yang, S | 1 |
| Zhou, Y | 2 |
| Hu, X | 1 |
| Li, M | 3 |
| Song, P | 1 |
| Zhang, Y | 3 |
| Zhou, G | 1 |
| Tang, J | 1 |
| Peng, L | 1 |
| Ma, Q | 1 |
| Chen, X | 5 |
| Bates, ER | 1 |
| Doukas, D | 1 |
| Schimmer, H | 1 |
| Zehtabchi, S | 1 |
| Marcano, AL | 1 |
| Lugo, LM | 1 |
| Besteiro, A | 1 |
| Gomez-Lara, J | 1 |
| Roura, G | 1 |
| Fuentes, L | 1 |
| Gracida, M | 1 |
| Teruel, L | 1 |
| Romaguera, R | 1 |
| Sosa, SG | 1 |
| Cequier, Á | 2 |
| Gómez-Hospital, JA | 2 |
| Comin-Colet, J | 1 |
| Ferreiro, JL | 12 |
| Biswas, M | 1 |
| Rahaman, S | 1 |
| Biswas, TK | 1 |
| Ibrahim, B | 4 |
| Saito, Y | 1 |
| Nishi, T | 2 |
| Wakabayashi, S | 2 |
| Ohno, Y | 1 |
| Kitahara, H | 5 |
| Ariyoshi, N | 2 |
| Kobayashi, Y | 6 |
| Campo, G | 3 |
| Vieceli Dalla Sega, F | 1 |
| Pavasini, R | 1 |
| Aquila, G | 1 |
| Gallo, F | 1 |
| Fortini, F | 1 |
| Tonet, E | 1 |
| Cimaglia, P | 1 |
| Del Franco, A | 1 |
| Pestelli, G | 1 |
| Pecoraro, A | 1 |
| Contoli, M | 1 |
| Balla, C | 1 |
| Biscaglia, S | 1 |
| Rizzo, P | 1 |
| Ferrari, R | 2 |
| Rubboli, A | 1 |
| Saia, F | 1 |
| Sciahbasi, A | 1 |
| Leone, AM | 1 |
| Palmieri, C | 1 |
| Bacchi-Reggiani, ML | 1 |
| Calabrò, P | 2 |
| Bordoni, B | 1 |
| Piccalò, G | 1 |
| Franco, N | 1 |
| Nicolino, A | 1 |
| Magnavacchi, P | 1 |
| Vignali, L | 1 |
| Mameli, S | 1 |
| Dallago, M | 1 |
| Maggiolini, S | 1 |
| Steffanon, L | 1 |
| Piovaccari, G | 1 |
| Di Pasquale, G | 1 |
| Zhai, Y | 1 |
| He, H | 1 |
| Ma, X | 2 |
| Xie, J | 1 |
| Meng, T | 1 |
| Dong, Y | 1 |
| Lu, J | 2 |
| Bömicke, T | 2 |
| Valina, CM | 4 |
| Stratz, C | 4 |
| Amann, M | 2 |
| Neumann, FJ | 15 |
| Hochholzer, W | 7 |
| Benedetto, U | 2 |
| Altman, DG | 1 |
| Gerry, S | 1 |
| Gray, A | 1 |
| Lees, B | 1 |
| Flather, M | 4 |
| Taggart, DP | 1 |
| Verdoia, M | 9 |
| Daffara, V | 2 |
| Pergolini, P | 7 |
| Rolla, R | 7 |
| Marino, P | 7 |
| Bellomo, G | 7 |
| Carriero, A | 1 |
| De Luca, G | 11 |
| Oimatsu, Y | 2 |
| Kaikita, K | 7 |
| Ishii, M | 2 |
| Mitsuse, T | 1 |
| Ito, M | 3 |
| Arima, Y | 4 |
| Sueta, D | 2 |
| Takahashi, A | 1 |
| Iwashita, S | 5 |
| Yamamoto, E | 1 |
| Kojima, S | 2 |
| Hokimoto, S | 7 |
| Tsujita, K | 3 |
| Secemsky, EA | 1 |
| Yeh, RW | 3 |
| Kereiakes, DJ | 9 |
| Cutlip, DE | 1 |
| Steg, PG | 11 |
| Massaro, JM | 1 |
| Apruzzese, PK | 1 |
| Mauri, L | 3 |
| Pareek, M | 1 |
| Bhatt, DL | 20 |
| Ten Berg, JM | 13 |
| Kristensen, SD | 3 |
| Grove, EL | 1 |
| Cerrato, E | 1 |
| Quirós, A | 1 |
| Echavarría-Pinto, M | 1 |
| Mejia-Renteria, H | 1 |
| Aldazabal, A | 1 |
| Ryan, N | 1 |
| Gonzalo, N | 1 |
| Jimenez-Quevedo, P | 5 |
| Nombela-Franco, L | 1 |
| Salinas, P | 1 |
| Núñez-Gil, IJ | 1 |
| Rumoroso, JR | 2 |
| Fernández-Ortiz, A | 9 |
| Macaya, C | 8 |
| Escaned, J | 6 |
| Choi, HI | 1 |
| Ahn, JM | 5 |
| Kang, SH | 3 |
| Lee, PH | 1 |
| Kang, SJ | 6 |
| Lee, SW | 12 |
| Kim, YH | 9 |
| Lee, CW | 10 |
| Park, SW | 9 |
| Park, DW | 9 |
| Park, SJ | 10 |
| Kern, A | 1 |
| Gil, RJ | 2 |
| Bojko, K | 1 |
| Sienkiewicz, E | 1 |
| Januszko-Giergielewicz, B | 1 |
| Górny, J | 1 |
| Bil, J | 1 |
| Li, Q | 3 |
| Yu, X | 2 |
| He, J | 3 |
| Gao, Y | 4 |
| Zhang, X | 4 |
| Wu, C | 2 |
| Luo, Y | 3 |
| Ren, X | 3 |
| Abnousi, F | 1 |
| Sundaram, V | 1 |
| Yong, CM | 1 |
| Prats, J | 4 |
| Deliargyris, EN | 4 |
| Hamm, CW | 4 |
| Gibson, CM | 7 |
| White, HD | 5 |
| Price, MJ | 13 |
| Généreux, P | 4 |
| Desai, M | 1 |
| Yang, L | 4 |
| Ding, VY | 1 |
| Harrington, RA | 9 |
| Mahaffey, KW | 6 |
| Olędzki, S | 1 |
| Kornacewicz-Jach, Z | 1 |
| Safranow, K | 1 |
| Kiedrowicz, R | 1 |
| Gawrońska-Szklarz, B | 1 |
| Jastrzębska, M | 1 |
| Gorący, J | 1 |
| Piccolo, R | 2 |
| Gargiulo, G | 2 |
| Franzone, A | 2 |
| Santucci, A | 2 |
| Ariotti, S | 4 |
| Baldo, A | 2 |
| Tumscitz, C | 1 |
| Moschovitis, A | 3 |
| Windecker, S | 7 |
| Valgimigli, M | 12 |
| Nakamura, M | 2 |
| Iijima, R | 3 |
| Ako, J | 1 |
| Shinke, T | 2 |
| Okada, H | 1 |
| Ito, Y | 1 |
| Ando, K | 1 |
| Anzai, H | 1 |
| Tanaka, H | 1 |
| Ueda, Y | 2 |
| Takiuchi, S | 1 |
| Nishida, Y | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 2 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 2 |
| Inoue, K | 1 |
| Ishiwata, S | 1 |
| Ochiai, M | 2 |
| Hamasaki, T | 1 |
| Yokoi, H | 2 |
| Didier, R | 1 |
| Morice, MC | 3 |
| Barragan, P | 3 |
| Noryani, AAL | 2 |
| Noor, HA | 2 |
| Majwal, T | 2 |
| Hovasse, T | 2 |
| Castellant, P | 2 |
| Schneeberger, M | 2 |
| Maillard, L | 3 |
| Bressolette, E | 2 |
| Wojcik, J | 2 |
| Delarche, N | 2 |
| Blanchard, D | 2 |
| Jouve, B | 2 |
| Ormezzano, O | 2 |
| Paganelli, F | 9 |
| Levy, G | 2 |
| Sainsous, J | 2 |
| Carrie, D | 4 |
| Furber, A | 3 |
| Berlan, J | 1 |
| Darremont, O | 2 |
| Le Breton, H | 2 |
| Lyuycx-Bore, A | 2 |
| Gommeaux, A | 2 |
| Cassat, C | 2 |
| Kermarrec, A | 2 |
| Cazaux, P | 2 |
| Druelles, P | 2 |
| Dauphin, R | 2 |
| Armengaud, J | 2 |
| Dupouy, P | 2 |
| Champagnac, D | 2 |
| Ohlmann, P | 3 |
| Ben Amer, H | 1 |
| Kiss, RG | 3 |
| Ungi, I | 3 |
| Gilard, M | 4 |
| So, DYF | 1 |
| Bagai, A | 1 |
| Tran, U | 1 |
| Verma, S | 1 |
| Mehta, SR | 2 |
| Lin, SH | 1 |
| Furer, A | 1 |
| Maehara, A | 5 |
| Giustino, G | 2 |
| Henry, TD | 5 |
| Cox, DA | 4 |
| Duffy, PL | 5 |
| Mazzaferri, EL | 5 |
| Ayele, GM | 1 |
| Mintz, GS | 3 |
| Schoos, M | 1 |
| Chandrasekhar, J | 1 |
| Baber, U | 8 |
| Bhasin, A | 1 |
| Sartori, S | 1 |
| Aquino, M | 1 |
| Vogel, B | 1 |
| Farhan, S | 3 |
| Sorrentino, S | 1 |
| Kini, A | 2 |
| Kruckoff, M | 1 |
| Moliterno, D | 1 |
| Iakovou, I | 1 |
| Colombo, A | 8 |
| Chieffo, A | 3 |
| Cohen, D | 1 |
| Stuckey, T | 1 |
| Ariti, C | 1 |
| Dangas, G | 1 |
| Pocock, S | 1 |
| Amin, AM | 3 |
| Sheau Chin, L | 3 |
| Mohamed Noor, DA | 3 |
| Mostafa, H | 3 |
| Abdul Kader, MASK | 2 |
| Kah Hay, Y | 3 |
| Teh, CH | 2 |
| Sk Abdul Kader, MA | 1 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 1 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 1 |
| von Birgelen, C | 1 |
| Li, JL | 1 |
| Fu, Y | 1 |
| Qin, SB | 1 |
| Liang, GK | 1 |
| Liu, J | 2 |
| Nie, XY | 1 |
| Chen, J | 1 |
| Shi, LW | 1 |
| Shao, H | 1 |
| Lu, Y | 1 |
| Zeb, I | 1 |
| Krim, N | 1 |
| Bella, J | 1 |
| Pereira, P | 1 |
| Kapoor, A | 1 |
| Sinha, A | 2 |
| Agarwal, SK | 1 |
| Pande, S | 1 |
| Khanna, R | 1 |
| Srivastava, N | 1 |
| Kumar, S | 1 |
| Garg, N | 1 |
| Tewari, S | 1 |
| Goel, P | 1 |
| Xie, W | 1 |
| Yin, Q | 1 |
| Zhang, M | 1 |
| Li, S | 1 |
| Chen, S | 1 |
| Golukhova, EZ | 1 |
| Grigoryan, MV | 1 |
| Ryabinina, MN | 1 |
| Bulaeva, NI | 1 |
| Brunner, S | 1 |
| Rizas, K | 1 |
| Hamm, W | 1 |
| Mehr, M | 1 |
| Lackermair, K | 1 |
| Arbel, Y | 2 |
| Velibey, Y | 1 |
| Tekkeşin, Aİ | 2 |
| Barutca, H | 1 |
| Yıldırımtürk, Ö | 2 |
| Bozbeyoğlu, E | 2 |
| Çakıllı, Y | 2 |
| Güzelburç, Ö | 1 |
| Bora Şişman, S | 1 |
| Çinier, G | 1 |
| Şahin, S | 1 |
| Alper, AT | 2 |
| Rosano, GMC | 1 |
| Seferovic, P | 1 |
| Wang, JY | 1 |
| Zhang, YJ | 1 |
| Vranckx, P | 5 |
| Jüni, P | 2 |
| Hamm, C | 1 |
| Heg, D | 2 |
| van Es, GA | 1 |
| McFadden, EP | 2 |
| Onuma, Y | 2 |
| van Meijeren, C | 1 |
| Chichareon, P | 1 |
| Benit, E | 1 |
| Möllmann, H | 1 |
| Janssens, L | 1 |
| Ferrario, M | 1 |
| Zurakowski, A | 1 |
| Dominici, M | 1 |
| Van Geuns, RJ | 1 |
| Huber, K | 13 |
| Slagboom, T | 1 |
| Serruys, PW | 2 |
| Pavlovic, M | 1 |
| Apostolovic, S | 1 |
| Stokanovic, D | 1 |
| Lilic, J | 1 |
| Konstantinovic, SS | 1 |
| Zvezdanovic, JB | 1 |
| Marinkovic, V | 1 |
| Nikolic, VN | 1 |
| Toba, T | 1 |
| Otake, H | 1 |
| Sugizaki, Y | 1 |
| Takeshige, R | 1 |
| Onishi, H | 1 |
| Nagasawa, A | 1 |
| Tsukiyama, Y | 1 |
| Yanaka, K | 1 |
| Nagano, Y | 1 |
| Yamamoto, H | 2 |
| Kawamori, H | 1 |
| Matsuura, A | 1 |
| Ishihara, T | 1 |
| Matsumoto, D | 1 |
| Igarashi, N | 1 |
| Hayashi, T | 1 |
| Fujii, T | 1 |
| Shite, J | 1 |
| Okada, M | 1 |
| Sakakibara, T | 1 |
| Hirata, KI | 1 |
| Zhao, X | 1 |
| Wu, H | 2 |
| Xu, H | 1 |
| Shen, L | 1 |
| Fan, B | 1 |
| Ge, J | 1 |
| Tousoulis, D | 5 |
| Siasos, G | 5 |
| Zaromitidou, M | 5 |
| Oikonomou, E | 5 |
| Maniatis, K | 4 |
| Kioufis, S | 5 |
| Kokkou, E | 4 |
| Papavassiliou, AG | 4 |
| Stefanadis, C | 4 |
| Park, KW | 5 |
| Park, JJ | 2 |
| Kang, J | 1 |
| Jeon, KH | 1 |
| Han, JK | 1 |
| Lee, SE | 1 |
| Yang, HM | 2 |
| Lee, HY | 2 |
| Kang, HJ | 3 |
| Koo, BK | 5 |
| Oh, BH | 2 |
| Park, YB | 1 |
| Kim, HS | 16 |
| Alexopoulos, D | 4 |
| Xanthopoulou, I | 4 |
| Chen, F | 2 |
| Lv, S | 1 |
| Bonello, L | 12 |
| Laine, M | 3 |
| Leoncini, M | 1 |
| Toso, A | 1 |
| Maioli, M | 1 |
| Angiolillo, DJ | 51 |
| Giusti, B | 3 |
| Marcucci, R | 11 |
| Abbate, R | 10 |
| Bellandi, F | 1 |
| Sellke, FW | 1 |
| Akturk, IF | 1 |
| Caglar, FN | 1 |
| Erturk, M | 1 |
| Tuncer, N | 1 |
| Yalcın, AA | 1 |
| Surgit, O | 1 |
| Uzun, F | 1 |
| Caglar, IM | 1 |
| Fujikawa, T | 2 |
| Noda, T | 1 |
| Tada, S | 1 |
| Tanaka, A | 2 |
| Kaufmann, J | 1 |
| Wellnhofer, E | 1 |
| Kappert, K | 1 |
| Urban, D | 1 |
| Meyborg, H | 1 |
| Hauptmann, T | 1 |
| Müller, A | 1 |
| Meixner, M | 1 |
| Graf, K | 1 |
| Fleck, E | 1 |
| Stawowy, P | 1 |
| Tantry, US | 26 |
| Jeong, YH | 9 |
| Navarese, EP | 2 |
| Kubica, J | 3 |
| Gurbel, PA | 32 |
| Karathanos, A | 2 |
| Geisler, T | 14 |
| Bliden, KP | 19 |
| Logan, DK | 1 |
| Lasseter, KC | 1 |
| White, A | 1 |
| Nolin, TD | 1 |
| Maa, JF | 1 |
| Bailey, WL | 2 |
| Jakubowski, JA | 23 |
| Ojeh, CK | 2 |
| Baker, BA | 6 |
| Kang, YH | 1 |
| Lao, HY | 1 |
| Lai, WH | 1 |
| Li, XX | 1 |
| Yu, XY | 1 |
| Chen, JY | 2 |
| Zhong, SL | 1 |
| Franken, CC | 1 |
| Kaiser, AF | 1 |
| Krüger, JC | 2 |
| Overbeck, K | 1 |
| Mügge, A | 3 |
| Neubauer, H | 3 |
| Ardati, AK | 1 |
| Pitt, B | 1 |
| Smith, DE | 1 |
| Aronow, HD | 2 |
| Share, D | 1 |
| Moscucci, M | 1 |
| Chetcuti, S | 1 |
| Grossman, PM | 1 |
| Gurm, HS | 1 |
| Lee, JK | 1 |
| Tsui, KL | 1 |
| Cheung, CY | 1 |
| Chau, CH | 1 |
| Chan, HL | 1 |
| Wu, KL | 1 |
| Cheung, GS | 1 |
| Choi, MC | 1 |
| Chan, KK | 1 |
| Li, SK | 1 |
| Rouine-Rapp, K | 1 |
| McDermott, MW | 1 |
| Erlinge, D | 10 |
| James, S | 10 |
| Lindahl, TL | 2 |
| Svensson, P | 2 |
| Foley, DP | 2 |
| Wagner, H | 4 |
| Brown, PB | 6 |
| Luo, J | 4 |
| Zhou, C | 5 |
| Moser, BA | 5 |
| Small, DS | 7 |
| Winters, KJ | 15 |
| Frère, C | 3 |
| Kim, IS | 4 |
| Park, Y | 4 |
| Lee, DH | 2 |
| Koh, JS | 3 |
| Park, JR | 2 |
| Jang, JS | 4 |
| Hwang, SJ | 5 |
| Koh, EH | 1 |
| Kwak, CH | 4 |
| Hwang, JY | 4 |
| Kim, S | 4 |
| Tsantes, AE | 1 |
| Ikonomidis, I | 1 |
| Papadakis, I | 1 |
| Bonovas, S | 1 |
| Gialeraki, A | 1 |
| Kottaridi, C | 1 |
| Kyriakou, E | 1 |
| Kokori, S | 1 |
| Douramani, P | 1 |
| Kopterides, P | 1 |
| Karakitsos, P | 1 |
| Lekakis, J | 1 |
| Kapsimali, V | 1 |
| Luchessi, AD | 2 |
| Silbiger, VN | 2 |
| Hirata, RD | 2 |
| Lima-Neto, LG | 1 |
| Cavichioli, D | 1 |
| Iñiguez, A | 3 |
| Bravo, M | 2 |
| Bastos, G | 2 |
| Sousa, AG | 4 |
| Brión, M | 2 |
| Carracedo, A | 2 |
| Hirata, MH | 2 |
| Xie, X | 1 |
| Ma, YT | 1 |
| Yang, YN | 1 |
| Li, XM | 1 |
| Zheng, YY | 1 |
| Fu, ZY | 1 |
| Li, Y | 15 |
| Yu, ZX | 1 |
| Chen, Y | 1 |
| Chen, BD | 1 |
| Liu, F | 2 |
| Huang, Y | 3 |
| Liu, C | 2 |
| Baituola, G | 1 |
| Li, L | 3 |
| Han, JL | 1 |
| Li, HY | 1 |
| Qiao, R | 1 |
| Yu, HY | 1 |
| Zhang, J | 1 |
| Gao, W | 1 |
| McCormack, T | 1 |
| Panchal, HB | 1 |
| Shah, T | 1 |
| Patel, P | 1 |
| Albalbissi, K | 1 |
| Molnar, J | 1 |
| Coffey, B | 1 |
| Khosla, S | 2 |
| Ramu, V | 1 |
| Lee, S | 2 |
| Choi, DJ | 3 |
| Kim, MA | 2 |
| Tanboğa, IH | 1 |
| Can, MM | 1 |
| Ozkan, A | 1 |
| Tokgöz, HC | 1 |
| Akgün, T | 1 |
| Koca, F | 1 |
| Kurt, M | 1 |
| Kaymaz, C | 1 |
| Fujisue, K | 2 |
| Sugiyama, S | 3 |
| Ono, T | 3 |
| Matsuzawa, Y | 2 |
| Akiyama, E | 2 |
| Sugamura, K | 2 |
| Matsubara, J | 2 |
| Kurokawa, H | 2 |
| Sumida, H | 3 |
| Oniki, K | 4 |
| Nakagawa, K | 6 |
| Matsui, K | 3 |
| Ogawa, H | 7 |
| Darvish-Kazem, S | 1 |
| Gandhi, M | 1 |
| Marcucci, M | 1 |
| Douketis, JD | 1 |
| Galić, E | 1 |
| Vrbanić, L | 1 |
| Kapitanović, S | 1 |
| Catela Ivković, T | 1 |
| Petro, D | 1 |
| Vuković, I | 1 |
| Bsharat, RS | 1 |
| Milicević, Z | 1 |
| Vcev, A | 1 |
| Mirat, J | 1 |
| Rollini, F | 11 |
| Patel, R | 3 |
| Darlington, A | 5 |
| Wilson, RE | 2 |
| Franchi, F | 7 |
| Muñiz-Lozano, A | 3 |
| Desai, B | 13 |
| Bender, N | 1 |
| Sakariassen, KS | 2 |
| Suh, SY | 1 |
| Kang, WC | 2 |
| Oh, PC | 2 |
| Choi, H | 2 |
| Moon, CI | 1 |
| Lee, K | 4 |
| Han, SH | 1 |
| Ahn, T | 2 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Braun, OÖ | 4 |
| Effron, MB | 3 |
| Duvvuru, S | 3 |
| Costigan, TM | 1 |
| Sundseth, S | 2 |
| Walker, JR | 3 |
| Saucedo, JF | 2 |
| Kleiman, NS | 6 |
| Varenhorst, C | 6 |
| Scott, SA | 3 |
| Tan, Q | 1 |
| Yang, Y | 2 |
| Martis, S | 1 |
| Bander, J | 1 |
| Kornreich, R | 1 |
| Hulot, JS | 6 |
| Desnick, RJ | 2 |
| Chua, D | 1 |
| Nishi, C | 1 |
| Park, BE | 1 |
| Cha, KS | 5 |
| Rhew, JY | 2 |
| Jeon, HK | 2 |
| Shin, ES | 3 |
| Oh, JH | 3 |
| Jeong, MH | 6 |
| Hwang, KK | 2 |
| Yoon, JH | 5 |
| Lee, SY | 3 |
| Park, TH | 2 |
| Moon, KW | 1 |
| Kwon, HM | 2 |
| Chae, IH | 4 |
| Lavie, CJ | 1 |
| DiNicolantonio, JJ | 1 |
| Migliorini, A | 6 |
| Valenti, R | 7 |
| Parodi, G | 4 |
| Carrabba, N | 3 |
| Gensini, GF | 8 |
| Antoniucci, D | 8 |
| Lee, JY | 2 |
| Han, S | 3 |
| Park, YK | 1 |
| Lee, WS | 1 |
| Jang, JY | 1 |
| Kwon, CH | 1 |
| Park, GM | 1 |
| Cho, YR | 2 |
| Kim, WJ | 2 |
| Kim, JJ | 3 |
| Landel, JB | 1 |
| Bauters, A | 1 |
| Delhaye, C | 5 |
| Sudre, A | 4 |
| Susen, S | 1 |
| Bauters, C | 6 |
| Lablanche, JM | 4 |
| Lemesle, G | 8 |
| Lee, SG | 3 |
| Seong, IW | 6 |
| Rha, SW | 4 |
| Lim, DS | 2 |
| Hur, SH | 4 |
| Choi, YS | 2 |
| Yang, JY | 3 |
| Lee, NH | 5 |
| Lee, BK | 4 |
| Kim, KS | 4 |
| Lee, SU | 2 |
| Chae, JK | 2 |
| Cheong, SS | 3 |
| Suh, IW | 2 |
| Park, HS | 2 |
| Nah, DY | 2 |
| Jeon, DS | 2 |
| Seung, KB | 4 |
| Müller, KA | 1 |
| Tavlaki, E | 1 |
| Stimpfle, F | 1 |
| Meissner, M | 1 |
| Bigalke, B | 9 |
| Stellos, K | 8 |
| Schwab, M | 4 |
| Schaeffeler, E | 2 |
| Müller, II | 1 |
| Gawaz, M | 17 |
| Acharji, S | 1 |
| Lakshmanadoss, U | 1 |
| Rudzinski, W | 1 |
| Stapleton, DD | 1 |
| Kaluski, E | 1 |
| Storey, RF | 9 |
| James, SK | 1 |
| Siegbahn, A | 5 |
| Held, C | 1 |
| Ycas, J | 1 |
| Husted, SE | 3 |
| Cannon, CP | 6 |
| Becker, RC | 6 |
| Åsenblad, N | 1 |
| Wallentin, L | 7 |
| Barbato, E | 8 |
| Ha, SJ | 1 |
| Kim, SJ | 1 |
| Woo, JS | 2 |
| Kim, W | 2 |
| Kim, WS | 2 |
| Kim, MK | 2 |
| Bundhoo, S | 1 |
| Sagan, E | 1 |
| James, PE | 1 |
| Anderson, RA | 1 |
| Ueno, M | 11 |
| Guzman, LA | 10 |
| Bass, TA | 19 |
| Feres, F | 8 |
| Costa, RA | 3 |
| Abizaid, A | 8 |
| Leon, MB | 2 |
| Marin-Neto, JA | 3 |
| Botelho, RV | 2 |
| King, SB | 2 |
| Negoita, M | 1 |
| de Paula, JE | 2 |
| Mangione, JA | 3 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 2 |
| Devito, FS | 2 |
| Labrunie, A | 1 |
| Salvadori, D | 2 |
| Gusmão, M | 1 |
| Staico, R | 4 |
| Costa, JR | 4 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Pankert, M | 1 |
| Quilici, J | 3 |
| Loundou, AD | 1 |
| Verdier, V | 1 |
| Lambert, M | 3 |
| Deharo, P | 1 |
| Bonnet, G | 1 |
| Gaborit, B | 1 |
| Morange, PE | 3 |
| Valéro, R | 1 |
| Dutour, A | 1 |
| Bonnet, JL | 4 |
| Alessi, MC | 3 |
| Cuisset, T | 6 |
| Dridi, NP | 1 |
| Johansson, PI | 1 |
| Clemmensen, P | 1 |
| Stissing, T | 1 |
| Radu, MD | 1 |
| Qayyum, A | 1 |
| Pedersen, F | 1 |
| Helqvist, S | 1 |
| Saunamäki, K | 1 |
| Kelbæk, H | 1 |
| Jørgensen, E | 1 |
| Engstrøm, T | 1 |
| Holmvang, L | 1 |
| Cully, M | 1 |
| Viviani Anselmi, C | 1 |
| Briguori, C | 3 |
| Roncarati, R | 2 |
| Papa, L | 2 |
| Visconti, G | 2 |
| Focaccio, A | 2 |
| De Micco, F | 2 |
| Latronico, MV | 2 |
| Pagnotta, P | 2 |
| Condorelli, G | 2 |
| Bevan, P | 1 |
| Menon, A | 1 |
| Bunton, R | 1 |
| Ramadan, R | 1 |
| Dhawan, SS | 1 |
| Syed, H | 1 |
| Pohlel, FK | 1 |
| Binongo, JN | 1 |
| Ghazzal, ZB | 1 |
| Quyyumi, AA | 1 |
| Htun, P | 4 |
| Kan, T | 1 |
| Mueller, E | 1 |
| Pohle, C | 1 |
| Schindler, R | 1 |
| Bocksch, W | 2 |
| Fateh-Moghadam, S | 4 |
| Cho, JR | 4 |
| Haas, MJ | 1 |
| Ferrante, E | 2 |
| Enomoto, Y | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Hori, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Hara, H | 1 |
| Sugi, K | 1 |
| Pelliccia, F | 2 |
| Rosano, G | 1 |
| Marazzi, G | 1 |
| Vitale, C | 1 |
| Spoletini, I | 1 |
| Franzoni, F | 1 |
| Speziale, G | 1 |
| Polacco, M | 1 |
| Greco, C | 1 |
| Gaudio, C | 1 |
| Sels, JW | 1 |
| Rutten, B | 1 |
| van Holten, TC | 1 |
| Hillaert, MA | 1 |
| Waltenberger, J | 1 |
| Pijls, NH | 1 |
| Pasterkamp, G | 1 |
| de Groot, PG | 2 |
| Roest, M | 2 |
| Gremmel, T | 2 |
| Xhelili, E | 1 |
| Steiner, S | 1 |
| Koppensteiner, R | 1 |
| Kopp, CW | 1 |
| Panzer, S | 4 |
| Small, D | 2 |
| Sundseth, SS | 1 |
| Li, W | 1 |
| Heiselman, DE | 1 |
| Badr Eslam, R | 2 |
| Posch, F | 1 |
| Lang, IM | 4 |
| Eichelberger, B | 1 |
| Ay, C | 1 |
| Youn, YJ | 1 |
| Lee, JW | 1 |
| Ahn, SG | 2 |
| Lee, SH | 6 |
| Yu, CW | 1 |
| Hong, YJ | 1 |
| Yoon, J | 2 |
| Lamberts, M | 1 |
| Gislason, GH | 1 |
| Lip, GY | 4 |
| Lassen, JF | 1 |
| Olesen, JB | 1 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Hansen, ML | 1 |
| Komosa, A | 2 |
| Siller-Matula, JM | 8 |
| Kowal, J | 2 |
| Lesiak, M | 2 |
| Siniawski, A | 2 |
| Mączyński, M | 2 |
| Michalak, M | 2 |
| Mularek-Kubzdela, T | 2 |
| Grajek, S | 2 |
| Cavallari, I | 1 |
| Patti, G | 4 |
| Vizzi, V | 2 |
| D'Ambrosio, A | 2 |
| De Bruyne, B | 3 |
| Wijns, W | 8 |
| Di Sciascio, G | 6 |
| Kreutz, RP | 2 |
| Bitar, A | 1 |
| Owens, J | 2 |
| Desta, Z | 2 |
| Breall, JA | 2 |
| von der Lohe, E | 1 |
| Vatta, M | 1 |
| Nystrom, P | 2 |
| Jin, Y | 2 |
| Flockhart, DA | 2 |
| Willoughby, SR | 1 |
| Luu, LJ | 1 |
| Cameron, JD | 1 |
| Nelson, AJ | 1 |
| Schultz, CD | 1 |
| Worthley, SG | 2 |
| Worthley, MI | 1 |
| Tang, XF | 1 |
| Fan, JY | 1 |
| Meng, J | 1 |
| Jin, C | 1 |
| Yuan, JQ | 1 |
| Yang, YJ | 1 |
| Oestreich, JH | 2 |
| Best, LG | 1 |
| Dobesh, PP | 1 |
| Asencio, LA | 1 |
| Huang, JJ | 1 |
| Alpert, JS | 1 |
| Wisman, PP | 1 |
| Asselbergs, FW | 1 |
| Moll, FL | 1 |
| van der Graaf, Y | 1 |
| de Borst, GJ | 1 |
| Yasmina, A | 1 |
| de Boer, A | 1 |
| Klungel, OH | 1 |
| Deneer, VH | 3 |
| Fiedler, KA | 1 |
| Byrne, RA | 5 |
| Schulz, S | 6 |
| Sibbing, D | 12 |
| Mehilli, J | 10 |
| Ibrahim, T | 2 |
| Maeng, M | 2 |
| Laugwitz, KL | 5 |
| Kastrati, A | 21 |
| Sarafoff, N | 3 |
| Bellandi, B | 1 |
| Comito, V | 2 |
| Ramazzotti, RN | 1 |
| Gasparovic, H | 2 |
| Petricevic, M | 3 |
| Kopjar, T | 1 |
| Djuric, Z | 1 |
| Svetina, L | 1 |
| Biocina, B | 3 |
| Song, PS | 1 |
| Song, YB | 1 |
| Yang, JH | 1 |
| Hahn, JY | 1 |
| Choi, SH | 2 |
| Choi, JH | 2 |
| Gwon, HC | 3 |
| Ndrepepa, G | 2 |
| Richardt, G | 2 |
| Pöhler, A | 1 |
| Pache, J | 4 |
| Asher, E | 1 |
| Fefer, P | 1 |
| Shechter, M | 2 |
| Beigel, R | 1 |
| Varon, D | 2 |
| Shenkman, B | 2 |
| Savion, N | 2 |
| Hod, H | 2 |
| Matetzky, S | 3 |
| Bovier, P | 1 |
| Seebach, JD | 1 |
| Harr, T | 1 |
| Greene, SJ | 1 |
| Alkhawam, L | 1 |
| Vaduganathan, M | 3 |
| Breet, NJ | 4 |
| Anselmi, CV | 1 |
| Su, J | 2 |
| Li, X | 3 |
| Yu, Q | 1 |
| Liu, Y | 3 |
| Wang, Y | 2 |
| Song, H | 1 |
| Cui, H | 2 |
| Du, W | 1 |
| Fei, X | 1 |
| Lin, S | 2 |
| Wang, J | 2 |
| Zheng, W | 2 |
| Zhong, J | 1 |
| Zhang, L | 5 |
| Tong, M | 1 |
| Xu, J | 2 |
| Chitose, T | 1 |
| Mizobe, M | 2 |
| Akasaka, T | 2 |
| Morita, K | 2 |
| Miyazaki, H | 2 |
| Lu, D | 1 |
| Kreutz, Y | 1 |
| Timur, AA | 1 |
| Murugesan, G | 1 |
| Barnard, J | 1 |
| Kottke-Marchant, K | 1 |
| Jelliffe, R | 1 |
| Youn, YN | 1 |
| Yi, G | 1 |
| Joo, HC | 1 |
| Yoo, KJ | 1 |
| Liang, J | 1 |
| Wang, Z | 1 |
| Shi, D | 1 |
| Zhao, Y | 1 |
| Han, H | 1 |
| Liu, W | 2 |
| Hiasa, Y | 2 |
| Teng, R | 7 |
| Emanuelsson, H | 1 |
| Osnabrugge, RL | 1 |
| Head, SJ | 1 |
| Zijlstra, F | 2 |
| Hunink, MG | 1 |
| Kappetein, AP | 1 |
| Janssens, AC | 1 |
| Legrand, V | 1 |
| Chenu, P | 1 |
| Vrolix, M | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 1 |
| Claeys, MJ | 1 |
| Magne, J | 1 |
| Hou, X | 1 |
| Shi, J | 3 |
| Sun, H | 1 |
| Li, XJ | 1 |
| Chen, XM | 1 |
| Bergmeijer, TO | 2 |
| Collet, JP | 7 |
| Abtan, J | 1 |
| Anzaha, G | 1 |
| Kerneis, M | 1 |
| Silvain, J | 3 |
| Cayla, G | 4 |
| O'Connor, SA | 3 |
| Barthélémy, O | 3 |
| Beygui, F | 3 |
| Galier, S | 1 |
| Brugier, D | 1 |
| Stanek, EJ | 1 |
| Charland, SL | 1 |
| Gallois, V | 1 |
| Montalescot, G | 9 |
| Olivier, CB | 1 |
| Schnabel, K | 1 |
| Brandt, C | 2 |
| Weik, P | 1 |
| Olschewski, M | 1 |
| Zhou, Q | 1 |
| Bode, C | 3 |
| Diehl, P | 2 |
| Moser, M | 3 |
| Yan, L | 1 |
| Wang, D | 1 |
| Han, L | 1 |
| Tian, L | 1 |
| Liu, H | 3 |
| Ruff, CT | 1 |
| Mesa, RA | 1 |
| Mattimore, JF | 1 |
| Cyr, JF | 1 |
| Lei, L | 1 |
| Frelinger, AL | 5 |
| Michelson, AD | 6 |
| Berg, DD | 1 |
| O'Donoghue, ML | 3 |
| Sabatine, MS | 5 |
| Mega, JL | 3 |
| Priyadharsini, R | 1 |
| Shewade, DG | 1 |
| Subraja, K | 1 |
| Ravindra, BK | 1 |
| Umamaheswaran, G | 1 |
| Dkhar, SA | 1 |
| Satheesh, S | 1 |
| Sridhar, MG | 1 |
| Narayan, SK | 1 |
| Adithan, C | 1 |
| Gruber, C | 1 |
| Francesconi, M | 2 |
| Dechant, C | 2 |
| Jilma, B | 5 |
| Delle-Karth, G | 3 |
| Grohs, K | 2 |
| Podczeck-Schweighofer, A | 2 |
| Christ, G | 3 |
| Lordkipanidzé, M | 7 |
| Diodati, JG | 7 |
| Schampaert, E | 6 |
| Palisaitis, DA | 6 |
| Pharand, C | 7 |
| Ahn, DG | 1 |
| Kim, BJ | 1 |
| Kim, JW | 1 |
| Kim, JG | 1 |
| Sugidachi, A | 3 |
| Une, D | 1 |
| Al-Atassi, T | 1 |
| Kulik, A | 2 |
| Voisine, P | 2 |
| Le May, M | 1 |
| Ruel, M | 2 |
| Thompson, PL | 1 |
| Verheugt, FW | 5 |
| Hess, CN | 3 |
| Lopes, RD | 3 |
| Hager, R | 1 |
| Wojdyla, DM | 1 |
| Englum, BR | 1 |
| Mack, MJ | 1 |
| Califf, RM | 3 |
| Kouchoukos, NT | 1 |
| Peterson, ED | 7 |
| Alexander, JH | 3 |
| Clavijo, L | 1 |
| Carlson, G | 2 |
| Caplan, R | 2 |
| Maya, J | 3 |
| Duru, OK | 1 |
| Edgington, S | 1 |
| Mangione, C | 1 |
| Turk, N | 1 |
| Tseng, CH | 1 |
| Kimbro, L | 1 |
| Ettner, S | 1 |
| Kim, N | 1 |
| Tresukosol, D | 1 |
| Suktitipat, B | 1 |
| Hunnangkul, S | 1 |
| Kamkaew, R | 1 |
| Poldee, S | 1 |
| Tassaneetrithep, B | 1 |
| Likidlilid, A | 1 |
| Lev, EI | 5 |
| Pandya, S | 1 |
| Kang, K | 1 |
| Franzese, C | 1 |
| Chyrchel, B | 1 |
| Totoń-Żurańska, J | 1 |
| Kruszelnicka, O | 1 |
| Chyrchel, M | 1 |
| Mielecki, W | 2 |
| Kołton-Wróż, M | 1 |
| Wołkow, P | 2 |
| Surdacki, A | 1 |
| Higaki, T | 1 |
| Kurisu, S | 1 |
| Watanabe, N | 1 |
| Ikenaga, H | 1 |
| Shimonaga, T | 1 |
| Iwasaki, T | 1 |
| Mitsuba, N | 1 |
| Ishibashi, K | 1 |
| Dohi, Y | 1 |
| Fukuda, Y | 1 |
| Kihara, Y | 1 |
| Vavuranakis, M | 4 |
| Papageorgiou, N | 2 |
| Mourouzis, K | 2 |
| Papaioannou, S | 2 |
| Tsalamandris, S | 2 |
| Feldman, L | 1 |
| Tubach, F | 1 |
| Juliard, JM | 1 |
| Himbert, D | 1 |
| Ducrocq, G | 2 |
| Sorbets, E | 1 |
| Triantafyllou, K | 1 |
| Kerner, A | 1 |
| Abergel, H | 1 |
| Huisse, MG | 1 |
| Roussel, R | 1 |
| Esposito-Farèse, M | 1 |
| Ajzenberg, N | 1 |
| Berland, J | 1 |
| Endresen, K | 1 |
| Benamer, H | 1 |
| Boschat, J | 2 |
| Sardar, P | 1 |
| Nairooz, R | 1 |
| Pekler, G | 1 |
| Tourikis, P | 1 |
| Kim, SH | 3 |
| Sung, JH | 1 |
| Shin, J | 1 |
| Lee, HJ | 1 |
| Lee, HS | 1 |
| Cho, DK | 2 |
| Lim, SW | 2 |
| Schulz-Schüpke, S | 1 |
| Han, Y | 5 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 3 |
| Zrenner, B | 1 |
| Jacobshagen, C | 1 |
| Mudra, H | 1 |
| von Hodenberg, E | 1 |
| Wöhrle, J | 1 |
| von Merzljak, B | 1 |
| Rifatov, N | 1 |
| Kufner, S | 1 |
| Morath, T | 10 |
| Feuchtenberger, A | 1 |
| Janssen, PW | 1 |
| Valina, C | 1 |
| Desmet, W | 1 |
| Abdel-Wahab, M | 1 |
| Tiroch, K | 1 |
| Hengstenberg, C | 1 |
| Bernlochner, I | 5 |
| Fischer, M | 1 |
| Schunkert, H | 2 |
| Schömig, A | 16 |
| Fujita, K | 1 |
| Ikeda, T | 2 |
| Suga, T | 1 |
| Yamaji, K | 1 |
| Ikuta, S | 1 |
| Kobuke, K | 1 |
| Iwanaga, Y | 1 |
| Miyazaki, S | 1 |
| Hamilos, M | 2 |
| Saloustros, I | 1 |
| Skalidis, E | 1 |
| Igoumenidis, N | 1 |
| Kambouris, M | 1 |
| Chlouverakis, G | 1 |
| Vougia, D | 1 |
| Loggakis, I | 1 |
| Vardas, PE | 1 |
| Kochiadakis, G | 1 |
| Manchuelle, A | 1 |
| Schurtz, G | 2 |
| Hurt, C | 1 |
| Puymirat, E | 2 |
| Cortese, B | 1 |
| Wilensky, M | 1 |
| Liu, T | 3 |
| Helft, G | 3 |
| Costa, F | 4 |
| Leonardi, S | 4 |
| Moscarella, E | 1 |
| Ando, G | 1 |
| Oreto, G | 1 |
| Patialiakas, A | 1 |
| Thury, A | 1 |
| McFadden, E | 1 |
| Colangelo, S | 2 |
| Tebaldi, M | 1 |
| Tondi, S | 1 |
| Roffi, M | 2 |
| Menozzi, A | 1 |
| de Cesare, N | 2 |
| Garbo, R | 1 |
| Meliga, E | 2 |
| Testa, L | 1 |
| Gabriel, HM | 1 |
| Airoldi, F | 1 |
| Ferlini, M | 1 |
| Liistro, F | 1 |
| Dellavalle, A | 1 |
| Kandzari, DE | 3 |
| Lhermusier, T | 1 |
| Lipinski, MJ | 1 |
| Escarcega, RO | 1 |
| Baker, N | 1 |
| Magalhaes, MA | 1 |
| Ota, H | 1 |
| Tian, W | 1 |
| Pendyala, L | 1 |
| Minha, S | 1 |
| Torguson, R | 4 |
| Waksman, R | 8 |
| Modrau, IS | 1 |
| Würtz, M | 1 |
| Hvas, AM | 1 |
| Amsallem, M | 1 |
| Manzo-Silberman, S | 1 |
| Dillinger, JG | 2 |
| Sideris, G | 2 |
| Voicu, S | 2 |
| Bal dit Sollier, C | 2 |
| Drouet, L | 2 |
| Henry, P | 3 |
| Lancé, MD | 1 |
| Cohen, DJ | 1 |
| Yazkan, R | 1 |
| Ceviker, K | 1 |
| Camas, HE | 1 |
| Nührenberg, T | 1 |
| Trenk, D | 7 |
| Ignjatovic, V | 1 |
| Pavlovic, S | 1 |
| Miloradovic, V | 1 |
| Andjelkovic, N | 1 |
| Davidovic, G | 1 |
| Djurdjevic, P | 1 |
| Stolic, R | 1 |
| Iric-Cupic, V | 1 |
| Simic, I | 1 |
| Ignjatovic, VD | 1 |
| Petrovic, N | 1 |
| Smiljanic, Z | 1 |
| Zdravkovic, V | 1 |
| Simovic, S | 1 |
| Jovanovic, D | 1 |
| Nesic, J | 1 |
| Ang, L | 2 |
| Mahmud, E | 2 |
| Gao, F | 3 |
| Shen, H | 2 |
| Wang, ZJ | 3 |
| Yang, SW | 2 |
| Liu, XL | 3 |
| Zhou, YJ | 3 |
| Sardella, G | 2 |
| Calcagno, S | 2 |
| Mancone, M | 2 |
| Lucisano, L | 2 |
| Pennacchi, M | 2 |
| Stio, RE | 2 |
| Placentino, F | 1 |
| Di Roma, A | 2 |
| Cavallo, E | 1 |
| Palmirotta, R | 2 |
| Guadagni, F | 2 |
| Fedele, F | 2 |
| Brener, SJ | 2 |
| Helmy, T | 1 |
| Chen, HB | 1 |
| Zhang, XL | 1 |
| Liang, HB | 1 |
| Liu, XW | 1 |
| Zhang, XY | 1 |
| Huang, BY | 1 |
| Xiu, J | 1 |
| Nardin, M | 6 |
| Barbieri, L | 8 |
| Schaffer, A | 6 |
| Suryapranata, H | 8 |
| Simon, N | 1 |
| Finzi, J | 1 |
| Carlson, GF | 1 |
| Caplan, RJ | 1 |
| Ferdinand, KC | 1 |
| Siddiqi, OK | 1 |
| Smoot, KJ | 2 |
| Dufour, AB | 2 |
| Cho, K | 2 |
| Young, M | 1 |
| Gagnon, DR | 2 |
| Ly, S | 2 |
| Temiyasathit, S | 2 |
| Faxon, DP | 3 |
| Gaziano, JM | 2 |
| Kinlay, S | 2 |
| Gielen, CL | 1 |
| Bruggemans, EF | 1 |
| Stijnen, T | 1 |
| Eikenboom, J | 1 |
| Tavilla, G | 1 |
| Brand, A | 1 |
| Klautz, RJ | 1 |
| Arya, V | 1 |
| Mahajan, P | 1 |
| Saraf, A | 1 |
| Mohanty, A | 1 |
| Sawhney, JP | 1 |
| Bhargava, M | 1 |
| Nührenberg, TG | 1 |
| Leggewie, S | 1 |
| Gick, M | 1 |
| Nakayama, T | 2 |
| Fujimoto, Y | 2 |
| Sugimoto, K | 2 |
| Takahara, M | 1 |
| Koshizaka, M | 1 |
| Hanaoka, H | 1 |
| Zografos, T | 1 |
| Antonopoulos, A | 1 |
| Dimitropoulos, S | 1 |
| Izumi, D | 1 |
| Miyahara, M | 1 |
| Fujimoto, N | 1 |
| Fukuoka, S | 1 |
| Sakai, M | 1 |
| Dohi, K | 1 |
| Thukkani, AK | 1 |
| Agrawal, K | 1 |
| Prince, L | 1 |
| Sokolovskaya, G | 1 |
| Bittl, JA | 1 |
| Adamo, M | 1 |
| Ferrante, G | 1 |
| Garcia-Garcia, H | 1 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Dreyfus, X | 1 |
| Leclercq, F | 1 |
| Eltchaninoff, H | 1 |
| Falquier, JF | 1 |
| Cattan, S | 1 |
| Sebagh, L | 1 |
| Michel, PL | 1 |
| Tuambilangana, A | 1 |
| Hammoudi, N | 1 |
| Boccara, F | 1 |
| Douard, H | 1 |
| Diallo, A | 1 |
| Berman, E | 1 |
| Komajda, M | 1 |
| Metzger, JP | 1 |
| Vicaut, E | 1 |
| Kuliczkowski, W | 5 |
| Sliwka, J | 1 |
| Kaczmarski, J | 1 |
| Zysko, D | 1 |
| Zembala, M | 2 |
| Steter, D | 1 |
| Gierlotka, M | 1 |
| Kim, MH | 6 |
| Serebruany, V | 6 |
| Mizrahi, E | 1 |
| Suryadevara, RS | 1 |
| Barn, K | 2 |
| Boga, G | 1 |
| Akram, MM | 1 |
| Ismail-Sayed, I | 1 |
| Henry, YM | 1 |
| Troup, MA | 1 |
| Berger, PB | 6 |
| Schneider, DJ | 2 |
| Agarwal, Z | 1 |
| Seecheran, N | 4 |
| Gogo, P | 1 |
| Marrani, M | 1 |
| Cantini, G | 1 |
| Joob, B | 1 |
| Wiwanitkit, V | 1 |
| Kim, DW | 1 |
| Hong, BK | 1 |
| Kim, DS | 2 |
| Kwan, J | 2 |
| Choi, CU | 1 |
| Yang, YM | 1 |
| Bae, JH | 2 |
| Jung, KT | 1 |
| Choi, WG | 2 |
| Jeon, DW | 1 |
| Pyun, WB | 1 |
| Cha, TJ | 1 |
| Chun, KJ | 3 |
| Kim, YD | 1 |
| Kim, BS | 1 |
| Kim, DI | 2 |
| Kim, TI | 1 |
| Clavijo, LC | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Briasoulis, A | 1 |
| Palla, M | 1 |
| Kim, YS | 1 |
| Lee, SR | 2 |
| Lim, S | 1 |
| Kim, PJ | 1 |
| Baek, C | 1 |
| Kim, TH | 1 |
| Koh, YS | 1 |
| Park, HJ | 1 |
| Kim, HY | 1 |
| Chang, K | 1 |
| Chung, WS | 1 |
| Danchin, N | 3 |
| Schiele, F | 1 |
| Sherwood, MW | 1 |
| Melloni, C | 2 |
| Jones, WS | 1 |
| Washam, JB | 1 |
| Hasselblad, V | 2 |
| Dolor, RJ | 1 |
| Guo, LZ | 1 |
| De Jin, C | 1 |
| Park, K | 1 |
| Park, JS | 3 |
| King, R | 1 |
| Phoenix, F | 1 |
| Bhatti, M | 2 |
| DeGroat, C | 2 |
| Zenni, MM | 4 |
| Ajjan, RA | 1 |
| Khalili, H | 1 |
| Singh, R | 1 |
| Wood, M | 1 |
| Edwards, A | 1 |
| Cooper, M | 1 |
| Ayers, C | 1 |
| Moss, E | 1 |
| Berry, JD | 1 |
| Vongpatanasin, W | 1 |
| de Lemos, JA | 2 |
| Das, SR | 1 |
| Shen, DL | 1 |
| Wang, B | 1 |
| Bai, J | 1 |
| Han, Q | 1 |
| Huang, XH | 1 |
| Zhang, JY | 1 |
| Dignat-George, F | 4 |
| Sakamoto, K | 1 |
| Meurice, T | 1 |
| Tricot, O | 1 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Lamblin, N | 1 |
| Rao, M | 1 |
| Simon, DN | 1 |
| Thomas, L | 2 |
| Ansell, J | 1 |
| Fonarow, GC | 2 |
| Gersh, BJ | 2 |
| Go, AS | 1 |
| Hylek, EM | 1 |
| Kowey, P | 1 |
| Piccini, JP | 2 |
| Singer, DE | 1 |
| Chang, P | 1 |
| Wiśniewski, S | 1 |
| Sakr, HI | 1 |
| Alamri, HS | 1 |
| Almoghairi, AM | 1 |
| Alkhudair, AA | 1 |
| AlMasood, AS | 1 |
| Singh, K | 1 |
| Dunn, EC | 1 |
| Inaba, S | 1 |
| Shimizu, T | 1 |
| Reed, GW | 1 |
| Waalen, J | 1 |
| Teirstein, PS | 4 |
| Tanguay, JF | 1 |
| Capodanno, D | 11 |
| Musallam, A | 1 |
| Orvin, K | 1 |
| Perl, L | 1 |
| Mosseri, M | 1 |
| Roguin, A | 1 |
| Hellkamp, AS | 1 |
| Roe, MT | 4 |
| Scirica, BM | 2 |
| Peng, SA | 1 |
| Wang, TY | 1 |
| Fioranelli, M | 1 |
| Bianchi, M | 1 |
| Roccia, MG | 1 |
| Di Nardo, V | 1 |
| Fan, W | 1 |
| Plent, S | 1 |
| Zhang, D | 1 |
| Liu, D | 1 |
| Cai, W | 1 |
| Yan, C | 1 |
| Carreras, ET | 1 |
| Nordio, F | 1 |
| Wiviott, SD | 2 |
| Lim, WH | 1 |
| Yoon, CH | 1 |
| Park, WJ | 2 |
| Doh, JH | 1 |
| Ahn, YK | 2 |
| Hyon, MS | 2 |
| Kim, YK | 1 |
| Lee, HC | 2 |
| Seol, SH | 2 |
| Choi, SW | 4 |
| Han, KR | 3 |
| Kim, SW | 1 |
| Zhou, CF | 1 |
| Ren, YH | 1 |
| Song, YQ | 1 |
| Yi, J | 1 |
| Han, BS | 1 |
| Xue, Q | 1 |
| Fu, ZH | 1 |
| Li, DY | 1 |
| Kubica, A | 1 |
| Obońska, K | 1 |
| Fabiszak, T | 1 |
| Etxeberria-Lekuona, D | 1 |
| Méndez-López, I | 1 |
| Mercado, MR | 1 |
| Oteiza, J | 1 |
| Arteaga, M | 1 |
| Jarne, V | 1 |
| He, M | 1 |
| Liu, B | 1 |
| Sun, D | 1 |
| Pan, Y | 1 |
| Zhao, S | 1 |
| Dong, X | 1 |
| Lu, S | 1 |
| Serebruany, VL | 7 |
| Golukhova, E | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Cattaneo, M | 3 |
| Marciniak, TA | 1 |
| Metzger, C | 1 |
| Dangas, GD | 2 |
| Francese, DP | 1 |
| Ozan, O | 1 |
| Gillette, M | 1 |
| Morneau, K | 1 |
| Hoang, V | 1 |
| Virani, S | 1 |
| Jneid, H | 1 |
| Vigen, R | 1 |
| Maddox, TM | 1 |
| O'Donnell, CI | 1 |
| Grunwald, GK | 1 |
| Tsai, TT | 2 |
| Rumsfeld, JS | 1 |
| Ho, PM | 2 |
| Lood, C | 1 |
| Borna, C | 1 |
| Gidlöf, O | 1 |
| Truedsson, L | 1 |
| Brown, P | 1 |
| Winters, K | 1 |
| Wang, SH | 1 |
| Hou, FL | 1 |
| Tian, YJ | 1 |
| Liu, YH | 1 |
| Zheng, SL | 1 |
| Shah, RR | 1 |
| Pillai, A | 1 |
| Omar, A | 1 |
| Zhao, J | 1 |
| Arora, V | 1 |
| Kapoor, D | 1 |
| Poommipanit, P | 1 |
| Peter, I | 1 |
| Linderman, M | 1 |
| Sload, J | 1 |
| Qiao, W | 1 |
| Kini, AS | 2 |
| Sharma, SK | 3 |
| Fuster, V | 2 |
| Hajjar, RJ | 1 |
| Mimoso, J | 1 |
| Faza, NN | 1 |
| Mentias, A | 1 |
| Parashar, A | 1 |
| Chaudhury, P | 1 |
| Barakat, AF | 1 |
| Agarwal, S | 1 |
| Wayangankar, S | 1 |
| Ellis, SG | 1 |
| Murat Tuzcu, E | 1 |
| Kapadia, SR | 1 |
| Zhang, ZF | 1 |
| Sha, WH | 1 |
| Tan, GY | 1 |
| Wang, QY | 1 |
| Kaya, A | 1 |
| Türkkan, C | 1 |
| Hayıroğlu, Mİ | 1 |
| Borklu, EB | 1 |
| Kalenderoğlu, K | 1 |
| Gümüşdağ, A | 1 |
| Tatlısu, MA | 1 |
| Mayer, K | 1 |
| Orban, M | 1 |
| Jaitner, J | 1 |
| Rössner, L | 1 |
| Gross, L | 1 |
| Furtado, RHM | 1 |
| Giugliano, RP | 1 |
| Strunz, CMC | 1 |
| Filho, CC | 1 |
| Ramires, JAF | 1 |
| Filho, RK | 1 |
| Neto, PAL | 1 |
| Pereira, AC | 1 |
| Rocha, TR | 1 |
| Freire, BT | 1 |
| D'Amico, EA | 1 |
| Nicolau, JC | 2 |
| Parvataneni, R | 1 |
| Siu, H | 1 |
| Kaliyadan, A | 1 |
| Fischman, DL | 1 |
| Nardone, E | 1 |
| Poll, D | 1 |
| Savage, MP | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 1 |
| Kedhi, E | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Seo, JB | 1 |
| Shin, DH | 3 |
| Tahk, SJ | 1 |
| Golański, J | 1 |
| Syska, K | 1 |
| Chiżynski, K | 1 |
| Kassasir, H | 1 |
| Watała, C | 1 |
| Sakowicz, A | 1 |
| Sartori, C | 1 |
| Magnani, G | 1 |
| Marino, M | 1 |
| Esposito, G | 1 |
| González-Pérez, A | 1 |
| Sáez, ME | 1 |
| Johansson, S | 1 |
| Himmelmann, A | 1 |
| García Rodríguez, LA | 1 |
| Ghantous, AE | 1 |
| Ferneini, EM | 1 |
| Vries, MJ | 1 |
| Bouman, HJ | 5 |
| Olie, RH | 1 |
| Veenstra, LF | 1 |
| Zwaveling, S | 1 |
| Verhezen, PW | 1 |
| Ten Cate-Hoek, AJ | 1 |
| Ten Cate, H | 3 |
| Henskens, YM | 1 |
| van der Meijden, PE | 1 |
| Panaioli, E | 1 |
| Colaiori, I | 1 |
| Lauria Pantano, A | 1 |
| Pozzilli, P | 1 |
| Palmerini, T | 4 |
| Russo, M | 1 |
| Nardi, P | 1 |
| Saitto, G | 1 |
| Bovio, E | 1 |
| Pellegrino, A | 2 |
| Scafuri, A | 1 |
| Ruvolo, G | 1 |
| Zhang, JJ | 1 |
| Gao, XF | 1 |
| Ge, Z | 1 |
| Tian, NL | 1 |
| Liu, ZZ | 1 |
| Ye, F | 2 |
| Chen, SL | 1 |
| Lee, HW | 1 |
| Hong, TJ | 1 |
| Tantray, JA | 1 |
| Reddy, KP | 1 |
| Jamil, K | 1 |
| Kumar, YS | 1 |
| Yun, YM | 1 |
| Chae, HJ | 1 |
| Cho, HJ | 1 |
| Ji, M | 1 |
| Wee, KA | 1 |
| Lee, W | 1 |
| Song, SH | 1 |
| Woo, HI | 1 |
| Chun, S | 1 |
| Sawlani, NN | 1 |
| Marchini, JF | 1 |
| Pinto, MR | 1 |
| Novaes, GC | 1 |
| Badran, AV | 1 |
| Pavão, RB | 1 |
| Figueiredo, GL | 1 |
| Lago, IM | 1 |
| Lima-Filho, MO | 1 |
| Lemos, DC | 1 |
| Tonani, M | 1 |
| Antloga, CM | 1 |
| Oliveira, L | 1 |
| Lorenzi, JC | 1 |
| Hong, LF | 1 |
| Yan, XN | 1 |
| Lu, ZH | 1 |
| Fan, Y | 2 |
| Wu, Q | 1 |
| Luo, SH | 1 |
| Yang, B | 1 |
| Li, JJ | 1 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 2 |
| Angelini, GD | 1 |
| Pufulete, M | 1 |
| White, J | 1 |
| Saydam, F | 1 |
| Değirmenci, İ | 1 |
| Birdane, A | 1 |
| Özdemir, M | 2 |
| Ulus, T | 1 |
| Özbayer, C | 1 |
| Çolak, E | 1 |
| Ata, N | 1 |
| Güneş, HV | 1 |
| Strisciuglio, T | 1 |
| Di Gioia, G | 1 |
| De Biase, C | 1 |
| Delrue, L | 1 |
| Pellicano, M | 1 |
| Bartunek, J | 3 |
| Vanderheyden, M | 1 |
| Izzo, R | 1 |
| Trimarco, B | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Ancona, MB | 1 |
| Yu, J | 1 |
| Ooi, SY | 1 |
| Xu, K | 1 |
| Zuliani Mauro, MF | 1 |
| Costa, R | 3 |
| Piva E Mattos, LA | 1 |
| Siqueira, D | 3 |
| Sousa, A | 1 |
| Goodman, SG | 2 |
| Requena, G | 1 |
| Maguire, A | 1 |
| Blankenberg, S | 2 |
| Granger, CB | 2 |
| Grieve, R | 1 |
| Pocock, SJ | 1 |
| Simon, T | 1 |
| Yasuda, S | 1 |
| Vega, AM | 1 |
| Brieger, D | 2 |
| Koltowski, L | 1 |
| Tomaniak, M | 1 |
| Aradi, D | 2 |
| Huczek, Z | 2 |
| Filipiak, KJ | 1 |
| Kochman, J | 2 |
| Balsam, P | 1 |
| Gajda, S | 1 |
| Opolski, G | 1 |
| Gupta, R | 1 |
| Ozan, MO | 1 |
| Grinshtein, IY | 1 |
| Savchenko, AA | 1 |
| Grinshtein, YI | 1 |
| Filonenko, IV | 1 |
| Kosinova, AA | 1 |
| van Klaveren, D | 1 |
| Räber, L | 2 |
| Pilgrim, T | 2 |
| Zanchin, T | 1 |
| Steyerberg, EW | 1 |
| Brar, SS | 1 |
| Kim, J | 1 |
| Brar, SK | 1 |
| Zadegan, R | 1 |
| Ree, M | 1 |
| Liu, IL | 1 |
| Mansukhani, P | 1 |
| Aharonian, V | 1 |
| Hyett, R | 1 |
| Shen, AY | 1 |
| Prasad, A | 1 |
| Tsimikas, S | 1 |
| Capranzano, P | 5 |
| Goto, S | 3 |
| Aslam, M | 1 |
| Charlton, RK | 5 |
| Suzuki, Y | 1 |
| Box, LC | 1 |
| Shoemaker, SB | 2 |
| Meade, TW | 2 |
| Ezekowitz, M | 2 |
| O'Connor, CM | 3 |
| Vorchheimer, DA | 3 |
| Guyatt, GH | 2 |
| Mark, DB | 2 |
| Addad, F | 1 |
| Chakroune, T | 1 |
| Asma, A | 1 |
| Abderazek, F | 1 |
| Zohra, D | 1 |
| Ghrissi, I | 1 |
| Hassine, M | 1 |
| Gamra, H | 1 |
| Elalamy, I | 2 |
| Pokov, I | 1 |
| Chesebro, J | 1 |
| Badimon, J | 1 |
| Fukushima, K | 3 |
| Iwata, Y | 4 |
| Kuroda, N | 3 |
| Ooyama, M | 3 |
| Nomura, F | 3 |
| Komuro, I | 3 |
| Abuzahra, M | 1 |
| Pillai, M | 1 |
| Caldera, A | 1 |
| Hartley, WB | 1 |
| Gonzalez, R | 1 |
| Bobek, J | 1 |
| Dokainish, H | 2 |
| Lakkis, N | 2 |
| Duzenli, MA | 1 |
| Ozdemir, K | 1 |
| Aygul, N | 1 |
| Soylu, A | 1 |
| Tokac, M | 1 |
| De Miguel, A | 2 |
| Ibanez, B | 1 |
| Badimón, JJ | 3 |
| de la Cruz, KI | 1 |
| Tsai, PI | 1 |
| Cohn, WE | 1 |
| Cooley, DA | 1 |
| Gori, AM | 5 |
| Moschi, G | 1 |
| Paniccia, R | 3 |
| Buonamici, P | 2 |
| Vergara, R | 1 |
| Guthikonda, S | 1 |
| Alviar, CL | 2 |
| Arikan, M | 1 |
| Tellez, A | 2 |
| DeLao, T | 1 |
| Granada, JF | 2 |
| Dong, JF | 1 |
| Dippon, J | 1 |
| Winter, S | 2 |
| Buse, V | 1 |
| Bischofs, C | 2 |
| Zuern, C | 1 |
| Moerike, K | 1 |
| Peace, AJ | 1 |
| Tedesco, AF | 1 |
| Dicker, P | 1 |
| Berndt, MC | 1 |
| Kenny, D | 1 |
| Nguyen, TA | 2 |
| Tanaka, N | 1 |
| Terashima, M | 1 |
| Kinoshita, Y | 1 |
| Kimura, M | 1 |
| Nasu, K | 1 |
| Ehara, M | 1 |
| Tsuchikane, E | 1 |
| Matsubara, T | 1 |
| Asakura, Y | 1 |
| Katoh, O | 1 |
| Suzuki, T | 1 |
| Cervinka, P | 1 |
| Bystron, M | 1 |
| Spacek, R | 1 |
| Kvasnak, M | 1 |
| Adhikari, S | 1 |
| Jakabcin, J | 1 |
| Horowitz, JD | 1 |
| Chirkov, YY | 1 |
| Schäfer, A | 5 |
| Weinberger, S | 1 |
| Flierl, U | 4 |
| Eigenthaler, M | 2 |
| Störk, S | 1 |
| Walter, U | 3 |
| Ertl, G | 1 |
| Bauersachs, J | 5 |
| Johnell, M | 1 |
| Brandt, JT | 4 |
| Ivandic, BT | 2 |
| Kurz, K | 1 |
| Keck, F | 1 |
| Staritz, P | 2 |
| Lehrke, S | 1 |
| Katus, HA | 2 |
| Giannitsis, E | 2 |
| Tourmousoglou, CE | 1 |
| Rokkas, CK | 1 |
| Ferguson, AD | 1 |
| Xiang, YZ | 1 |
| Béres, BJ | 1 |
| Tóth-Zsámboki, E | 1 |
| Vargová, K | 1 |
| László, A | 1 |
| Masszi, T | 1 |
| Kerecsen, G | 1 |
| Préda, I | 1 |
| Mende, A | 1 |
| Obata, JE | 1 |
| Sano, K | 1 |
| Hirano, M | 1 |
| Kitta, Y | 1 |
| Kodama, Y | 1 |
| Nakamura, T | 1 |
| Kawabata, K | 1 |
| Saitoh, Y | 1 |
| Fujioka, D | 1 |
| Kobayashi, T | 2 |
| Satoh, K | 1 |
| Ozaki, Y | 2 |
| Yano, T | 1 |
| Kugiyama, K | 1 |
| Kim, KE | 1 |
| Woo, KS | 2 |
| Goh, RY | 2 |
| Quan, ML | 1 |
| Han, JY | 3 |
| Li, J | 3 |
| Jian, Z | 1 |
| Huang, L | 1 |
| Guo, H | 1 |
| Huang, J | 1 |
| Qian, D | 1 |
| Fu, W | 1 |
| Li, A | 1 |
| Song, Y | 1 |
| Ernest, CS | 2 |
| Rohatagi, S | 2 |
| Salazar, DE | 1 |
| Wrishko, RE | 1 |
| Cairns, JA | 1 |
| Eikelboom, J | 1 |
| Ozturk, B | 1 |
| Tacoy, G | 1 |
| Coskun, U | 1 |
| Yaman, E | 1 |
| Sahin, G | 1 |
| Buyukberber, S | 1 |
| Yildiz, R | 1 |
| Kaya, AO | 1 |
| Topal, S | 1 |
| Benekli, M | 1 |
| Roy, P | 2 |
| de Labriolle, A | 3 |
| Slottow, TL | 1 |
| Steinberg, DH | 1 |
| Kaneshige, K | 3 |
| Xue, Z | 3 |
| Satler, LF | 5 |
| Kent, KM | 5 |
| Suddath, WO | 5 |
| Pichard, AD | 5 |
| Lindsay, J | 1 |
| Acikel, S | 1 |
| Akdemir, R | 1 |
| Cagirci, G | 2 |
| Yesilay, AB | 1 |
| Dogan, M | 1 |
| Kilic, H | 1 |
| Haberl, K | 1 |
| Prillinger, K | 1 |
| Lang, I | 1 |
| Steinhubl, SR | 8 |
| Brennan, DM | 1 |
| Topol, EJ | 5 |
| Broucqsault, D | 1 |
| Rosey, G | 1 |
| Motovska, Z | 6 |
| Widimsky, P | 5 |
| Petr, R | 2 |
| Bilkova, D | 2 |
| Marinov, I | 2 |
| Simek, S | 2 |
| Kala, P | 3 |
| Jennings, LK | 2 |
| Braun, S | 6 |
| Vogt, W | 2 |
| von Beckerath, N | 9 |
| Mahla, E | 1 |
| Antonino, MJ | 5 |
| Brilakis, ES | 2 |
| Lichtenwalter, C | 1 |
| Roesle, M | 1 |
| Obel, O | 1 |
| Haagen, D | 1 |
| Saeed, B | 1 |
| Gadiparthi, C | 1 |
| Bissett, JK | 1 |
| Sachdeva, R | 1 |
| Voudris, VV | 1 |
| Karyofillis, P | 1 |
| Kar, B | 1 |
| Rossen, J | 1 |
| Fasseas, P | 1 |
| Berger, P | 1 |
| Banerjee, S | 2 |
| Merlini, P | 1 |
| Dean, J | 1 |
| Yujie, Z | 1 |
| Yingxin, Z | 1 |
| Yuyang, L | 1 |
| Yonghe, G | 1 |
| Wanjun, C | 1 |
| Zheng, C | 1 |
| Jung, JH | 1 |
| Min, PK | 1 |
| Sung, CW | 1 |
| Choi, S | 1 |
| Lee, N | 1 |
| Byun, KH | 1 |
| Holt, J | 1 |
| Dunn, SP | 1 |
| Smyth, SS | 1 |
| Campbell, CL | 1 |
| Charnigo, R | 1 |
| Akers, WS | 1 |
| Augoustides, JG | 1 |
| Ramakrishna, H | 1 |
| Pastor-Pérez, FJ | 1 |
| Rivera, J | 1 |
| Lozano, ML | 1 |
| Marín, F | 1 |
| Mirabella, F | 1 |
| Francaviglia, B | 1 |
| Di Salvo, ME | 1 |
| Galassi, AR | 2 |
| Tamburino, C | 1 |
| Ionescu, CN | 1 |
| Chrissoheris, M | 1 |
| Caraccciolo, EA | 1 |
| Stegherr, J | 4 |
| Hadamitzky, M | 1 |
| Spinler, SA | 1 |
| Kosuge, M | 3 |
| Ebina, T | 3 |
| Hibi, K | 3 |
| Morita, S | 3 |
| Komura, N | 1 |
| Hashiba, K | 2 |
| Kiyokuni, M | 1 |
| Nakayama, N | 1 |
| Umemura, S | 3 |
| Kimura, K | 3 |
| Morton, J | 1 |
| Nelluri, S | 1 |
| Dai, X | 1 |
| Makaryus, AN | 1 |
| Makaryus, JN | 1 |
| Jauhar, R | 1 |
| Steinwender, C | 1 |
| Hartenthaler, B | 1 |
| Lambert, T | 1 |
| Kypta, A | 1 |
| Kammler, J | 1 |
| Hönig, S | 1 |
| Hofmann, R | 1 |
| Kerschner, K | 1 |
| Leisch, F | 1 |
| Siddique, A | 1 |
| Butt, M | 1 |
| Shantsila, E | 2 |
| Guerra, M | 1 |
| Mota, JC | 1 |
| Veloso, M | 1 |
| Gama, V | 1 |
| Vouga, L | 1 |
| Bruskina, O | 1 |
| Massberg, S | 2 |
| Dirschinger, J | 3 |
| Yun, SC | 5 |
| Tanajura, LF | 2 |
| Mattos, LA | 1 |
| Bonan, R | 2 |
| Sousa, JE | 2 |
| Aleil, B | 2 |
| Jacquemin, L | 1 |
| De Poli, F | 1 |
| Zaehringer, M | 1 |
| Cazenave, JP | 2 |
| Dickele, MC | 1 |
| Monassier, JP | 1 |
| Gachet, C | 4 |
| Gladding, P | 1 |
| Webster, M | 1 |
| Zeng, I | 1 |
| Farrell, H | 1 |
| Stewart, J | 1 |
| Ruygrok, P | 2 |
| Ormiston, J | 1 |
| El-Jack, S | 1 |
| Armstrong, G | 1 |
| Kay, P | 1 |
| Scott, D | 1 |
| Gunes, A | 1 |
| Dahl, ML | 1 |
| Saw, J | 3 |
| Densem, C | 1 |
| Walsh, S | 1 |
| Jokhi, P | 1 |
| Starovoytov, A | 1 |
| Fox, R | 1 |
| Wong, G | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Mancini, GB | 1 |
| Fung, A | 1 |
| Mouret, JP | 1 |
| Bali, L | 1 |
| Moro, PJ | 1 |
| Margolis, JR | 1 |
| Jing, Q | 2 |
| Xu, B | 2 |
| Shang, X | 1 |
| Jiang, T | 2 |
| Li, Z | 1 |
| Zhang, H | 2 |
| Qiu, J | 1 |
| Gao, R | 2 |
| Versaci, F | 1 |
| Reimers, B | 1 |
| Del Giudice, C | 1 |
| Schofer, J | 2 |
| Giacomin, A | 1 |
| Saccà, S | 1 |
| Gandini, R | 1 |
| Albiero, R | 1 |
| Bertoldo, F | 1 |
| Simonetti, G | 1 |
| Chiariello, L | 1 |
| Maldonado, G | 1 |
| Awata, M | 1 |
| Nanto, S | 1 |
| Uematsu, M | 1 |
| Morozumi, T | 1 |
| Watanabe, T | 1 |
| Onishi, T | 1 |
| Iida, O | 1 |
| Sera, F | 1 |
| Minamiguchi, H | 1 |
| Kotani, J | 1 |
| Nagata, S | 1 |
| Mrdovic, I | 2 |
| Savic, L | 2 |
| Perunicic, J | 2 |
| Asanin, M | 2 |
| Lasica, R | 2 |
| Marinkovic, J | 2 |
| Vasiljevic, Z | 2 |
| Ostojic, M | 2 |
| Kumar, A | 1 |
| Kao, J | 1 |
| Furgieri, A | 1 |
| Sabatè, M | 9 |
| Hamon, M | 1 |
| Repetto, A | 1 |
| Brugaletta, S | 2 |
| Parrinello, G | 1 |
| Percoco, G | 1 |
| Kvasnicka, J | 1 |
| Hajkova, J | 1 |
| Malmström, RE | 1 |
| Ostergren, J | 1 |
| Jørgensen, L | 1 |
| Hjemdahl, P | 2 |
| Kogushi, M | 1 |
| Dastros-Pitei, D | 1 |
| Lee, JM | 1 |
| Park, S | 1 |
| Shin, DJ | 1 |
| Shim, CY | 1 |
| Chang, CW | 1 |
| Lee, JE | 1 |
| Ben-Dor, I | 3 |
| Lev, E | 1 |
| Undas, A | 4 |
| Stepień, E | 1 |
| Branicka, A | 1 |
| Zmudka, K | 3 |
| Tracz, W | 1 |
| Li, YG | 3 |
| Ni, L | 1 |
| Payne, CD | 3 |
| Farid, NA | 1 |
| Perez de Prado, A | 1 |
| Cuellas, C | 1 |
| Diego, A | 1 |
| Fernandez-Vazquez, F | 1 |
| Kim, H | 1 |
| Lee, HK | 1 |
| Walsh, SN | 1 |
| Kerchner, K | 1 |
| Sangüeza, OP | 1 |
| Turgeon, J | 1 |
| Vassilev, D | 1 |
| Formuszewicz, R | 1 |
| Rusicka-Piekarz, T | 1 |
| Doganov, A | 1 |
| Shuldiner, AR | 5 |
| O'Connell, JR | 3 |
| Gandhi, A | 1 |
| Ryan, K | 4 |
| Horenstein, RB | 3 |
| Damcott, CM | 2 |
| Pakyz, R | 1 |
| Gibson, Q | 3 |
| Pollin, TI | 2 |
| Post, W | 1 |
| Parsa, A | 2 |
| Mitchell, BD | 3 |
| Faraday, N | 2 |
| Herzog, W | 2 |
| Alberts, P | 1 |
| Fontana, P | 1 |
| Mann, J | 1 |
| Bounameaux, H | 1 |
| Sorensen, AS | 1 |
| Ghenim, R | 1 |
| Roncalli, J | 1 |
| Tidjane, AM | 1 |
| Bongard, V | 1 |
| Ziani, A | 1 |
| Boudou, N | 1 |
| Dumonteil, N | 1 |
| Marcheix, B | 1 |
| Léobon, B | 1 |
| Latif, F | 1 |
| Heldman, AW | 1 |
| Hennebry, TA | 1 |
| Ensor, CR | 1 |
| Cahoon, WD | 1 |
| Castillo-Sang, M | 1 |
| Tsang, AW | 1 |
| Almaroof, B | 1 |
| Cireddu, J | 1 |
| Sferra, J | 1 |
| Zelenock, GB | 1 |
| Engoren, M | 1 |
| Kasper, G | 1 |
| Bagur, R | 2 |
| Bertrand, OF | 3 |
| Rodés-Cabau, J | 3 |
| Larose, E | 3 |
| Rinfret, S | 3 |
| Nguyen, CM | 2 |
| Noel, B | 2 |
| Larochellière, RD | 1 |
| Poirier, P | 1 |
| Costerousse, O | 3 |
| Roy, L | 3 |
| Zuern, CS | 1 |
| Lutilsky, N | 1 |
| Zürn, C | 2 |
| Simonenko, R | 1 |
| Rapin, M | 1 |
| Kraibooj, H | 1 |
| Kilias, A | 1 |
| May, AE | 5 |
| Herdeg, C | 3 |
| Stephens, G | 1 |
| Gretler, DD | 2 |
| Jurek, MM | 1 |
| Pakyz, RE | 2 |
| Conley, PB | 1 |
| Proulx, G | 2 |
| Gleeton, O | 2 |
| De Larochellière, R | 2 |
| Dewilde, W | 3 |
| Berg, JT | 1 |
| Rao, SV | 2 |
| Silva, MA | 1 |
| Donovan, JL | 1 |
| Kannan, AO | 1 |
| Makarov, L | 1 |
| Atar, D | 3 |
| Chapman, N | 1 |
| Schachter, M | 1 |
| Stakos, D | 1 |
| Henkelmann, N | 1 |
| Raymond, C | 1 |
| Menon, V | 1 |
| Bonello-Palot, N | 2 |
| Armero, S | 3 |
| Bonello, C | 2 |
| Mokhtar, OA | 1 |
| Arques, S | 2 |
| Camoin-Jau, L | 2 |
| Giuliani, G | 1 |
| Cerisano, G | 1 |
| Butler, K | 5 |
| Gesheff, T | 2 |
| Wei, C | 6 |
| Patil, SB | 2 |
| Karunakaran, A | 2 |
| Parris, C | 1 |
| Purdy, D | 1 |
| Wilson, V | 1 |
| Ledley, GS | 1 |
| Mancini, J | 2 |
| Lévy, N | 1 |
| Olivier, C | 1 |
| Halscheid, C | 1 |
| Helbing, T | 1 |
| Gilchrist, IC | 3 |
| Cherala, G | 1 |
| Williams, C | 1 |
| Surigin, S | 1 |
| Booze, C | 1 |
| Dedaj, R | 1 |
| Levy, W | 1 |
| Youn, TJ | 1 |
| Cho, SI | 1 |
| Kwon, DA | 1 |
| Suh, JW | 1 |
| Chang, HJ | 1 |
| Cho, YS | 1 |
| Chung, WY | 1 |
| Choi, YJ | 2 |
| Sharma, RK | 1 |
| Reddy, HK | 1 |
| Singh, VN | 1 |
| Sharma, R | 1 |
| Voelker, DJ | 1 |
| Bhatt, G | 1 |
| Rudez, G | 1 |
| van Werkum, JW | 6 |
| Leebeek, FW | 1 |
| Kruit, A | 1 |
| Ruven, HJ | 2 |
| de Maat, MP | 1 |
| Hackeng, CM | 5 |
| Parlak, E | 1 |
| Taubert, D | 2 |
| Koch, W | 1 |
| Gebhard, D | 1 |
| Schuster, T | 1 |
| Kuwabara, Y | 1 |
| Sparling, JM | 1 |
| Resnic, FS | 1 |
| Akhter, M | 1 |
| Kothari, S | 1 |
| Nie, R | 1 |
| Luo, N | 1 |
| Muller, O | 2 |
| Trana, C | 2 |
| Ntalianis, A | 2 |
| Heyndrickx, G | 1 |
| Sofi, F | 2 |
| Szlam, F | 1 |
| Tanaka, KA | 1 |
| Rumph, B | 1 |
| Bolliger, D | 1 |
| Levy, JH | 1 |
| Breet, N | 2 |
| Ten Berg, J | 3 |
| Pasceri, V | 2 |
| Pristipino, C | 1 |
| Irini, D | 1 |
| Varveri, A | 1 |
| Roncella, A | 1 |
| Speciale, G | 1 |
| Morino, Y | 1 |
| Kimura, T | 4 |
| Hayashi, Y | 1 |
| Muramatsu, T | 1 |
| Noguchi, Y | 1 |
| Kato, K | 1 |
| Shibata, Y | 1 |
| Doi, O | 1 |
| Yamashita, T | 1 |
| Morimoto, T | 2 |
| Abe, M | 2 |
| Hinohara, T | 1 |
| Mitsudo, K | 2 |
| Tsukahara, K | 1 |
| Okuda, J | 1 |
| Iwahashi, N | 2 |
| Maejima, N | 2 |
| Nakachi, T | 1 |
| Ohtsuka, F | 1 |
| Tahara, Y | 1 |
| Sugano, T | 1 |
| Kelder, JC | 3 |
| Bal, ET | 1 |
| Harmsze, AM | 2 |
| van der Heyden, JA | 1 |
| Rensing, BJ | 1 |
| Suttorp, MJ | 1 |
| Rasmussen, L | 1 |
| Nielsen, T | 1 |
| Eikelboom, JW | 2 |
| Sabe-Affaki, G | 1 |
| Husted, S | 1 |
| Henderson, D | 1 |
| Patel, DV | 1 |
| Tapp, L | 1 |
| Gao, P | 1 |
| Xiong, H | 1 |
| Zheng, Z | 2 |
| Hu, SS | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Bernardo, E | 8 |
| Vivas, D | 2 |
| Alfonso, F | 10 |
| Momary, KM | 1 |
| Dorsch, MP | 1 |
| Vergara-Jimenez, J | 1 |
| Tricoci, P | 1 |
| Gatto, L | 1 |
| Lippi, G | 1 |
| Franchini, M | 1 |
| Favaloro, EJ | 1 |
| Behan, MW | 1 |
| Chew, DP | 2 |
| Aylward, PE | 1 |
| Tomlin, ME | 1 |
| Gajos, G | 3 |
| Rostoff, P | 2 |
| Piwowarska, W | 3 |
| Engelhardt, A | 2 |
| Lask, S | 2 |
| Börgel, J | 1 |
| Endres, HG | 1 |
| Wong, YW | 1 |
| Prakash, R | 1 |
| Adams, HP | 1 |
| Schill, DM | 1 |
| Scheinowitz, M | 1 |
| Wakabayashi, K | 1 |
| Maluenda, G | 2 |
| Syed, AI | 2 |
| Collins, SD | 2 |
| Gonzalez, MA | 1 |
| Gaglia, MA | 2 |
| Eshtehardi, P | 2 |
| Cook, S | 2 |
| Billinger, M | 1 |
| Togni, M | 2 |
| Garachemani, A | 2 |
| Meier, B | 3 |
| Hess, OM | 2 |
| Wenaweser, P | 3 |
| Mezilis, N | 1 |
| Dardas, P | 1 |
| Ninios, V | 1 |
| Tsikaderis, D | 1 |
| Judge, HM | 2 |
| Buckland, RJ | 1 |
| Polydorou, AD | 1 |
| Megaloikonomos, P | 1 |
| Moutiris, JA | 1 |
| Polydorou, V | 1 |
| Antypa, E | 1 |
| Testembasi, E | 1 |
| Tziakouri, CH | 1 |
| Palatianos, G | 1 |
| Nikas, D | 1 |
| Bolos, K | 1 |
| Polydorou, A | 1 |
| Kang, MK | 2 |
| Ahn, YJ | 1 |
| Mueller, K | 1 |
| Aichele, S | 2 |
| Ninci, E | 1 |
| Senay, S | 1 |
| Toraman, F | 1 |
| Karabulut, H | 1 |
| Alhan, C | 1 |
| Huang, CC | 2 |
| Chen, YC | 1 |
| Leu, HB | 2 |
| Chen, TJ | 1 |
| Lin, SJ | 1 |
| Chan, WL | 1 |
| Chen, JW | 1 |
| Pförtsch, S | 1 |
| Seydelmann, N | 1 |
| Micka, J | 1 |
| Zeymer, U | 1 |
| Madan, M | 1 |
| McClure, MW | 1 |
| Paynter, GE | 1 |
| Thompson, V | 1 |
| Welsh, RC | 1 |
| Ostad, MA | 2 |
| Nick, E | 1 |
| Paixao-Gatinho, V | 1 |
| Schnorbus, B | 1 |
| Schiewe, R | 1 |
| Tschentscher, P | 2 |
| Munzel, T | 2 |
| Warnholtz, A | 2 |
| Gratsianskiĭ, NA | 1 |
| Abrecht, L | 1 |
| Zwahlen, M | 1 |
| Schmidlin, K | 1 |
| Haeberli, A | 1 |
| Gassanov, N | 1 |
| Caglayan, E | 1 |
| Nia, AM | 1 |
| Erdmann, E | 1 |
| Er, F | 1 |
| Camoin Jau, L | 1 |
| Omar Aït Mokhtar, O | 1 |
| Burignat-Bonello, C | 1 |
| Tahirou, I | 1 |
| Stankovic, G | 1 |
| Zivkovic, M | 1 |
| Müller, K | 2 |
| Herkommer, M | 1 |
| Ferreira-González, I | 2 |
| Marsal, JR | 2 |
| Ribera, A | 2 |
| Permanyer-Miralda, G | 2 |
| García-Del Blanco, B | 2 |
| Martí, G | 2 |
| Cascant, P | 2 |
| Martín-Yuste, V | 2 |
| Capote, ML | 1 |
| De La Torre, JM | 2 |
| Ruíz-Lera, M | 1 |
| Sanmiguel, D | 1 |
| Cárdenas, M | 1 |
| Pujol, B | 1 |
| Baz, JA | 1 |
| Trillo, R | 1 |
| González-Béjar, O | 1 |
| Casanova, J | 1 |
| Sánchez-Gila, J | 1 |
| García-Dorado, D | 2 |
| Siriswangvat, S | 1 |
| Sansanayudh, N | 1 |
| Nathisuwan, S | 1 |
| Panomvana, D | 1 |
| Komócsi, A | 2 |
| Vorobcsuk, A | 1 |
| Rideg, O | 1 |
| Tokés-Füzesi, M | 1 |
| Magyarlaki, T | 1 |
| Horváth, IG | 2 |
| Blindt, R | 1 |
| Becker, R | 1 |
| Kereiakes, D | 1 |
| Jin, B | 1 |
| Ni, HC | 1 |
| Shen, W | 1 |
| Shi, HM | 1 |
| Koessler, J | 1 |
| Kobsar, AL | 1 |
| Rajkovic, MS | 1 |
| Pfoertsch, S | 1 |
| Steigerwald, U | 1 |
| Rechner, AR | 1 |
| Freedman, JE | 1 |
| Iafrati, HF | 1 |
| Yong, AS | 1 |
| Pennings, GJ | 1 |
| Chang, M | 1 |
| Hamzah, A | 1 |
| Chung, T | 1 |
| Qi, M | 1 |
| Behnia, M | 1 |
| Krilis, SA | 1 |
| Ng, MK | 1 |
| Lowe, HC | 1 |
| Kritharides, L | 1 |
| Kim, BR | 1 |
| Kim, JE | 1 |
| Yu, LH | 1 |
| Cryer, BL | 1 |
| Contant, CF | 2 |
| Cohen, M | 1 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 1 |
| Murphy, SA | 1 |
| Lozano, I | 1 |
| Fernández-Cimadevilla, OC | 1 |
| Barriales, V | 1 |
| Barker, CM | 1 |
| Murray, SS | 1 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 1 |
| Gao, G | 1 |
| Pi, Y | 1 |
| Lu, B | 1 |
| Hu, S | 1 |
| Southworth, MR | 1 |
| Temple, R | 1 |
| Armstrong, M | 1 |
| Hudzik, B | 1 |
| Szkodzinski, J | 1 |
| Danikiewicz, A | 1 |
| Wilczek, K | 1 |
| Romanowski, W | 1 |
| Lekston, A | 1 |
| Polonski, L | 1 |
| Zubelewicz-Szkodzinska, B | 1 |
| Chello, M | 1 |
| Colonna, D | 1 |
| Colonna, G | 1 |
| Pepe, LL | 1 |
| Montinaro, A | 2 |
| Covino, E | 1 |
| Vanesson, L | 1 |
| Koussa, M | 1 |
| Fayad, G | 1 |
| Modine, T | 1 |
| Le May, MR | 1 |
| Tardif, JC | 2 |
| Delarochelliere, R | 1 |
| Naidoo, S | 1 |
| Wells, GA | 1 |
| Mesana, TG | 1 |
| Yang, Q | 1 |
| Ge, HL | 1 |
| Liu, YY | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Muñoz-Torrero, JF | 1 |
| Escudero, D | 1 |
| Suárez, C | 1 |
| Sanclemente, C | 1 |
| Pascual, MT | 1 |
| Zamorano, J | 1 |
| Trujillo-Santos, J | 1 |
| Monreal, M | 1 |
| Maeda, A | 1 |
| Ando, H | 1 |
| Asai, T | 1 |
| Ishiguro, H | 1 |
| Umemoto, N | 1 |
| Ohta, M | 1 |
| Morishima, M | 1 |
| Sumida, A | 1 |
| Hosohata, K | 1 |
| Ushijima, K | 1 |
| Fujimura, A | 1 |
| Awidi, A | 1 |
| Saleh, A | 1 |
| Dweik, M | 1 |
| Kailani, B | 1 |
| Abu-Fara, M | 1 |
| Nabulsi, R | 1 |
| Bener, A | 1 |
| Endo, M | 1 |
| Okada, K | 1 |
| Ishikawa, T | 1 |
| Masumura, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Antonucci, E | 2 |
| Maggini, N | 1 |
| Miranda, M | 1 |
| Romano, E | 1 |
| Prisco, D | 2 |
| Tomasello, SD | 5 |
| Kodali, M | 4 |
| Dharmashankar, K | 5 |
| Alissa, R | 1 |
| Caixeta, A | 1 |
| Lansky, AJ | 2 |
| Hermiller, JB | 2 |
| Gordon, P | 1 |
| Yaqub, M | 1 |
| Miquel-Hebert, K | 1 |
| Veldhof, S | 1 |
| Sood, P | 1 |
| Su, X | 1 |
| Jonnavithula, L | 1 |
| Sudhir, K | 1 |
| Zhu, B | 2 |
| Bonatti, J | 1 |
| Zimrin, D | 1 |
| Kulkarni, MP | 1 |
| Miller, DL | 1 |
| Banya, W | 1 |
| Cay, S | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Sarno, G | 1 |
| Dierickx, K | 1 |
| Meeus, P | 1 |
| Chen, H | 2 |
| Yan, W | 1 |
| Wu, XY | 2 |
| Juurlink, DN | 1 |
| Sadek, A | 1 |
| Ford, AC | 1 |
| Rossini, R | 2 |
| Musumeci, G | 2 |
| Lettieri, C | 2 |
| Lortkipanidze, N | 1 |
| Romano, M | 2 |
| Nijaradze, T | 1 |
| Tarantini, G | 1 |
| Cicorella, N | 1 |
| Sirbu, V | 1 |
| Guagliumi, G | 3 |
| Rosiello, R | 2 |
| Valsecchi, O | 2 |
| Gavazzi, A | 2 |
| Loenko, VB | 1 |
| Sorokina, EA | 1 |
| Bobrov, VS | 1 |
| Demakova, NL | 1 |
| Faĭl', IL | 1 |
| Gubenko, AV | 1 |
| Neumann, L | 1 |
| Lee, JH | 3 |
| Cho, YH | 3 |
| Shin, WY | 1 |
| Bang, DW | 1 |
| Park, HK | 1 |
| Park, CB | 1 |
| Park, KH | 1 |
| Peng, Y | 2 |
| Chen, M | 2 |
| Chai, H | 2 |
| Liu, XJ | 2 |
| Yan, SD | 1 |
| Wei, JF | 1 |
| Xu, YN | 1 |
| Wu, WC | 1 |
| Huang, DJ | 2 |
| Hara, M | 1 |
| Nishino, M | 1 |
| Taniike, M | 1 |
| Makino, N | 1 |
| Kato, H | 1 |
| Egami, Y | 1 |
| Shutta, R | 1 |
| Tanouchi, J | 1 |
| Yamada, Y | 1 |
| Korte, W | 1 |
| Chassot, PG | 1 |
| Eichinger, S | 1 |
| von Heymann, C | 1 |
| Hofmann, N | 1 |
| Rickli, H | 1 |
| Spannagl, M | 1 |
| Ziegler, B | 1 |
| Verheugt, F | 1 |
| Arima, M | 1 |
| Matsuda, A | 1 |
| Nitta, M | 1 |
| Yoshida, K | 1 |
| Shimizu, M | 1 |
| Yukhanyan, L | 1 |
| Freynhofer, MK | 2 |
| Siller-Matula, J | 2 |
| Schrör, K | 2 |
| Sung, JK | 1 |
| Kim, JY | 1 |
| Tentzeris, I | 2 |
| Jarai, R | 1 |
| Wojta, J | 2 |
| Yang, EH | 1 |
| Perez, E | 1 |
| Zhiroff, KA | 1 |
| Burstein, S | 1 |
| El Ghannudi, S | 1 |
| Jesel, L | 1 |
| Radulescu, B | 1 |
| El Adraa, E | 1 |
| Crimizade, U | 1 |
| Wiesel, ML | 1 |
| Morel, O | 1 |
| Karantalis, V | 1 |
| Mitropoulou, G | 1 |
| Damelou, A | 1 |
| Davlouros, P | 3 |
| Egred, M | 1 |
| Rajendran, S | 1 |
| Parikh, D | 1 |
| Shugman, I | 1 |
| French, JK | 1 |
| Juergens, CP | 1 |
| Camilleri, E | 1 |
| Jacquin, L | 1 |
| Zalewski, J | 2 |
| Nessler, J | 2 |
| Zabalza, M | 1 |
| Subirana, I | 1 |
| Sala, J | 1 |
| Lluis-Ganella, C | 1 |
| Lucas, G | 1 |
| Tomás, M | 1 |
| Masiá, R | 1 |
| Marrugat, J | 1 |
| Brugada, R | 1 |
| Elosua, R | 1 |
| Pappalardo, A | 1 |
| Mamas, MA | 1 |
| Imola, F | 1 |
| Ramazzotti, V | 1 |
| Manzoli, A | 1 |
| Prati, F | 1 |
| El-Omar, M | 1 |
| Limacher, A | 1 |
| Löffel, L | 1 |
| Stauffer, JC | 1 |
| Vogel, R | 1 |
| Khattab, AA | 1 |
| Seiler, C | 1 |
| Biancari, F | 2 |
| Airaksinen, KE | 2 |
| Niccoli, G | 1 |
| Minelli, S | 1 |
| Cosentino, N | 1 |
| Crea, F | 1 |
| Ecob, R | 1 |
| Tantry, U | 1 |
| Flaherty, MP | 1 |
| Johnston, PV | 1 |
| Rade, JJ | 1 |
| Cassese, S | 1 |
| Villari, B | 1 |
| Berti, S | 1 |
| Bellone, P | 1 |
| Alfieri, A | 1 |
| Quaranta, G | 1 |
| Marraccini, P | 1 |
| Piscione, F | 1 |
| Gesheff, M | 1 |
| Bhala, N | 1 |
| Taggar, JS | 1 |
| Rajasekhar, P | 1 |
| Banerjee, A | 1 |
| Sambu, N | 1 |
| Dent, H | 1 |
| Englyst, N | 1 |
| Warner, TD | 1 |
| Leadbeater, P | 1 |
| Roderick, P | 1 |
| Gray, H | 1 |
| Simpson, I | 1 |
| Corbett, S | 1 |
| Calver, A | 1 |
| Morgan, J | 1 |
| Curzen, N | 1 |
| McGlasson, DL | 1 |
| Shah, AD | 1 |
| Fritsma, GA | 1 |
| Doazan, JP | 1 |
| Bisdas, T | 1 |
| Haverich, A | 1 |
| Teebken, OE | 1 |
| Höchtl, T | 1 |
| Kassimis, G | 1 |
| Stavrou, EF | 1 |
| Athanassiadou, A | 1 |
| Arai, T | 1 |
| Kawamura, A | 1 |
| Matsubara, Y | 1 |
| Yokoyama, K | 1 |
| Ikeda, Y | 2 |
| Fukuda, K | 1 |
| Murata, M | 1 |
| Barone-Rochette, G | 1 |
| Foote, A | 1 |
| Motreff, P | 1 |
| Vanzetto, G | 1 |
| Quesada, JL | 1 |
| Machecourt, J | 1 |
| Yamamoto, K | 1 |
| Miyazaki, Y | 1 |
| Horio, E | 1 |
| Sato, K | 1 |
| Abe, T | 1 |
| Deguchi, M | 1 |
| Tayama, S | 1 |
| Yamabe, H | 1 |
| Nakamura, S | 2 |
| Cummings, CC | 1 |
| Dubois, BV | 1 |
| Herzog, WR | 1 |
| Kafian, S | 1 |
| Mobarrez, F | 1 |
| Kalani, M | 1 |
| Wallén, H | 1 |
| Samad, BA | 1 |
| Avdeeva, LV | 1 |
| Shtegman, OA | 1 |
| Mosina, VA | 1 |
| Guo, J | 1 |
| Zakhem, B | 1 |
| Pham, JP | 1 |
| Borsiczky, B | 1 |
| Sarszegi, Z | 1 |
| Konyi, A | 1 |
| Szabados, S | 1 |
| Gaszner, B | 1 |
| Hall, HM | 1 |
| McGuire, DK | 1 |
| Labarthe, B | 2 |
| Babin, J | 1 |
| Bryckaert, M | 1 |
| Théroux, P | 2 |
| Bonnefoy, A | 1 |
| Plakomyti, TE | 1 |
| Panagiotou, A | 1 |
| Mavronasiou, E | 1 |
| Hahalis, G | 1 |
| Bonaventura, K | 1 |
| Sonntag, S | 1 |
| Kleber, FX | 1 |
| Pathak, A | 1 |
| Gruel, Y | 1 |
| Vignalou, JB | 1 |
| Huerre, Y | 1 |
| de la Briolle, A | 1 |
| Allanic, F | 1 |
| Cerda, A | 1 |
| Russo, MW | 1 |
| Pierson, J | 1 |
| Narang, T | 1 |
| Montegudo, A | 1 |
| Eskind, L | 1 |
| Gulati, S | 1 |
| Krljanac, G | 1 |
| Antonijevic, N | 1 |
| Kocev, N | 1 |
| Zhao, YT | 1 |
| Verdo, A | 1 |
| Qi, WG | 1 |
| Zhang, DF | 1 |
| Hu, B | 1 |
| Jung, KH | 1 |
| Lew, JH | 1 |
| Lee, TW | 1 |
| Lim, CK | 1 |
| Roth, GA | 1 |
| Morden, NE | 1 |
| Zhou, W | 1 |
| Malenka, DJ | 1 |
| Skinner, J | 1 |
| Odvodyova, D | 1 |
| Fischerova, M | 1 |
| Stepankova, S | 1 |
| Maly, M | 1 |
| Morawska, P | 1 |
| Isshiki, T | 1 |
| França, CN | 1 |
| Pinheiro, LF | 1 |
| Izar, MC | 1 |
| Brunialti, MK | 1 |
| Salomão, R | 1 |
| Bianco, HT | 1 |
| Kasmas, SH | 1 |
| Barbosa, SP | 1 |
| de Nucci, G | 1 |
| Fonseca, FA | 1 |
| Aihara, H | 1 |
| Sato, A | 1 |
| Takeyasu, N | 1 |
| Nishina, H | 1 |
| Hoshi, T | 1 |
| Akiyama, D | 1 |
| Kakefuda, Y | 1 |
| Watabe, H | 1 |
| Aonuma, K | 1 |
| Neunteufl, T | 1 |
| Kozinski, M | 1 |
| Maurer, G | 2 |
| Linkowska, K | 1 |
| Grzybowski, T | 1 |
| Xu, S | 1 |
| Shetterly, S | 1 |
| Powers, D | 1 |
| Raebel, MA | 1 |
| Magid, D | 1 |
| Bruno, V | 1 |
| Willheim, M | 1 |
| Hübl, W | 1 |
| Mutnick, JL | 1 |
| Gerotziafas, GT | 1 |
| Zarifis, J | 1 |
| Bandi, A | 1 |
| Mossialos, L | 1 |
| Galea, V | 1 |
| Tsinopoulos, G | 1 |
| Chaari, M | 1 |
| Baccouche, H | 1 |
| Sassi, M | 1 |
| Feng, XR | 1 |
| Liu, ML | 1 |
| Tian, QP | 1 |
| Liu, QZ | 1 |
| Gupta, N | 1 |
| Fernández-Ruiz, M | 1 |
| Carbonell-Porras, A | 1 |
| García-Reyne, A | 1 |
| López-Medrano, F | 1 |
| Duerschmied, D | 1 |
| Ahrens, I | 1 |
| Mauler, M | 1 |
| Weidner, S | 1 |
| Kiviniemi, T | 1 |
| Karjalainen, P | 1 |
| Pietilä, M | 1 |
| Ylitalo, A | 1 |
| Niemelä, M | 1 |
| Vikman, S | 1 |
| Puurunen, M | 1 |
| Yamane, K | 1 |
| Kato, Y | 1 |
| Tazaki, J | 2 |
| Tada, T | 2 |
| Makiyama, T | 1 |
| Imai, M | 1 |
| Jinnai, T | 1 |
| Shirakawa, R | 1 |
| Horiuchi, H | 1 |
| Ren, LH | 1 |
| Peng, JJ | 1 |
| Xu, XL | 1 |
| Ye, HM | 1 |
| Jia, KY | 1 |
| Ahn, JH | 1 |
| Kwon, TJ | 1 |
| Gho, EH | 1 |
| Bliden, K | 1 |
| Høimark, L | 1 |
| Müller, U | 1 |
| Lu, X | 1 |
| Cao, J | 3 |
| Liu, X | 1 |
| Ma, C | 3 |
| Fan, L | 3 |
| Huang, B | 1 |
| Yao, H | 1 |
| Jing, X | 1 |
| Huang, H | 1 |
| Wang, P | 1 |
| Zhou, S | 1 |
| Zhou, R | 1 |
| Liu, G | 1 |
| Tang, P | 1 |
| He, Y | 1 |
| Yang, J | 1 |
| Cho, KI | 1 |
| Jin, HY | 1 |
| Seo, JS | 1 |
| Yang, TH | 1 |
| Kim, DK | 1 |
| Kim, BH | 1 |
| Park, YH | 1 |
| Je, HG | 1 |
| Chirumamilla, AP | 1 |
| Kanwal, S | 1 |
| Hassanin, A | 1 |
| Hakim, D | 1 |
| Guo, N | 1 |
| Pyo, R | 1 |
| Moses, JW | 1 |
| Fahy, M | 1 |
| Kovacic, JC | 2 |
| Steg, GW | 1 |
| Todd, M | 1 |
| Dietrich, M | 1 |
| Gallup, D | 1 |
| Skerjanec, S | 1 |
| Lu, XC | 1 |
| Liu, XF | 1 |
| Natsuaki, M | 1 |
| Furukawa, Y | 1 |
| Nakagawa, Y | 1 |
| Kadota, K | 1 |
| Iwabuchi, M | 1 |
| Shizuta, S | 1 |
| Shiomi, H | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Inada, T | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Taniguchi, R | 1 |
| Eizawa, H | 1 |
| Nakano, A | 1 |
| Suwa, S | 1 |
| Takizawa, A | 1 |
| Nohara, R | 1 |
| Fujiwara, H | 1 |
| Nobuyoshi, M | 1 |
| Kita, T | 1 |
| Shah, S | 1 |
| Chan, MY | 2 |
| Cornel, JH | 1 |
| Ohman, EM | 2 |
| Fraccarollo, D | 1 |
| Lausenmeyer, E | 1 |
| Rosenstock, T | 1 |
| Schulz, C | 1 |
| Rai, M | 1 |
| Seip, RL | 1 |
| Gupta, A | 2 |
| McKay, RG | 1 |
| Hirst, J | 1 |
| Thompson, PD | 1 |
| Ruaño, G | 1 |
| Dai, ZL | 1 |
| Konosic, S | 1 |
| Kar, R | 1 |
| Meena, A | 1 |
| Yadav, BK | 1 |
| Yadav, R | 1 |
| Kar, SS | 1 |
| Saxena, R | 1 |
| Lee, P | 1 |
| Karajgikar, R | 1 |
| Narechania, B | 1 |
| Suleman, J | 1 |
| Moreno, PR | 1 |
| Liang, Y | 1 |
| Johnston, M | 1 |
| Hirsh, J | 1 |
| Pare, G | 1 |
| Li, C | 1 |
| Mehta, S | 1 |
| Teo, KK | 1 |
| Sloane, D | 1 |
| Yi, Q | 1 |
| Zhu, J | 1 |
| Liang, M | 1 |
| Liew, TV | 1 |
| Puri, A | 1 |
| Hyde, L | 1 |
| Devlin, G | 1 |
| Jiang, J | 1 |
| Sun, Y | 1 |
| Xiang, MX | 1 |
| Dong, L | 1 |
| Liu, XB | 1 |
| Hu, XY | 1 |
| Feng, Y | 1 |
| Wang, JA | 1 |
| Nagata, Y | 1 |
| Inomata, J | 1 |
| Kinoshita, M | 1 |
| Kurokawa, K | 1 |
| Aburadani, I | 1 |
| Maruyama, M | 1 |
| Usuda, K | 1 |
| El Mallah, W | 1 |
| Moliterno, DJ | 1 |
| Klein, AJ | 1 |
| Wang, X | 2 |
| Yan, G | 1 |
| Ma, Y | 1 |
| Wang, G | 2 |
| Wang, S | 1 |
| Zhu, G | 1 |
| Lv, H | 1 |
| Yuan, S | 1 |
| Ji, H | 1 |
| Lønnebakken, MT | 1 |
| Gerdts, E | 1 |
| Pedersen, OM | 1 |
| Masotti-Centol, M | 1 |
| Carrillo, X | 1 |
| Mauri, J | 1 |
| Batalla, N | 1 |
| Larrousse, E | 1 |
| Martín, E | 1 |
| Serra, A | 1 |
| Ruiz-Salmerón, R | 1 |
| Canali, E | 1 |
| Benedetti, G | 1 |
| Paulu, P | 1 |
| Osmancik, P | 1 |
| Tousek, P | 1 |
| Minarik, M | 1 |
| Benesova, L | 1 |
| Bednar, F | 1 |
| Kocka, V | 1 |
| Hu, J | 1 |
| Fang, R | 1 |
| Drissa, A | 1 |
| Manzo Silberman, S | 1 |
| Logeart, D | 1 |
| Broderick, S | 1 |
| Alexander, KP | 1 |
| Newby, LK | 1 |
| Shaw, LK | 2 |
| Darwish, OS | 1 |
| Iqbal, E | 1 |
| Foley, D | 1 |
| Moser, B | 1 |
| Bergmeijer, T | 1 |
| Eisenstein, EL | 2 |
| Wojdyla, D | 1 |
| Anstrom, KJ | 2 |
| Brennan, JM | 1 |
| Douglas, PS | 1 |
| Lewis, JP | 2 |
| Tanner, K | 2 |
| Chai, S | 1 |
| Peer, CJ | 1 |
| Figg, WD | 1 |
| Spencer, SD | 1 |
| Pacanowski, MA | 1 |
| Kodali, MK | 1 |
| Kozan, Ö | 1 |
| Bennett, MR | 1 |
| Han, YL | 1 |
| Yang, LX | 1 |
| Liu, HL | 1 |
| Qu, P | 1 |
| Li, WM | 1 |
| Jiang, TM | 1 |
| Li, SM | 1 |
| Jing, QM | 1 |
| Zhang, QY | 1 |
| Gao, RL | 1 |
| Lee, SP | 1 |
| Lee, HL | 1 |
| Lee, KN | 1 |
| Gusmão, MO | 1 |
| Castello, H | 1 |
| Nicolela, E | 1 |
| Mulukutla, SR | 1 |
| Marroquin, OC | 1 |
| Vlachos, HA | 1 |
| Selzer, F | 1 |
| Toma, C | 1 |
| Kip, KE | 1 |
| Abbott, JD | 1 |
| Holper, E | 1 |
| Lee, JS | 1 |
| Khandhar, S | 1 |
| Kutcher, M | 1 |
| Kelsey, S | 1 |
| Smith, C | 1 |
| Faxon, D | 1 |
| Williams, DO | 1 |
| Song, HG | 1 |
| Ohkubo, K | 1 |
| Kadohira, T | 1 |
| Morino, T | 1 |
| Belardi, JA | 1 |
| Albertal, M | 1 |
| Lin, Y | 1 |
| Lu, Z | 1 |
| Luo, C | 1 |
| shi, Y | 1 |
| Zeng, Q | 1 |
| Cao, Y | 1 |
| Liu, L | 1 |
| Ji, Q | 1 |
| Thani, KB | 1 |
| Ilapakurti, M | 1 |
| Lee, MS | 1 |
| Palakodeti, V | 1 |
| Bellemain-Appaix, A | 1 |
| Cucherat, M | 1 |
| Jacq, L | 1 |
| Bernasconi, F | 1 |
| Kaider, A | 1 |
| Park, JB | 1 |
| Kim, SY | 1 |
| Park, J | 1 |
| Park, CG | 2 |
| Huang, KW | 1 |
| Luo, JC | 1 |
| Hou, MC | 1 |
| Chen, TS | 1 |
| Lu, CL | 1 |
| Lin, HC | 1 |
| Lee, FY | 1 |
| Chang, FY | 1 |
| Wang, XQ | 1 |
| Zhao, ZG | 1 |
| Zhang, C | 1 |
| Luo, XL | 1 |
| Leng, WX | 1 |
| Ren, JW | 1 |
| Cong, YL | 1 |
| Hu, GL | 1 |
| Hu, QQ | 1 |
| Niu, H | 1 |
| Feng, CH | 1 |
| White, AA | 1 |
| Stevenson, DD | 1 |
| Singh, M | 1 |
| Bolla, VH | 1 |
| Berg, R | 1 |
| Beitelshees, AL | 1 |
| Pakzy, R | 1 |
| Post, WS | 1 |
| Gong, Y | 1 |
| Pepine, CJ | 1 |
| Johnson, JA | 1 |
| Kübler, W | 1 |
| Kim, HJ | 1 |
| Jagroop, IA | 1 |
| Malley, M | 1 |
| Mikhailidis, DP | 1 |
| Bahrmann, P | 1 |
| Sigusch, HH | 1 |
| Surber, R | 1 |
| Figulla, HR | 1 |
| Klinkhardt, U | 1 |
| Bauersachs, R | 1 |
| Adams, J | 1 |
| Graff, J | 1 |
| Lindhoff-Last, E | 1 |
| Harder, S | 1 |
| Mueller, C | 1 |
| Roskamm, H | 1 |
| Hunziker, P | 1 |
| Marsch, S | 1 |
| Perruchoud, A | 1 |
| Buettner, HJ | 1 |
| Fujita, M | 1 |
| Mizuno, K | 1 |
| Ho, M | 1 |
| Tsukahara, R | 1 |
| Miyamoto, A | 1 |
| Miki, O | 1 |
| Ishii, K | 1 |
| Miwa, K | 1 |
| Ziegler, BK | 1 |
| Rasmussen, LH | 1 |
| Hildebrandt, PR | 1 |
| Nielsen, HK | 1 |
| Hiatt, BL | 1 |
| Voskoboĭ, VI | 1 |
| Rebrov, AP | 1 |
| Brennan, D | 1 |
| Averkov, OV | 1 |
| Shalaev, SV | 1 |
| Remes, V | 1 |
| Helenius, I | 1 |
| Tendera, M | 1 |
| Wojakowski, W | 1 |
| Ortolani, P | 1 |
| Marzocchi, A | 2 |
| Gaiba, W | 1 |
| Neri, S | 1 |
| Marrozzini, C | 1 |
| Aquilina, M | 1 |
| Branzi, A | 1 |
| Chen, WH | 2 |
| Lee, PY | 1 |
| Ng, W | 1 |
| Tse, HF | 1 |
| Lau, CP | 1 |
| Cavuşoğlu, E | 1 |
| Santa-Cruz, RA | 1 |
| Guetta, V | 1 |
| Beinart, R | 1 |
| Bienart, R | 1 |
| Goldenberg, I | 1 |
| Novikov, I | 1 |
| Pres, H | 1 |
| Yalcin, R | 1 |
| Erkan, A | 1 |
| Ergun, MA | 1 |
| Yurtcu, E | 1 |
| Vishnevetsky, D | 1 |
| Kiyanista, VA | 1 |
| Gandhi, PJ | 1 |
| Inoue, T | 1 |
| Uchida, T | 1 |
| Sakuma, M | 1 |
| Imoto, Y | 1 |
| Ozeki, Y | 1 |
| Hikichi, Y | 1 |
| Node, K | 1 |
| Fangio, P | 1 |
| De Jonghe, B | 1 |
| Lachérade, JC | 1 |
| Terville, JP | 1 |
| Outin, H | 1 |
| Diehm, C | 1 |
| Lawall, H | 1 |
| Huber, R | 1 |
| Rioufol, G | 1 |
| Finet, G | 1 |
| Ginon, I | 1 |
| André-Fouët, X | 1 |
| Füessl, HS | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| Schulman, SP | 1 |
| Gorchakova, O | 1 |
| Mocz, A | 1 |
| Joost, A | 1 |
| Ramírez, C | 4 |
| Bañuelos, C | 5 |
| Hernández-Antolín, R | 3 |
| Moreno, R | 5 |
| Schühlen, H | 1 |
| Dibra, A | 1 |
| Dotzer, F | 1 |
| Bollwein, H | 1 |
| Berger, PP | 1 |
| Kubler, PA | 1 |
| Pillans, PI | 1 |
| Marrinan, MC | 1 |
| Frogley, M | 1 |
| Goldberg, SL | 1 |
| Kuchulakanti, P | 1 |
| Kapetanakis, EI | 1 |
| Lew, R | 1 |
| Cheneau, E | 1 |
| Pakala, R | 1 |
| Haile, E | 1 |
| Corso, P | 1 |
| Raja, SG | 1 |
| Silberman, S | 1 |
| Neukirch-Stoop, C | 1 |
| Borja, J | 1 |
| Bernstein, RA | 1 |
| Albers, GW | 1 |
| Pintér, T | 1 |
| Smith, SM | 1 |
| Peters, G | 1 |
| Bavry, AA | 1 |
| Kumbhani, DJ | 1 |
| Helton, TJ | 1 |
| Dziewierz, A | 1 |
| Dudek, D | 2 |
| Heba, G | 1 |
| Rakowski, T | 1 |
| Dubiel, JS | 2 |
| Savonitto, S | 1 |
| Ambrosini, V | 1 |
| Tolaro, S | 1 |
| Petronio, AS | 1 |
| Bongo, AS | 1 |
| Gaglione, A | 1 |
| Bolognese, L | 1 |
| Salam, AM | 1 |
| Baumann, PQ | 1 |
| Whitaker, DA | 1 |
| Sobel, BE | 1 |
| Cavallari, U | 2 |
| Trabetti, E | 2 |
| Hernández, R | 3 |
| Costa, MA | 5 |
| Pignatti, PF | 2 |
| Blann, A | 1 |
| Meyer, N | 1 |
| Mossard, JM | 1 |
| Almsherqi, ZA | 1 |
| McLachan, C | 1 |
| Deng, Y | 1 |
| Baggish, AL | 1 |
| Dropinski, J | 2 |
| Musial, J | 1 |
| Jakiela, B | 2 |
| Wegrzyn, W | 2 |
| Sanak, M | 2 |
| Szczeklik, A | 2 |
| Azar, RR | 1 |
| Kassab, R | 1 |
| Zoghbi, A | 1 |
| Aboujaoudé, S | 1 |
| El-Osta, H | 1 |
| Ghorra, P | 1 |
| Germanos, M | 1 |
| Salamé, E | 1 |
| Ekman, M | 1 |
| Sjögren, I | 1 |
| Cooke, GE | 1 |
| Liu-Stratton, Y | 1 |
| Ferketich, AK | 1 |
| Moeschberger, ML | 1 |
| Frid, DJ | 1 |
| Magorien, RD | 1 |
| Bray, PF | 1 |
| Binkley, PF | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Vallurupalli, NG | 1 |
| Goldhaber, SZ | 1 |
| Kelly, RV | 1 |
| Hsu, A | 1 |
| Topol, E | 1 |
| Steinhubl, S | 1 |
| Klutmann, M | 1 |
| Tillmanns, C | 1 |
| Gulba, DC | 1 |
| Skowasch, D | 1 |
| Viktor, A | 1 |
| Schneider-Schmitt, M | 1 |
| Lüderitz, B | 1 |
| Nickenig, G | 1 |
| Bauriedel, G | 1 |
| Frundi, D | 1 |
| Lau, WC | 2 |
| Radke, PW | 1 |
| Hoffmann, R | 1 |
| Zernecke, A | 1 |
| Kaiser, A | 1 |
| Weber, C | 1 |
| Jernberg, T | 1 |
| Darstein, C | 1 |
| Naganuma, H | 1 |
| Heitzer, T | 1 |
| Rudolph, V | 1 |
| Schwedhelm, E | 2 |
| Karstens, M | 1 |
| Sydow, K | 1 |
| Ortak, M | 1 |
| Meinertz, T | 1 |
| Böger, R | 1 |
| Baldus, S | 1 |
| Lee-Wong, M | 1 |
| Gadhvi, D | 1 |
| Resnick, D | 1 |
| Olivier, AC | 1 |
| Hollman, JL | 1 |
| Furman, MI | 2 |
| Linden, MD | 2 |
| Fox, ML | 2 |
| Barnard, MR | 2 |
| Waehre, T | 1 |
| Damås, JK | 1 |
| Pedersen, TM | 1 |
| Gullestad, L | 1 |
| Yndestad, A | 1 |
| Andreassen, AK | 1 |
| Frøland, SS | 1 |
| Semb, AG | 1 |
| Hansteen, V | 1 |
| Gjertsen, E | 1 |
| Ueland, T | 1 |
| Brosstad, F | 1 |
| Solum, NO | 1 |
| Aukrust, P | 1 |
| Granitskiĭ, NA | 1 |
| Késmárky, G | 1 |
| Fehér, G | 2 |
| Koltai, K | 1 |
| Horváth, B | 1 |
| Tóth, K | 1 |
| von Beckerath, O | 1 |
| McLaughlin, TJ | 1 |
| Wang, XY | 1 |
| Miao, F | 1 |
| Langer, H | 2 |
| Wydymus, M | 1 |
| Göhring, K | 1 |
| Pamukcu, B | 2 |
| Oflaz, H | 2 |
| Oncul, A | 2 |
| Umman, B | 2 |
| Mercanoglu, F | 2 |
| Ozcan, M | 2 |
| Meric, M | 2 |
| Nisanci, Y | 2 |
| Nait-Saidi, L | 1 |
| Carvajal, J | 1 |
| Lehmann, A | 1 |
| Nesto, RW | 1 |
| Grimberg, G | 1 |
| Lazar, A | 1 |
| Jung, N | 1 |
| Goeser, T | 1 |
| Schömig, E | 1 |
| Kong, DF | 1 |
| Tuttle, RH | 1 |
| Kramer, JM | 1 |
| Matchar, DB | 1 |
| Schulman, KA | 1 |
| Jawien, J | 1 |
| Csanyi, G | 1 |
| Gajda, M | 1 |
| Mateuszuk, L | 1 |
| Lomnicka, M | 1 |
| Korbut, R | 1 |
| Chlopicki, S | 1 |
| Velich, N | 1 |
| Trautmann, C | 1 |
| Schinzel, R | 1 |
| Lepor, NE | 1 |
| Szük, T | 1 |
| Gyöngyösi, M | 1 |
| Homorodi, N | 1 |
| Kristóf, E | 1 |
| Király, C | 1 |
| Edes, IF | 1 |
| Facskó, A | 1 |
| Pavo, N | 1 |
| Sodeck, G | 1 |
| Strehblow, C | 1 |
| Glogar, D | 1 |
| Domanovits, H | 1 |
| Edes, I | 1 |
| Yuan, H | 1 |
| Malinin, AI | 1 |
| Shammas, NW | 1 |
| Dippel, EJ | 1 |
| Avila, A | 1 |
| Gehbauer, L | 1 |
| Farland, L | 1 |
| Brosius, S | 1 |
| Jerin, M | 1 |
| Winter, M | 1 |
| Stoakes, P | 1 |
| Byrd, J | 1 |
| Majetic, L | 1 |
| Shammas, G | 1 |
| Sharis, P | 1 |
| Robken, J | 1 |
| Onur, I | 1 |
| Stellbaum, C | 1 |
| Willich, T | 1 |
| Boltzen, U | 1 |
| Ayral, Y | 1 |
| Szotowski, B | 1 |
| Piorkowski, M | 1 |
| Schultheiss, HP | 1 |
| Rauch, U | 1 |
| Schlick, P | 1 |
| Hohlfeld, T | 1 |
| Eshaghian, S | 1 |
| Kaul, S | 1 |
| Amin, S | 1 |
| Shah, PK | 1 |
| Diamond, GA | 1 |
| Biondi-Zoccai, GG | 1 |
| Lotrionte, M | 1 |
| Agostoni, P | 1 |
| Abbate, A | 1 |
| Sangiorgi, G | 1 |
| Moretti, C | 1 |
| Sheiban, I | 1 |
| Tibold, A | 1 |
| Csejtei, A | 1 |
| Tettinger, A | 1 |
| Kiss, I | 1 |
| Karlsson, G | 1 |
| Rehman, J | 1 |
| Kalaria, V | 1 |
| Cheng, JW | 1 |
| Falcone, EL | 1 |
| Tangri, N | 1 |
| Tickoo, S | 1 |
| Milford-Beland, S | 1 |
| Gibler, WB | 1 |
| Pollack, CV | 1 |
| Buch, AN | 1 |
| Singh, S | 2 |
| Javaid, A | 1 |
| Smith, KA | 1 |
| George, CE | 1 |
| Kapp, M | 1 |
| Göhring-Frischholz, K | 1 |
| Daub, K | 1 |
| Dösch, C | 1 |
| Zavalloni, D | 1 |
| Belli, G | 1 |
| Rossi, M | 1 |
| Presbitero, P | 1 |
| Gulmez, O | 1 |
| Yildirir, A | 1 |
| Kaynar, G | 1 |
| Konas, D | 1 |
| Aydinalp, A | 1 |
| Ertan, C | 1 |
| Ozin, B | 1 |
| Muderrisoglu, H | 1 |
| Biernat, M | 1 |
| Dziedzina, S | 1 |
| Plutecka, H | 1 |
| Parikh, SA | 1 |
| Beckman, JA | 1 |
| Unverdorben, M | 1 |
| Degenhardt, R | 1 |
| Wiemer, M | 1 |
| Horstkotte, D | 1 |
| Schneider, H | 1 |
| Nienaber, C | 1 |
| Gross, M | 1 |
| Boxberger, M | 1 |
| Vallbracht, C | 1 |
| Giglioli, C | 1 |
| Joyal, D | 1 |
| Rudski, L | 1 |
| Valencia, R | 2 |
| Sawhney, N | 1 |
| Lee, SS | 1 |
| Wong, GB | 1 |
| Gollapudi, RR | 1 |
| Banares, M | 1 |
| Schatz, RA | 1 |
| Ko, JK | 2 |
| Park, JH | 2 |
| Kim, JH | 3 |
| Arikan, ME | 1 |
| Mathuria, N | 1 |
| Builes, A | 1 |
| del Conde, I | 1 |
| Palazuelos, J | 2 |
| Simon, DI | 1 |
| Schmaier, AH | 1 |
| Grube, E | 1 |
| Dawkins, KD | 2 |
| Banning, AP | 1 |
| Thuesen, L | 1 |
| Hauptman, K | 1 |
| Marco, J | 1 |
| Popma, JJ | 1 |
| Buellesfeld, L | 1 |
| Koglin, J | 1 |
| Russell, ME | 1 |
| Grass, D | 1 |
| Drosch, T | 1 |
| Dietz, K | 1 |
| Gebel, JM | 1 |
| Christiaens, L | 1 |
| Macchi, L | 1 |
| Mann, KG | 1 |
| Bierend, A | 1 |
| Rau, T | 1 |
| Maas, R | 1 |
| Böger, RH | 1 |
| von Tiehl, KF | 1 |
| Ludington, KJ | 1 |
| Simon, RA | 1 |
| Perneby, C | 1 |
| Wallén, NH | 1 |
| Hofman-Bang, C | 1 |
| Tornvall, P | 1 |
| Ivert, T | 1 |
| Li, N | 1 |
| Lu, YL | 1 |
| Chen, YD | 1 |
| Lü, SZ | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Ahn, Y | 1 |
| Jeong, JW | 1 |
| Kim, KH | 2 |
| Ahn, TH | 1 |
| Nam, CW | 1 |
| Kim, KY | 1 |
| Oh, SK | 1 |
| Arora, R | 1 |
| Khraisat, A | 1 |
| Handa, K | 1 |
| Bahekar, A | 1 |
| Trivedi, A | 1 |
| Rott, D | 1 |
| Leibowitz, D | 1 |
| Amit, G | 1 |
| Zahger, D | 1 |
| Weiss, AT | 1 |
| Johnson, SG | 1 |
| Rogers, K | 1 |
| Delate, T | 1 |
| Witt, DM | 1 |
| Weisberg, I | 1 |
| Zenni, MZ | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Owen, P | 1 |
| Garner, J | 1 |
| Hergott, L | 1 |
| Page, RL | 1 |
| Sheehy, O | 1 |
| LeLorier, J | 1 |
| Hobbs, L | 1 |
| Lyle, B | 1 |
| Faurie, B | 1 |
| Déry, JP | 1 |
| Beyar, R | 1 |
| Nikolsky, E | 1 |
| Topcu, Y | 1 |
| Postma, S | 1 |
| L'Allier, PL | 1 |
| Pranno, N | 1 |
| Noble, S | 1 |
| Ibrahim, R | 1 |
| Grégoire, JC | 1 |
| Azzari, F | 1 |
| Nozza, A | 1 |
| Berry, C | 1 |
| Doucet, S | 1 |
| Vincent, C | 1 |
| Brewster, JB | 1 |
| Kedar, V | 1 |
| Sundaram, CP | 1 |
| Andrade, J | 1 |
| Al Ali, A | 1 |
| Wong, GC | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Krucoff, MW | 1 |
| Petersen, JL | 1 |
| Fitzgerald, PJ | 1 |
| Garg, J | 1 |
| Turco, MA | 1 |
| Simonton, CA | 1 |
| Verheye, S | 1 |
| Dubois, CL | 1 |
| Gammon, R | 1 |
| Batchelor, WB | 1 |
| O'Shaughnessy, CD | 1 |
| Buchbinder, M | 1 |
| Pinkau, T | 1 |
| Mann, JF | 1 |
| Hamdalla, HN | 1 |
| Fox, KA | 1 |
| Cohen, MG | 1 |
| Dyke, CK | 1 |
| Myles, SK | 1 |
| Aberle, LG | 1 |
| Lin, M | 1 |
| Walder, J | 1 |
| Chronos, N | 1 |
| Tonkens, RM | 1 |
| Rusconi, CP | 1 |
| de Lorgeril, M | 1 |
| Boissonnat, P | 1 |
| Dureau, G | 1 |
| Guidollet, J | 1 |
| Renaud, S | 1 |
| Grollier, G | 1 |
| Bedossa, M | 1 |
| Leclercq, C | 1 |
| Vahanian, A | 1 |
| Van Belle, E | 1 |
| Bertrand, ME | 1 |
| Coukell, AJ | 1 |
| Markham, A | 1 |
| Feldman, TE | 1 |
| Hall, P | 1 |
| Almagor, Y | 1 |
| Maiello, L | 1 |
| Martini, G | 1 |
| Tobis, JM | 1 |
| Jackson, A | 1 |
| Luisi, AF | 1 |
| Calver, AL | 1 |
| Blows, LJ | 1 |
| Harmer, S | 1 |
| Gray, HH | 1 |
| Morgan, JH | 1 |
| Simpson, IA | 1 |
| Osende, JI | 1 |
| Zaman, AG | 1 |
| Rodriguez, OJ | 1 |
| Farkouh, ME | 1 |
| Chesebro, JH | 1 |
| Park, JC | 2 |
| Kang, KT | 1 |
| Cho, JH | 1 |
| Kim, NH | 1 |
| Bae, Y | 1 |
| Cho, JG | 1 |
| Kang, JC | 1 |
| Hutten, BA | 1 |
| Plokker, HW | 1 |
| Marx, SO | 1 |
| Marks, AR | 1 |
| Robinson, N | 1 |
| Golledge, P | 1 |
| Timmis, A | 1 |
| Zymek, P | 1 |
| Bartuś, S | 1 |
| Hall, D | 1 |
| Horwich, TB | 1 |
| Rupprecht, HJ | 1 |
| Espinola-Klein, C | 1 |
| Meyer, J | 1 |
| Nickolaus, MJ | 1 |
| Momplaisir, T | 1 |
| Miller, L | 1 |
| Bertolet, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [NCT02513810] | 3,020 participants (Anticipated) | Interventional | 2015-12-02 | Active, not recruiting | |||
| The Effect of Cocoa on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad and Tobago: The ECLAIR Study[NCT04554901] | 25 participants (Actual) | Interventional | 2020-09-01 | Completed | |||
| Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI[NCT02519608] | Phase 2 | 44 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Multimodality Investigation of Intermediate Culprit Lesion With Negative Fractional Flow Reserve in Patients With no ST-segment Elevation Acute Coronary Syndrome.[NCT03205514] | 35 participants (Actual) | Observational [Patient Registry] | 2017-06-28 | Completed | |||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor[NCT02698618] | Phase 4 | 50 participants (Anticipated) | Interventional | 2016-03-31 | Not yet recruiting | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699] | Phase 4 | 2,690 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | ||
| Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity[NCT01335048] | Phase 4 | 50 participants (Anticipated) | Interventional | 2011-04-30 | Completed | ||
| Impact of LDL-cholesterol Lowering on Platelet Activation[NCT03331666] | Phase 4 | 4 participants (Actual) | Interventional | 2018-11-16 | Terminated (stopped due to Terminated Prematurely due to COVID-19) | ||
| The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease[NCT01260584] | Phase 4 | 110 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease[NCT01107912] | Phase 1 | 155 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial[NCT01830491] | Phase 4 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events[NCT01186146] | Phase 4 | 5,000 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells[NCT01283282] | Phase 4 | 48 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724] | Phase 4 | 630 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639] | Phase 4 | 200 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patie[NCT01118325] | Phase 2 | 146 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease[NCT01107925] | Phase 1 | 72 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [NCT01710436] | 880 participants (Anticipated) | Observational | 2012-10-31 | Active, not recruiting | |||
| Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56[NCT01235351] | Phase 2 | 335 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures[NCT00042081] | Phase 3 | 3,000 participants | Interventional | 2002-07-31 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020] | 1,240 participants (Anticipated) | Observational | 2011-11-30 | Not yet recruiting | |||
| Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206] | Phase 4 | 4,005 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Platelet Function in Resuscitated Patients-2[NCT03445546] | 25 participants (Actual) | Observational | 2016-05-01 | Completed | |||
| Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319] | Phase 3 | 1,606 participants (Actual) | Interventional | 2011-06-30 | Active, not recruiting | ||
| Impact of Hybrid Coronary Revascularization on Antiplatelet Effect of Aspirin and Clopidogrel[NCT02293928] | 40 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome[NCT02809820] | Phase 4 | 100 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254] | Phase 4 | 420 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation[NCT01543932] | Phase 3 | 81 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease[NCT01523392] | Phase 4 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.[NCT01979445] | Phase 2 | 15 participants (Actual) | Interventional | 2013-12-02 | Completed | ||
| A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease[NCT01852175] | 110 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study[NCT01896557] | Phase 4 | 92 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial[NCT03078465] | Phase 3 | 0 participants (Actual) | Interventional | 2017-06-20 | Withdrawn (stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.) | ||
| TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904] | 9,284 participants (Actual) | Observational | 2013-06-19 | Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.) | |||
| "Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733] | 1,000 participants (Actual) | Observational [Patient Registry] | 2018-06-18 | Completed | |||
| Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803] | Phase 4 | 2,808 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766] | 150 participants (Anticipated) | Observational | 2020-09-30 | Not yet recruiting | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Periprocedural Cangrelor in Patients With ST-Elevation Myocardial Infarction to Reduce Development of Myocardial Necrosis[NCT03043274] | Phase 4 | 23 participants (Actual) | Interventional | 2017-01-31 | Terminated | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions[NCT00247208] | Phase 3 | 80 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)[NCT00133237] | Phase 4 | 607 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [NCT01032668] | Phase 3 | 192 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent[NCT00331578] | Phase 4 | 2,077 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Prospective Evaluation for Hybrid Cardiac Procedures[NCT05143671] | 111 participants (Anticipated) | Observational | 2021-05-13 | Recruiting | |||
| Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463] | Phase 4 | 263 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Regular DES Versus BiOSS Expert® Stent in Coronary Bifurcation Treatment - Randomized, Multicenter, Open-label, Controlled POLBOS I (POLish Bifurcation Optimal Stenting) Study[NCT02192840] | Phase 4 | 243 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome[NCT01994941] | Phase 4 | 133 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Clopidogrel Pharmacogenetics Bench to Bedside - A Practical Application[NCT01341600] | 18 participants (Actual) | Interventional | 2010-07-31 | Completed | |||
| Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy[NCT01452152] | Phase 4 | 9 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to Terminated by study sponsor.) | ||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study[NCT00370045] | Phase 4 | 200 participants | Interventional | 2006-03-31 | Recruiting | ||
| Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)[NCT00799396] | Phase 4 | 682 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.[NCT01611545] | 130 participants (Actual) | Observational | 2012-06-30 | Completed | |||
| What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing[NCT00769938] | Phase 4 | 573 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects[NCT02086903] | Phase 3 | 12 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea[NCT00528411] | Phase 2 | 123 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial.[NCT03252665] | Phase 4 | 600 participants (Anticipated) | Interventional | 2017-09-01 | Not yet recruiting | ||
| Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Prospective Observational Clinical Study：The Impact of Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention[NCT04033861] | Phase 4 | 352 participants (Anticipated) | Interventional | 2019-06-19 | Recruiting | ||
| An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II）[NCT02201667] | Phase 4 | 444 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon[NCT03296670] | Phase 4 | 57 participants (Actual) | Interventional | 2015-08-01 | Completed | ||
| Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture[NCT02475187] | 33 participants (Anticipated) | Observational | 2015-09-30 | Terminated | |||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND][NCT00642811] | Phase 2 | 98 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction[NCT03487445] | Phase 2 | 48 participants (Actual) | Interventional | 2018-07-10 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study[NCT05643586] | Phase 4 | 50 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study[NCT06015477] | 180 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation[NCT00465322] | 100 participants | Observational | Completed | ||||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease[NCT00557921] | Phase 3 | 5,000 participants (Anticipated) | Interventional | 2007-12-31 | Terminated (stopped due to Terminated by Sponsor) | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [NCT00776477] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-12-31 | Recruiting | ||
| A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions[NCT00180310] | Phase 3 | 300 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00180479] | Phase 3 | 1,002 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.[NCT00642174] | Phase 2 | 35 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927] | Phase 4 | 486 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| Randomized Clinical Trial Comparing A Titanium-Nitride-Oxide Coated Stent With A Zotarolimus-Eluting Stent in Patients With Coronary Artery Disease[NCT00492908] | Phase 4 | 303 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771] | Phase 4 | 64 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry[NCT02264912] | 2,016 participants (Actual) | Observational [Patient Registry] | 2008-07-31 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes[NCT01107899] | Phase 1 | 29 participants (Actual) | Interventional | 2009-10-31 | Terminated (stopped due to Terminated due to Enrollment futility) | ||
| Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent[NCT00910299] | Phase 2 | 423 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Due to the low rate of primary endpoint events experienced in the study to date) | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| PhaRmacodynamic Effects of Switching thErapy in paTients With High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel RESET GENE Trial[NCT01465828] | Phase 3 | 30 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [NCT01584791] | Phase 4 | 148 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Platelet Function in Resuscitated Patients[NCT02914795] | 99 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451] | Phase 4 | 1,721 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure[NCT01112137] | Phase 4 | 46 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544] | Phase 4 | 187 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions.[NCT00934752] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy.[NCT01212302] | 500 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.[NCT01796691] | 600 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries[NCT00165035] | Phase 3 | 1,701 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model[NCT00728286] | 90 participants (Actual) | Observational | 2008-10-31 | Completed | |||
| Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[NCT00728156] | Phase 4 | 90 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression[NCT01889992] | Phase 1 | 42 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to PI left University and project not continued) | ||
| Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003] | Phase 4 | 2,022 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow Aspirin assay (Accriva Diagnostics) will be performed. Unit: Aspirin Reaction Unit (ARU) (NCT03331666)
Timeframe: Day 7, Day 14, Day 21, Day 28, Day 84
| Intervention | ARU (Number) | ||||
|---|---|---|---|---|---|
| Aspirin Test, Day 7 | Aspirin Test Day 14 | Aspirin Test, Day 21 | Aspirin Test, Day 28 | Aspirin Test, Day 84 | |
| Evolocumab | 521 | 608 | 533 | 530 | 406 |
| Placebo | 432 | 401 | 490 | 512 | 386 |
ADP- or arachidonic acid-stimulated platelet aggregation as assessed by the commercially-available VerifyNow P2Y12 (VerifyNow PRUTest) will be performed. Unit: PRU (NCT03331666)
Timeframe: Day 7, Day 14, Day 21, Day 28, Day 84
| Intervention | PRU (Number) | ||||
|---|---|---|---|---|---|
| P2Y12 Test, Day 7 | P2Y12 Test, Day 14 | P2Y12 test, Day 21 | P2Y12 Test, Day 28 | P2Y12 Test, Day 84 | |
| Evolocumab | 266 | 268 | 268 | 276 | 256 |
| Placebo | 216 | 226 | 233 | 225 | 267 |
"Day 10 occurs in each treatment period at which time data collections are made. 12.1.4. Responders and Poor Responders~Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of responders and poor responders following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose." (NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | P2Y12 reaction unit (Least Squares Mean) |
|---|---|
| Prasugrel Smokers | 85.1 |
| Prasugrel Non-Smokers | 106.3 |
| Clopidogrel Smokers | 178.9 |
| Clopidogrel Non-Smokers | 215.1 |
"Day 10 occurs in each treatment period at which time data collections are made. Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of responders and poor responders following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose." (NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | % vasodilator stimulated phosphoprotein (Least Squares Mean) |
|---|---|
| Prasugrel Smokers | 25.4 |
| Prasugrel Non-Smokers | 31.2 |
| Clopidogrel Smokers | 48.1 |
| Clopidogrel Non-Smokers | 55.7 |
Blood samples for determination of plasma concentrations of the prasugrel active metabolite, clopidogrel active metabolite, and clopidogrel inactive metabolite will be collected following the administration of the 10th (last) maintenance dose of each of the 2 Active Treatment Periods at 0.5, 1, 2, 4, and 6 hours post-dose. (NCT01260584)
Timeframe: After dose on Day 10 of Active Treatment Periods 1 and 2
| Intervention | hr*ng/mL (Geometric Mean) |
|---|---|
| Prasugrel Smokers | 53.7 |
| Prasugrel Non-Smokers | 48.1 |
| Clopidogrel Smokers | 19.9 |
| Clopidogrel Non-Smokers | 16.2 |
(NCT01260584)
Timeframe: After dose on Day 10 of Active Treatment Periods 1 and 2
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Prasugrel Smokers | 42.9 |
| Prasugrel Non-Smokers | 35.9 |
| Clopidogrel Smokers | 14.1 |
| Clopidogrel Non-Smokers | 10.8 |
IPA will be measured by the Accumetrics P2Y12 Assay Device. Response will be assessed in P2Y12 Reaction Units and as Platelet Reactivity Index (vasodilator-stimulated phosphoprotein assay). (NCT01260584)
Timeframe: Baseline to day 10 for Active Treatment Periods 1 and 2
| Intervention | percentage of device derived inhibition (Least Squares Mean) |
|---|---|
| Prasugrel Smokers | 70.3 |
| Prasugrel Non-Smokers | 65.6 |
| Clopidogrel Smokers | 38.6 |
| Clopidogrel Non-Smokers | 30.9 |
(NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | % participants with PRU <=235 (Number) |
|---|---|
| Prasugrel Smokers | 98.0 |
| Prasugrel Non-Smokers | 96.2 |
| Clopidogrel Smokers | 76.6 |
| Clopidogrel Non-Smokers | 61.1 |
"Numerous studies have established an association between high on-treatment platelet reactivity with clopidogrel and an increased risk for post-PCI ischemic events. In this study, the percentages of responders and poor responders following treatment with prasugrel and clopidogrel were compared. Poor responders were defined based on an Accumetrics VerifyNow PRU >235 and a VASP PRI >50%, as assessed 24 hours after the 9th maintenance dose." (NCT01260584)
Timeframe: Day 10 for Active Treatment Periods 1 and 2
| Intervention | % participants with PRI <=50% (Number) |
|---|---|
| Prasugrel Smokers | 96.0 |
| Prasugrel Non-Smokers | 82.7 |
| Clopidogrel Smokers | 51.1 |
| Clopidogrel Non-Smokers | 44.4 |
A descriptive pharmacokinetic-pharmacodynamic (PK-PD) analysis comparing prasugrel and clopidogrel active metabolite exposures to MPA in response to 20 µM ADP (by LTA) was conducted as originally intended; however, the graphic output from that analysis is not possible here. Therefore, the PK portion is presented here as AUC and the PD portion is presented in Secondary Outcome Measure #5. AUC was calculated through the last scheduled sampling time of 4 hours [AUC (0-4)] or through the sampling time of the last quantifiable concentration prior to 4 hours. AUC values were denoted AUC(0-tlast) in both instances. (NCT01107912)
Timeframe: Baseline up to 4 hours post-dose
| Intervention | nanogram*hour/milliliter (ng*hr/mL) (Geometric Mean) |
|---|---|
| 5 mg Prasugrel (Elderly) | 18.9 |
| 10 mg Prasugrel (Elderly) | 41.2 |
| 75 mg Clopidogrel (Elderly) | 13.0 |
| 5 mg Prasugrel (Non-Elderly) | 16.1 |
| 10 mg Prasugrel (Non-Elderly) | 36.7 |
| 75 mg Clopidogrel (Non-Elderly) | 11.8 |
Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition. (NCT01107912)
Timeframe: Baseline, Day 12
| Intervention | percentage of aggregation (Mean) | |
|---|---|---|
| Baseline | Day 12 (n=71, 70, 70, 78, 79, 79) | |
| 10 mg Prasugrel (Elderly) | 78.75 | 45.54 |
| 10 mg Prasugrel (Non-Elderly) | 76.61 | 45.83 |
| 5 mg Prasugrel (Elderly) | 79.10 | 57.05 |
| 5 mg Prasugrel (Non-Elderly) | 76.61 | 56.83 |
| 75 mg Clopidogrel (Elderly) | 79.11 | 63.08 |
| 75 mg Clopidogrel (Non-Elderly) | 76.61 | 59.09 |
Maximum Platelet Aggregation (MPA) to 20 μM ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing the platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). Lower MPA values reflect stronger platelet inhibition, whereas higher MPA values reflect weaker inhibition. (NCT01107912)
Timeframe: Baseline, 12 days
| Intervention | percentage of aggregation (Median) | |
|---|---|---|
| Baseline | Period 1 (12 days) (n=71, 79) | |
| 10 mg Prasugrel (Non-Elderly) | 75.00 | 46.00 |
| 5 mg Prasugrel (Elderly) | 78.00 | 58.00 |
Vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation levels, expressed as the platelet reactivity index (PRI), reflect the degree of thienopyridine-mediated P2Y12 receptor inhibition. A lower PRI reflects stronger inhibition of P2Y12, whereas a higher PRI reflects weaker inhibition of P2Y12. (NCT01107912)
Timeframe: Baseline, Day 12
| Intervention | percentage platelet reactive index (PRI) (Mean) | |
|---|---|---|
| Baseline (n=68, 66, 67, 71, 72, 72) | Day 12 (n=67, 65, 67, 73, 74, 73) | |
| 10 mg Prasugrel (Elderly) | 85.66 | 22.66 |
| 10 mg Prasugrel (Non-Elderly) | 86.18 | 27.74 |
| 5 mg Prasugrel (Elderly) | 85.62 | 44.30 |
| 5 mg Prasugrel (Non-Elderly) | 86.10 | 54.72 |
| 75 mg Clopidogrel (Elderly) | 85.60 | 54.95 |
| 75 mg Clopidogrel (Non-Elderly) | 86.18 | 54.53 |
The Accumetrics VerifyNow® P2Y12 assay measures platelet aggregation in whole blood and is reported in P2Y12 reaction units (PRU). PRU report the extent of P2Y12 receptor-mediated platelet aggregation calculated as a function of the rate and extent of platelet aggregation in the presence of adenosine phosphate ADP. A lower PRU reflects stronger inhibition of P2Y12, whereas a higher PRU reflects weaker inhibition of P2Y12. (NCT01107912)
Timeframe: Baseline, Day 12
| Intervention | P2Y12 reaction units (PRU) (Mean) | |
|---|---|---|
| Baseline | Day 12 (n=71, 67, 69, 77, 79, 79) | |
| 10 mg Prasugrel (Elderly) | 314.11 | 84.13 |
| 10 mg Prasugrel (Non-Elderly) | 291.62 | 85.46 |
| 5 mg Prasugrel (Elderly) | 315.63 | 175.52 |
| 5 mg Prasugrel (Non-Elderly) | 291.81 | 177.01 |
| 75 mg Clopidogrel (Elderly) | 314.14 | 212.33 |
| 75 mg Clopidogrel (Non-Elderly) | 291.62 | 181.22 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Flow-mediated dilation (FMD) collected by an ultrasound and is measured by the percent change in diameter of the brachial artery from baseline to 12 weeks. (NCT01283282)
Timeframe: Baseline, Week 12
| Intervention | percent change in diameter (Mean) |
|---|---|
| Clopridogrel | 4.89 |
| Placebo | 4.81 |
CD40 ligand levels were measured. The level of CD40 ligand were measured using the Flurokine MultiAnalyte profiling (MAP) Human Base Kit B. (NCT01283282)
Timeframe: Week 12
| Intervention | pg/mL (Mean) |
|---|---|
| Clopridogrel | 1202.21 |
| Placebo | 2169.32 |
High-sensitivity C-reactive protein (hsCRP) was measured. The hsCRP levels were measured by Dade Behring nephelometry. (NCT01283282)
Timeframe: Week 12
| Intervention | mg/L (Mean) |
|---|---|
| Clopridogrel | 5.98 |
| Placebo | 4.31 |
Nitroglycerin (NTG)-mediated vasodilation was measured after 0.4 mg of NTG was administered sublingually. Brachial artery images were obtained via ultrasound after three minutes of NTG administration. Measurements from the twelve frames will be averaged to calculate the percent change in diameter of the brachial artery from baseline to 12 weeks. (NCT01283282)
Timeframe: Baseline, Week 12
| Intervention | percent change in diameter (Mean) |
|---|---|
| Clopridogrel | 19.31 |
| Placebo | 17.10 |
PWV was measured between the carotid and femoral arteries using the SphygmoCor device. Pressure waveforms at the carotid and femoral arteries were acquired using EKG gating. Velocity (distance per time in seconds) was calculated using the foot-to-foot method and the distance between the sites was measured manually. (NCT01283282)
Timeframe: Week 12
| Intervention | m/s (Mean) |
|---|---|
| Clopridogrel | 8.77 |
| Placebo | 9.044 |
The circulating progenitor-enriched population of cells was measured by the expression of surface antigens using direct flow cytometry for CD34+, CD34+/CD133+, CD34+/ VEGF2R+ and CD34+/CD133+/VEGF2R+ (NCT01283282)
Timeframe: Week 12
| Intervention | cells/µL (Mean) | |||
|---|---|---|---|---|
| CD34+ | CD34+/133+ | CD34+/VEGF2R+ | CD34+/CD133+/VEGF2R+ | |
| Clopidogrel | 1.46 | 0.68 | 0.08 | 0.03 |
| Placebo | 1.54 | 0.75 | 0.09 | 0.03 |
Oxidative stress was measured by using liquid chromatography to collect plasma cystine, cysteine, gluthione, and oxidized glutathione levels. (NCT01283282)
Timeframe: Week 12
| Intervention | µM (Mean) | |||
|---|---|---|---|---|
| Cystine | Cysteine | Glutathione | Oxidized glutathione | |
| Clopridogrel | 105.25 | 13.71 | 1.52 | 0.08 |
| Placebo | 102.39 | 14.75 | 1.71 | 0.19 |
Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval (NCT01118325)
Timeframe: Week 4
| Intervention | ng.h/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 1180 |
| AZD6140 45 mg bd in Non-Japanese Patients | 954 |
| AZD6140 90 mg bd in Japanese Patients | 2720 |
| AZD6140 90 mg bd in Non-Japanese Patients | 3380 |
Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX (NCT01118325)
Timeframe: Week 4
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 135 |
| AZD6140 45mg bd in Non-Jpanese Patients | 101 |
| AZD6140 90 mg bd in Japanese Patients | 326 |
| AZD6140 90 mg bd in Non-Jpanese Patients | 381 |
Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration (NCT01118325)
Timeframe: Week 4
| Intervention | hour (Median) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 4.0 |
| AZD6140 45 mg bd in Non-Japanese Patients | 4.0 |
| AZD6140 90 mg bd in Japanese Patients | 2.1 |
| AZD6140 90 mg bd in Non-Japanese Patients | 2.0 |
Area under the plasma concentration curve of AZD6140 from time zero to dosing interval (NCT01118325)
Timeframe: Week 4
| Intervention | ng.h/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 3050 |
| AZD6140 45 mg bd in Non-Japanese Patients | 2930 |
| AZD6140 90 mg bd in Japanese Patients | 6080 |
| AZD6140 90 mg bd in Non-Japanese Patients | 10900 |
Maximum plasma AZD6140 concentration (NCT01118325)
Timeframe: Week 4
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 422 |
| AZD6140 45 mg bd in Non-Japanese Patients | 341 |
| AZD6140 90 mg bd in Japanese Patients | 931 |
| AZD6140 90 mg bd in Non-Japanese Patients | 1380 |
Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration (NCT01118325)
Timeframe: Week 4
| Intervention | hour (Median) |
|---|---|
| AZD6140 45 mg bd in Japanese Patients | 2.0 |
| AZD6140 45 mg bd in Non-Japanese Patients | 4.0 |
| AZD6140 90 mg bd in Japanese Patients | 2.0 |
| AZD6140 90 mg bd in Non-Japanese Patients | 4.0 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 64.5 |
| AZD6140 90 mg bd | 73.0 |
| Clopidogrel 75 mg od | 38.9 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| Arm 1 - AZD6140 45 mg bd | 56.9 |
| AZD6140 90 mg bd | 66.8 |
| Clopidogrel 75 mg od | 41.8 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 46.2 |
| AZD6140 90 mg bd | 59.1 |
| Clopidogrel 75 mg od | 38.0 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 67.3 |
| AZD6140 90 mg bd | 73.2 |
| Clopidogrel 75 mg od | 43.7 |
"Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:~Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit." (NCT01118325)
Timeframe: Week 4
| Intervention | percentage inhibition (Mean) |
|---|---|
| AZD6140 45 mg bd | 62.7 |
| AZD6140 90 mg bd | 68.6 |
| Clopidogrel 75 mg od | 42.5 |
A pharmacokinetic-pharmacodynamic (PK-PD) analysis comparing MPA (LTA) and AUC was conducted as originally intended, however the graphic output is not possible here. Therefore, the PK portion is presented here as AUC and the PD portion is presented in Secondary Outcome Measure #5. AUC was calculated through the last scheduled sampling time of 4 hours [AUC (0-4)] or through the sampling time of the last quantifiable concentration prior to 4 hours. AUC values were denoted AUC(0-tlast) in both instances. (NCT01107925)
Timeframe: baseline (pre-dose) up to 4 hours post-dose
| Intervention | nanogram•hour/milliliter (ng•hr/mL) (Geometric Mean) |
|---|---|
| Prasugrel 5 mg (LBW) | 28.9 |
| Prasugrel 10 mg (LBW) | 59.3 |
| Clopidogrel 75 mg (LBW) | 18.4 |
| Prasugrel 5 mg (HBW) | 19.4 |
| Prasugrel 10 mg (HBW) | 46.7 |
| Clopidogrel 75 mg (HBW) | 12.7 |
MPA to 20 micromolar (μM) adenosine diphosphate (ADP) was assessed by LTA, an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition. (NCT01107925)
Timeframe: Baseline , Day 12
| Intervention | percent aggregation (Mean) | |
|---|---|---|
| Baseline | Day 12 ( n= 32,32,31,35,37,35) | |
| 10 mg Prasugrel (HBW) | 77.93 | 47.92 |
| 10 mg Prasugrel (LBW) | 76.20 | 38.11 |
| 5 mg Prasugrel (HBW) | 77.63 | 61.90 |
| 5 mg Prasugrel (LBW) | 76.27 | 48.10 |
| 75 mg Clopidogrel (HBW) | 77.63 | 65.28 |
| 75 mg Clopidogrel (LBW) | 76.20 | 51.41 |
MPA to 20 micromolar (μM) ADP was assessed by light transmission aggregometry (LTA), an assay that measures platelet aggregation by determining the amount of light transmitted through a cuvette containing platelet-rich plasma stimulated with a platelet activator, such as ADP, relative to platelet-poor plasma (100% light transmittance). A lower MPA reflects stronger platelet inhibition, whereas a higher MPA reflects weaker inhibition. (NCT01107925)
Timeframe: Baseline, Day 12
| Intervention | percent aggregation (Median) | |
|---|---|---|
| Baseline | Day 12 (n=32, 37) | |
| Prasugrel 10 mg (HBW) | 76.40 | 47.00 |
| Prasugrel 5 mg (LBW) | 75.00 | 47.00 |
VASP phosphorylation levels, expressed as the platelet reactivity index (PRI), reflect the degree of thienopyridine-mediated P2Y12 receptor inhibition and were used to compare prasugrel versus clopidogrel, in low body weight (LBW) participants compared to higher body weight (HBW) participants. PRI was calculated by VASP. The PRI indicates the level of P2Y12 receptor inhibition. A lower PRI reflects stronger inhibition of P2Y12 receptor thus stronger platelet inhibition, whereas a higher PRI reflects weaker inhibition of P2Y12 receptor and weaker platelet inhibition. (NCT01107925)
Timeframe: Baseline, Day 12
| Intervention | percentage PRI (Mean) | |
|---|---|---|
| Baseline | Day 12 (n=32,31,30,32,36,34) | |
| 10 mg Prasugrel (HBW) | 86.76 | 27.79 |
| 10 mg Prasugrel (LBW) | 86.44 | 15.09 |
| 5 mg Prasugrel (HBW) | 86.77 | 56.87 |
| 5 mg Prasugrel (LBW) | 86.57 | 33.54 |
| 75 mg Clopidogrel (HBW) | 86.77 | 56.35 |
| 75 mg Clopidogrel (LBW) | 86.44 | 39.01 |
The Accumetrics VerifyNow® P2Y12 assay measures platelet aggregation in whole blood and is reported in PRU. PRU indicates the extent of P2Y12 receptor-mediated platelet aggregation calculated as a function of rate and extent of platelet aggregation in an adenosine phosphate (ADP)-containing channel of the device. A lower PRU reflects stronger inhibition of platelet aggregation, whereas a higher PRU reflects weaker inhibition of platelet aggregation. (NCT01107925)
Timeframe: Baseline, Day 12
| Intervention | P2Y12 reaction units (PRU) (Mean) | |
|---|---|---|
| Baseline | Day 12 (n=32,31,32,35,34,34) | |
| 10 mg Prasugrel (HBW) | 311.0 | 102.1 |
| 10 mg Prasugrel (LBW) | 315.3 | 55.9 |
| 5 mg Prasugrel (HBW) | 312.8 | 193.9 |
| 5 mg Prasugrel (LBW) | 317.9 | 129.5 |
| 75 mg Clopidogrel (HBW) | 312.8 | 207.0 |
| 75 mg Clopidogrel (LBW) | 315.3 | 151.7 |
The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP. (NCT01235351)
Timeframe: Approximately every 2 weeks for 8 weeks
| Intervention | % of PRI (Mean) | |
|---|---|---|
| Clopidogrel 75 mg | Clopidogrel 150 mg | |
| CYP2C19*2 Non-Carriers | 57.5 | 46.9 |
The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP. (NCT01235351)
Timeframe: Approximately every 2 weeks for 8 weeks
| Intervention | % of PRI (Mean) | |||
|---|---|---|---|---|
| Clopidogrel 75 mg | Clopidogrel 150 mg | Clopidogrel 225 mg | Clopidogrel 300 mg | |
| CYP2C19*2 Carriers | 71.0 | 62.4 | 54.0 | 50.1 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
(NCT01523392)
Timeframe: At 2 hours after the loading dose
| Intervention | PRU (Least Squares Mean) |
|---|---|
| Ticagrelor | 27.6 |
| Clopidogrel | 211.2 |
The standard deviation (SD) is the geometric SD (NCT01523392)
Timeframe: Predose, 0.5 hour, 2 hours, 8 hours from loading dose and 0, 2 hours, 8 hours and 12 hours from last dose
| Intervention | ng/mL (Geometric Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (0 pre-dose hours) | 0.5 hours after the loading dose | 2 hours after the loading dose | 8 hours after the loading dose - Period 1 N=19 | 0 hours after multiple doses - Period 1 N=18 | 2 hours after multiple doses - Period 1 N=18 | 8 hours after multiple doses - Period 1 N=18 | End of dosing interval on Day 8 - Period 1 N=18 | |
| Ticagrelor (Treatment Period 1) | 1.0 | 9.8 | 222.6 | 119.0 | 93.2 | 136.7 | 89.8 | 140.8 |
| Ticagrelor (Treatment Period 2) | 1.0 | 2.3 | 150.9 | 54.8 | 74.5 | 172.3 | 112.6 | 110.3 |
(NCT01523392)
Timeframe: At 0.5 hour and 8 hours after the loading dose
| Intervention | PRU (Least Squares Mean) | |
|---|---|---|
| 0.5 hours | 8 hours (N=28 ticagrelor, N=27 clopidogrel) | |
| Clopidogrel | 270.1 | 192.6 |
| Ticagrelor | 166.3 | 27.2 |
(NCT01523392)
Timeframe: At 2 hours and 8 hours on Day 7 after multiple doses and at end of dosing interval on Day 8
| Intervention | PRU (Least Squares Mean) | ||
|---|---|---|---|
| 2 hours on Day 7 (N=27 for clopidogrel) | 8 hours on Day 7 | End of dosing interval on Day 8 | |
| Clopidogrel | 157.8 | 146.5 | 172.7 |
| Ticagrelor | 22.9 | 28.5 | 39.3 |
The standard deviation (SD) is the geometric SD (NCT01523392)
Timeframe: Predose, 0.5 hour, 2 hours, 8 hours from loading dose; 0, 2 hours, 8 hours and 12 hours from last dose
| Intervention | ng/mL (Geometric Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (0 pre-dose hours) | 0.5 hours after the loading dose | 2 hours after the loading dose | 8 hours after the loading dose - Period 1 N=19 | 0 hours after multiple doses - Period 1 N=18 | 2 hours after multiple doses - Period 1 N=18 | 8 hours after multiple doses - Period 1 N=18 | End of dosing interval on Day 8 - Period 1 N=18 | |
| Ticagrelor (Treatment Period 1) | 1.0 | 206.6 | 1167.3 | 395.9 | 168.4 | 324.6 | 179.2 | 284.9 |
| Ticagrelor (Treatment Period 2) | 1.2 | 33.7 | 756.9 | 141.9 | 187.4 | 608.8 | 311.3 | 295.7 |
"Bleeding was assessed by history, physical exam, and complete blood count (CBC) that was performed on study Day 1. Reports of bleeding were to be evaluated by performance of a CBC. Participants were assessed for bleeding events in accordance with the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) scale.~The severity of bleeding events by GUSTO Criteria is defined as the following:~Severe/life-threatening: fatal, intracranial hemorrhage, or if hemodynamic compromise results~Moderate: transfusion required~Mild: no transfusion or hemodynamic compromise~A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module." (NCT01979445)
Timeframe: Screening through the follow-up period (5 to 7 days after Day 1)
| Intervention | bleeding events (Number) | ||
|---|---|---|---|
| Mild | Moderate | Life-threatening/Severe | |
| Clopidogrel 1 Hr During Cangrelor | 0 | 0 | 0 |
| Clopidogrel 1.5 Hrs During Cangrelor | 0 | 0 | 0 |
| Clopidogrel Within 5 Min After Cangrelor | 0 | 0 | 0 |
| Prasugrel 30 Min After Cangrelor | 0 | 0 | 0 |
A reference point for prasugrel or clopidogrel was chosen for comparison and designated at 6 or 5.5 hrs after the administration of prasugrel or clopidogrel as the reference for the effect of the oral drug. Platelet function was assessed using light transmittance aggregometry (LTA). LTA measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was expressed as % aggregation in response to 20 micromolar (μM) adenosine diphosphate (ADP) at 300 seconds (sec) (final/terminal aggregation response). (NCT01979445)
Timeframe: Day 1 at 5.5 or 6 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 2.25, 2.5, 2.75, 3, 4, and 5.5 hrs after initiation of cangrelor infusion
| Intervention | % aggregation (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Prasugrel/Clopidogrel Reference (6 or 5.5 hrs) | 2.25 hrs | 2.5 hrs | 2.75 hrs | 3 hrs | 4 hrs | 5.5 hrs | |
| Clopidogrel 1 Hr During Cangrelor | 50.3 | 33.3 | 62.0 | 67.7 | 65.0 | 62.7 | NA |
| Clopidogrel 1.5 Hrs During Cangrelor | 50.0 | 22.2 | 54.3 | 56.8 | 56.2 | 51.2 | NA |
| Clopidogrel Within 5 Min After Cangrelor | 21.7 | 26.0 | 49.7 | 58.3 | 56.0 | 38.0 | 26.7 |
| Prasugrel 30 Min After Cangrelor | 1.3 | 16.3 | 60.0 | 63.3 | 65.0 | 16.3 | 1.3 |
A reference point for prasugrel or clopidogrel was chosen for comparison and designated at 6 or 5.5 hrs after the administration of prasugrel or clopidogrel as the reference for the effect of the oral drug. Platelet function was assessed using the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was assessed by platelet reaction units (PRU), determined by the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay is designed to directly measure the effects of drugs on the P2Y12 receptor, using prostaglandin E1 in addition to ADP to increase intraplatelet cyclic adenosine monophosphate (cAMP). Platelet reactivity was expressed in PRU. (NCT01979445)
Timeframe: Day 1 at 5.5 or 6 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 2.25, 2.5, 2.75, 3, 4, and 5.5 hrs after initiation of cangrelor infusion
| Intervention | PRU (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Prasugrel/Clopidogrel Reference (6 or 5.5 hrs) | 2.25 hrs | 2.5 hrs | 2.75 hrs | 3 hrs | 4 hrs | 5.5 hrs | |
| Clopidogrel 1 Hr During Cangrelor | 197.3 | 98.7 | 206.3 | 214.3 | 212.7 | 203.7 | NA |
| Clopidogrel 1.5 Hrs During Cangrelor | 211.3 | 90.3 | 229.8 | 255.8 | 234.5 | 215.5 | NA |
| Clopidogrel Within 5 Min Post Cangrelor | 159.0 | 99.0 | 220.7 | 233.0 | 215.7 | 182.0 | 155.0 |
| Prasugrel 30 Min After Cangrelor | 8.0 | 76.7 | 208.0 | 225.7 | 226.0 | 77.0 | 24.5 |
A reference point for cangrelor was chosen for comparison and designated as the administration time of prasugrel 60 mg or clopidogrel 600 mg (2.5, 2, 1.5, or 1 hrs). Platelet function was assessed using LTA. LTA measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was examined using LTA and expressed as % aggregation in response to 20 μM ADP at 300 sec (final/terminal aggregation response). (NCT01979445)
Timeframe: Day 1 at 1, 1.5, 2, or 2.5 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 1.75 and 2 hrs after initiation of cangrelor infusion
| Intervention | % aggregation (Mean) | ||
|---|---|---|---|
| Cangrelor Reference (2.5, 2, 1.5, or 1 hrs) | 1.75 hrs | 2 hrs | |
| Clopidogrel 1 Hr During Cangrelor | 3.0 | 1.3 | 2.3 |
| Clopidogrel 1.5 Hrs During Cangrelor | 2.0 | 1.8 | 1.5 |
| Clopidogrel Within 5 Min After Cangrelor | 0 | 1.0 | NA |
| Prasugrel 30 Min After Cangrelor | 60.0 | 0.3 | 0.3 |
A reference point for cangrelor was chosen for comparison and designated as the administration time of prasugrel 60 mg or clopidogrel 600 mg (2.5, 2, 1.5, or 1 hrs). Platelet function was assessed using the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay measures the aggregation or cross linking of platelets by fibrinogen and requires the activation of platelets plus the binding of fibrinogen. The extent of aggregation was assessed by PRU, determined by the VerifyNow P2Y12 assay. The VerifyNow P2Y12 assay is designed to directly measure the effects of drugs on the P2Y12 receptor, using prostaglandin E1 in addition to ADP to increase intraplatelet cAMP. Platelet reactivity was expressed in PRU. (NCT01979445)
Timeframe: Day 1 at 1, 1.5, 2, or 2.5 hrs after administration of prasugrel or clopidogrel (reference) and Day 1 at 1.75 and 2 hrs after initiation of cangrelor infusion
| Intervention | PRU (Mean) | ||
|---|---|---|---|
| Cangrelor Reference (2.5, 2, 1.5, or 1 hrs) | 1.75 hrs | 2 hrs | |
| Clopidogrel 1 Hr During Cangrelor | 7.0 | 6.3 | 5.7 |
| Clopidogrel 1.5 Hrs During Cangrelor | 17.7 | 25.0 | 28.8 |
| Clopidogrel Within 5 Min After Cangrelor | 7.3 | 3.7 | NA |
| Prasugrel 30 Min After Cangrelor | 208.0 | 3.3 | 5.3 |
The primary end-point of the study was the comparison in the platelet reactivity index (PRI%) determined by vasodilator-stimulated phosphoprotein (VASP) at 1 week between prasugrel and ticagrelor. (NCT01852175)
Timeframe: 1 week
| Intervention | PRI% (Least Squares Mean) |
|---|---|
| Prasugrel | 32.1 |
| Ticagrelor | 32.6 |
A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 2 hours after loading dose. (NCT01852175)
Timeframe: 2 hours
| Intervention | PRI% (Least Squares Mean) |
|---|---|
| Prasugrel | 13.4 |
| Ticagrelor | 15.6 |
A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 24 hours after loading dose. (NCT01852175)
Timeframe: 24 hours
| Intervention | PRI% (Least Squares Mean) |
|---|---|
| Prasugrel | 14.2 |
| Ticagrelor | 26.4 |
One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in P2Y12 Reactivity Units. (NCT01896557)
Timeframe: One week after randomized treatment exposure (omeprazole or ranitidine)
| Intervention | P2Y12 Reactivity Units (Mean) |
|---|---|
| Omeprazole | 173.54 |
| Ranitidine | 153.61 |
One week after starting double-blind, double-dummy, randomized therapy with ranitidin or omeprazole on patients treated with DAPT, platelet function will be compared with the method VerifyNow, in percent Inhibition of Platelet Aggregation (IPA) from baseline. IPA was calculated as the percent change in aggregability from baseline, with the formula IPA = (on-treatment aggregability minus baseline aggregability)/baseline aggregability. Since baseline aggregation is always, per definition, equal or more than on-treatment aggregation, there is no possibility that this number might be negative. (NCT01896557)
Timeframe: One week after drug exposure (omeprazole/ranitidine); 2 weeks after baseline
| Intervention | Percentage (Mean) |
|---|---|
| Omeprazole | 17.4 |
| Ranitidine | 30.1 |
After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: bioimpedance aggregometry with ADP 10 mcM as reagent (NCT01896557)
Timeframe: 1 week after drug exposure
| Intervention | Ohms (Mean) |
|---|---|
| Omeprazole | 2 |
| Ranitidine | 2.77 |
After 1 week of randomization to ranitidin or omeprazole, the platelet function will also be analysed by other method: PFA-100(Collagen/ADP cartridge). (NCT01896557)
Timeframe: 1 week after drug exposure
| Intervention | seconds (Mean) |
|---|---|
| Omeprazole | 95.1 |
| Ranitidine | 97.2 |
ELISA assay. (NCT03043274)
Timeframe: 6 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Cangrelor | 41.4 |
| No Cangrelor | 103.3 |
ELISA assay will be performed on plasma to quantify the amount of the inflammatory cytokine interleukin-6 in pg/mL. (NCT03043274)
Timeframe: 6 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Cangrelor | 33.2 |
| No Cangrelor | 57.8 |
ELISA assay macrophage-derived chemokine (NCT03043274)
Timeframe: 6 hours
| Intervention | pg/mL (Mean) |
|---|---|
| Cangrelor | 593.3 |
| No Cangrelor | 873.8 |
Cardiac MRI is obtained at 48 hours and 3 months to compare differences in infarct size. The outcome is assessed as the difference in infarct size between 48 hours and 3 months in each group. (NCT03043274)
Timeframe: 48 hours and 3 months
| Intervention | percent of left ventricular mass (Mean) | |
|---|---|---|
| 48 hours | 3 months | |
| Cangrelor | 8.6 | 6.7 |
| No Cangrelor | 11.1 | 6.98 |
Flow cytometry on peripheral blood will be performed to quantify peripheral counts of inflammatory cells, stem cells, and monocyte subtypes. (NCT03043274)
Timeframe: 6 hours
| Intervention | cells per microliter (Mean) | |
|---|---|---|
| granulocyte platelet aggregates | Monocyte-platelet aggregate | |
| Cangrelor | 1166.7 | 139.8 |
| No Cangrelor | 2550.4 | 333.9 |
Platelet reactivity testing will be performed 10 minutes after infusion has started. (NCT03043274)
Timeframe: 10 minutes
| Intervention | seconds (Mean) | |
|---|---|---|
| ADP-induced aggregation | TRAP-induced aggregation | |
| Cangrelor | 102.2 | 285.8 |
| No Cangrelor | 333.4 | 624.8 |
The change in maximum platelet aggregation in response to ADP 4-hours post dose on day 8 of therapy with clopidogrel and omeprazole will be compared to the baseline measure of platelet aggregation at day 1 prior to drug therapy (NCT01341600)
Timeframe: Baseline, Day 8
| Intervention | percentage of aggregation (Mean) |
|---|---|
| Poor Metabolizers | 11.6 |
| Intermediate Metabolizers | 27.9 |
| Extensive Metabolizers | 37.5 |
Adenosine diphosphate (ADP) mediated platelet aggregation measured 4 hours post-dose of clopidogrel on Day 1. (NCT01341600)
Timeframe: Day 1, 4 hours post clopidogrel dose
| Intervention | percentage of aggregation (Mean) | ||
|---|---|---|---|
| Clopidogrel 75mg | Clopidogrel 150mg | Clopidogrel 300mg | |
| Extensive Metabolizers | 62.5 | 53.9 | 38.6 |
| Intermediate Metabolizers | 68.1 | 57.8 | 47.8 |
| Poor Metabolizers | 62.9 | 63.2 | 53.3 |
ADP mediated platelet aggregation measured 4 hours post Day 8 clopidogrel dose (NCT01341600)
Timeframe: 4 hours post Day 8 dose
| Intervention | percentage of aggregation (Mean) | ||
|---|---|---|---|
| Clopidogrel 75mg | Clopidogrel 150mg | Clopidogrel 300mg | |
| Extensive Metabolizers | 31.3 | 25.1 | 19.5 |
| Intermediate Metabolizers | 37.8 | 33.2 | 25.7 |
| Poor Metabolizers | 55.0 | 44.2 | 32.6 |
The level of the active clopidogrel metabolite will be measured at at 0.25, 0.5, 1, 2, and 4 hours after the Day One dose is administered for pharmacokinetic analysis. The analysis will measure the Area Under the Curve. (NCT01341600)
Timeframe: Baseline, 0.25, 0.5, 1, 2, and 4 hours
| Intervention | ng h/mL (Mean) | ||
|---|---|---|---|
| Clopidogrel 75mg | Clopidogrel 150mg | Clopidogrel 300mg | |
| Extensive Metabolizers | 32.7 | 53.6 | 80.4 |
| Intermediate Metabolizers | 33.3 | 43.8 | 73.7 |
| Poor Metabolizers | 17.4 | 24.2 | 36 |
(NCT01452152)
Timeframe: One year
| Intervention | participants (Number) |
|---|---|
| Genotype-directed, Clopidogrel | 0 |
| Standard of Care | 0 |
The number of subjects reporting any AEs will be tabulated. (NCT01452152)
Timeframe: One year
| Intervention | participants (Number) |
|---|---|
| Genotype-directed, Clopidogrel | 1 |
| Standard of Care | 3 |
Bleeding events will classified by the Bleeding Academic Research Consortium definition. The number of bleeding events will be tabulated. (NCT01452152)
Timeframe: One year
| Intervention | events (Number) |
|---|---|
| Genotype-directed, Clopidogrel | 0 |
| Standard of Care | 0 |
Cardiovascular events include non-fatal myocardial infarction, non-fatal stroke, definite or probable stent thrombosis (ARC definition) and death secondary to any cardiovascular cause. (NCT01452152)
Timeframe: One year
| Intervention | participants (Number) |
|---|---|
| Genotype-directed, Clopidogrel | 0 |
| Standard of Care | 0 |
Platelet aggregation will be performed on a subset of subjects using VerifyNow P2Y12 which measures platelet reactivity due to the effect of a P2Y12. Values less than 180 P2Y12 Reaction Units (PRU) suggest evidence of a P2Y12 inhibitor effect. Platelet aggregation studies are optional and will not be used to modulate antiplatelet therapy. (NCT01452152)
Timeframe: 10 days
| Intervention | percentage of inhibition (Mean) |
|---|---|
| Genotype-directed, Clopidogrel | 33.7 |
Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation. (NCT00799396)
Timeframe: Measured at baseline, and after clopidogrel treatment
| Intervention | percentage of maximum aggregation change (Mean) | |
|---|---|---|
| PRP ADP 20 | PRP Collagen 5 | |
| Overall Study | 38.51 | 14.06 |
Baseline minus post clopidogrel/post-aspirin platelet rich plasma (PRP) maximum aggregation (NCT00799396)
Timeframe: Measured at baseline, and after clopidogrel plus aspirin treatment
| Intervention | percentage of max aggregation change (Mean) | |
|---|---|---|
| PRP ADP 20 | PRP Collagen 5 | |
| Overall Study | 41.21 | 56.64 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 96.59 |
| Clopidogrel | 96.78 |
| Placebo | 97.58 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 57.96 |
| Clopidogrel | 61.91 |
| Placebo | 59.92 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.71 |
| Placebo | 2.94 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.72 |
| Clopidogrel | 3.73 |
| Placebo | 4.03 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.89 |
| Placebo | 2.91 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.88 |
| Clopidogrel | 2.70 |
| Placebo | 2.50 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 12.92 |
| Clopidogrel | 12.17 |
| Placebo | 12.06 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: Baseline
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 163.34 |
| Clopidogrel | 185.98 |
| Placebo | 145.41 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: Baseline
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 75.01 |
| Clopidogrel | 73.04 |
| Placebo | 73.13 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.94 |
| Clopidogrel | 2.01 |
| Placebo | 1.91 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 14.79 |
| Clopidogrel | 14.15 |
| Placebo | 15.5 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 17.00 |
| Clopidogrel | 17.29 |
| Placebo | 15.83 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.96 |
| Clopidogrel | 0.89 |
| Placebo | 0.89 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.78 |
| Clopidogrel | 5.83 |
| Placebo | 6.10 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.74 |
| Placebo | 2.95 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 74.71 |
| Clopidogrel | 72.84 |
| Placebo | 74.27 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.70 |
| Clopidogrel | 3.78 |
| Placebo | 3.98 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 16.38 |
| Clopidogrel | 16.53 |
| Placebo | 16.09 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 60.70 |
| Clopidogrel | 62.38 |
| Placebo | 60.73 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.67 |
| Placebo | 2.91 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.73 |
| Clopidogrel | 2.79 |
| Placebo | 2.75 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 139.88 |
| Clopidogrel | 214.43 |
| Placebo | 140.68 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 15.21 |
| Clopidogrel | 15.10 |
| Placebo | 14.91 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.88 |
| Clopidogrel | 1.97 |
| Placebo | 1.90 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percentage (Mean) |
|---|---|
| Ticagrelor | 97.73 |
| Clopidogrel | 97.35 |
| Placebo | 98.56 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.70 |
| Clopidogrel | 5.85 |
| Placebo | 5.96 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 13.69 |
| Clopidogrel | 13.14 |
| Placebo | 11.45 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.92 |
| Clopidogrel | 0.93 |
| Placebo | 0.83 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: At 2 hours after first dose of study drug
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 93.15 |
| Clopidogrel | 31.05 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0 hour before last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 74.53 |
| Clopidogrel | 51.75 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0.5 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 45.39 |
| Clopidogrel | 4.71 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 1 hour after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 86.71 |
| Clopidogrel | 15.83 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 120 hours - Day 5 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 21.15 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 168 hours - Day 7 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 6.32 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 2 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 91.49 |
| Clopidogrel | 62.96 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 87.29 |
| Clopidogrel | 49.64 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 55.18 |
| Clopidogrel | 53.91 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 240 hours - Day 10 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 1.64 |
| Clopidogrel | 0.98 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 98.39 |
| Clopidogrel | 40.87 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.10 |
| Clopidogrel | 61.80 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 48 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 30.94 |
| Clopidogrel | 45.79 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 72 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 11.76 |
| Clopidogrel | 21.09 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.99 |
| Clopidogrel | 46.90 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 88.31 |
| Clopidogrel | 61.31 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour. (NCT00528411)
Timeframe: 4 to 72 Hours after last dose of study drug
| Intervention | Percentage/Hour (Least Squares Mean) |
|---|---|
| Ticagrelor | -1.037 |
| Clopidogrel | -0.482 |
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: Day 15, 4 hrs post switching
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 95.0 |
| Responder: Clopidogrel | 48.5 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: 4 hrs post first dose on day 28
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 77.4 |
| Responder: Clopidogrel | 60.8 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: Day 15, 4 hrs post switching
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 66.7 |
| Responder: Clopidogrel | 65.3 |
IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. Please refer to the protocol section for details about the interventions administered. (NCT00642811)
Timeframe: 4 hrs post first dose on day 28
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Responder: Ticagrelor | 91.0 |
| Responder: Clopidogrel | 61.2 |
The secondary definition of response to treatment is IPA >50% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00642811)
Timeframe: Day 14, and day 28, 4 hours post dose
| Intervention | Percent of participants (Number) |
|---|---|
| Non-responder: Ticagrelor | 81.3 |
| Non-responder: Clopidogrel | 25.0 |
The primary definition of response to treatment is IPA >10% post treatment. The response is reported as percentage of participants of each treatment. Please refer to the protocol section for details about the interventions administered. IPA(%)=(PAb-PAt)/PAb*100. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00642811)
Timeframe: Day 14 and Day 28, 4 Hrs Post Dose.
| Intervention | Percent of Participants (Number) |
|---|---|
| Non-responder: Ticagrelor | 100 |
| Non-responder: Clopidogrel | 93.8 |
"The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection.~The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles." (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Selatogrel 8 mg | 390.1 |
| Selatogrel 16 mg | 672.6 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) |
|---|---|
| Selatogrel 8 mg | 18 |
| Selatogrel 16 mg | 19 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) |
|---|---|
| Selatogrel 8 mg | 21 |
| Selatogrel 16 mg | 21 |
Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax). (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
| Intervention | hours (Median) |
|---|---|
| Selatogrel 8 mg | 1.00 |
| Selatogrel 16 mg | 0.97 |
The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU). (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes after administration of the subcutaneous injection
| Intervention | P2Y12 reaction units (PRU) (Median) | |||
|---|---|---|---|---|
| pre-dose | 15 minutes post-dose | 30 minutes post-dose | 60 minutes post-dose | |
| Selatogrel 16 mg | 181 | 9 | 9 | 7 |
| Selatogrel 8 mg | 194 | 51 | 59 | 9 |
The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU < 100, i.e., considering as a response a PRU < 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: pre-dose, 15, 30 and 60 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | |||
|---|---|---|---|---|
| pre-dose | 15 minutes post-dose | 30 minutes post-dose | 60 minutes post-dose | |
| Selatogrel 16 mg | 0 | 21 | 21 | 22 |
| Selatogrel 8 mg | 1 | 18 | 21 | 18 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age less than 55 years old | Age 55 years and older | Male | Female | Body Mass Index less than 25 | Body Mass Index less than 25 and up to 30 | Body Mass Index greater than 30 | Diabetes mellitus at baseline | No diabetes mellitus at baseline | No Chronic kidney disease at baseline | STEMI at baseline | NSTEMI at baseline | |
| Selatogrel 8 mg | 3 | 18 | 14 | 7 | 5 | 8 | 8 | 8 | 13 | 21 | 14 | 7 |
The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response. (NCT03487445)
Timeframe: 30 minutes after the administration of the subcutaneous injection
| Intervention | Count of participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age less than 55 years old | Age 55 years and older | Male | Female | Body Mass Index less than 25 | Body Mass Index less than 25 and up to 30 | Body Mass Index greater than 30 | Diabetes mellitus at baseline | No diabetes mellitus at baseline | Chronic kidney disease at baseline | No Chronic kidney disease at baseline | STEMI at baseline | NSTEMI at baseline | |
| Selatogrel 16 mg | 4 | 17 | 17 | 4 | 8 | 9 | 4 | 5 | 16 | 3 | 18 | 11 | 10 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS. (NCT00180479)
Timeframe: at 240 days
| Intervention | percent of volume obstruction (Mean) |
|---|---|
| XIENCE V® EECSS | 6.91 |
| TAXUS® EXPRESS2™ ECSS | 11.21 |
Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 98.3 |
| TAXUS® EXPRESS2™ ECSS | 98.7 |
Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 98.5 |
| TAXUS® EXPRESS2™ ECSS | 97.3 |
Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement) (NCT00180479)
Timeframe: 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.09 |
| TAXUS® EXPRESS2™ ECSS | 0.10 |
Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA (NCT00180479)
Timeframe: 240 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 4.7 |
| TAXUS® EXPRESS2™ ECSS | 8.9 |
Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: 240 days
| Intervention | percent of in-segment diameter stenosis (Mean) |
|---|---|
| XIENCE V® EECSS | 18.77 |
| TAXUS® EXPRESS2™ ECSS | 22.82 |
Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA) (NCT00180479)
Timeframe: at 240 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.3 |
| TAXUS® EXPRESS2™ ECSS | 5.7 |
In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: at 240 days
| Intervention | percent diameter stenosis (Mean) |
|---|---|
| XIENCE V® EECSS | 5.92 |
| TAXUS® EXPRESS2™ ECSS | 10.30 |
In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent) (NCT00180479)
Timeframe: at 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.16 |
| TAXUS® EXPRESS2™ ECSS | 0.30 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 6.0 |
| TAXUS® EXPRESS2™ ECSS | 10.3 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.9 |
| TAXUS® EXPRESS2™ ECSS | 5.2 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 5.0 |
| TAXUS® EXPRESS2™ ECSS | 8.8 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 9.7 |
| TAXUS® EXPRESS2™ ECSS | 16.4 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.3 |
| TAXUS® EXPRESS2™ ECSS | 3.0 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 12.8 |
| TAXUS® EXPRESS2™ ECSS | 18.5 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 14.4 |
| TAXUS® EXPRESS2™ ECSS | 22.0 |
"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 7.7 |
| TAXUS® EXPRESS2™ ECSS | 13.8 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 3.4 |
| TAXUS® EXPRESS2™ ECSS | 5.6 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.5 |
| TAXUS® EXPRESS2™ ECSS | 2.1 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 5.7 |
| TAXUS® EXPRESS2™ ECSS | 9.2 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.7 |
| TAXUS® EXPRESS2™ ECSS | 5.0 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 3 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 5.7 |
| TAXUS® EXPRESS2™ ECSS | 9.2 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 0.4 |
| TAXUS® EXPRESS2™ ECSS | 0.3 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 4 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.0 |
| TAXUS® EXPRESS2™ ECSS | 10.6 |
"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.9 |
| TAXUS® EXPRESS2™ ECSS | 12.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 3.1 |
| TAXUS® EXPRESS2™ ECSS | 4.7 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.2 |
| TAXUS® EXPRESS2™ ECSS | 1.8 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 4.9 |
| TAXUS® EXPRESS2™ ECSS | 6.6 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 2.9 |
| TAXUS® EXPRESS2™ ECSS | 4.1 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 6.7 |
| TAXUS® EXPRESS2™ ECSS | 8.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 0.3 |
| TAXUS® EXPRESS2™ ECSS | 0.9 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 7.8 |
| TAXUS® EXPRESS2™ ECSS | 9.6 |
"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.8 |
| TAXUS® EXPRESS2™ ECSS | 11.9 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 7.2 |
| TAXUS® EXPRESS2™ ECSS | 9.0 |
"Incomplete Apposition (Persisting & Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol & ARC definition.~Persisting dissection @ follow-up, present post-procedure." (NCT00180479)
Timeframe: at 240 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 24.4 |
| TAXUS® EXPRESS2™ ECSS | 14.0 |
In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment. (NCT00180479)
Timeframe: 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.14 |
| TAXUS® EXPRESS2™ ECSS | 0.28 |
Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) (NCT00180479)
Timeframe: at 240 days
| Intervention | millimeters (Mean) |
|---|---|
| XIENCE V® EECSS | 0.12 |
| TAXUS® EXPRESS2™ ECSS | 0.20 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 8.6 |
| TAXUS® EXPRESS2™ ECSS | 11.6 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 4.1 |
| TAXUS® EXPRESS2™ ECSS | 5.5 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 2 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 11.3 |
| TAXUS® EXPRESS2™ ECSS | 16.4 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 14.3 |
| TAXUS® EXPRESS2™ ECSS | 20.0 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 1.6 |
| TAXUS® EXPRESS2™ ECSS | 3.3 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 18.5 |
| TAXUS® EXPRESS2™ ECSS | 22.5 |
"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| XIENCE V® EECSS | 20.3 |
| TAXUS® EXPRESS2™ ECSS | 26.6 |
The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 4 hours after loading dose
| Intervention | percent inhibition (Least Squares Mean) | |
|---|---|---|
| Baseline | 4 Hours After Loading Dose | |
| Clopidogrel | 9.3 | 27.7 |
| Prasugrel | 9.4 | 89.3 |
Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)
| Intervention | percent inhibition (Least Squares Mean) | ||
|---|---|---|---|
| 1 Hour After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 13.4 | 29.3 | 44.2 |
| Prasugrel | 49.9 | 87.1 | 61.8 |
Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) - Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | millimeters (mm) (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 58.1 | 54.8 | 48.1 | 49.2 | 46.8 |
| Prasugrel | 56.8 | 38.5 | 24.2 | 29.3 | 44.2 |
Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent platelet aggregation (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (5 μM ADP) | 1 Hour After Loading Dose (5 μM ADP) | 4 Hours After Loading Dose (5 μM ADP) | 24 Hours After Loading Dose (5 μM ADP) | 24 Hours After Last Maintenance Dose (5 μM ADP) | Baseline (20 μM ADP) | 1 Hour After Loading Dose (20 μM ADP) | 4 Hours After Loading Dose (20 μM ADP) | 24 Hours After Loading Dose (20 μM ADP) | 24 Hours After Last Maintenance Dose (20 μM ADP) | |
| Clopidogrel | 65.7 | 56.7 | 44.6 | 45.6 | 38.3 | 76.9 | 69.8 | 57.5 | 58.4 | 50.7 |
| Prasugrel | 64.9 | 33.7 | 18.0 | 22.3 | 29.6 | 77.1 | 44.7 | 22.4 | 27.4 | 38.3 |
Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent inhibition (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 80.6 | 76.2 | 67.5 | 58.5 | 42.3 |
| Prasugrel | 83.5 | 40.0 | 14.5 | 15.7 | 27.4 |
Platelet aggregation was assessed by Accumetrics Verify Now™ P2Y12, and poor responders were those with PRU greater than or equal to 230. (NCT01107899)
Timeframe: 24 hours post-loading dose
| Intervention | percentage of participants (Number) |
|---|---|
| Clopidogrel 600 mg | 40.0 |
| Prasugrel 60 mg | 0 |
| Prasugrel 30 mg | 0 |
PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of ADP-stimulated platelet aggregation. (NCT01107899)
Timeframe: 24 hours post-loading dose
| Intervention | P2Y12 Reaction Units (PRU) (Mean) |
|---|---|
| Clopidogrel 600 mg | 193.0 |
| Prasugrel 60 mg | 32.5 |
| Prasugrel 30 mg | 70.0 |
To show effect of initial inhibition of platelet aggregation as measured by Accumetrics Verify Now™ P2Y12 on the day to return to baseline platelet function, a regression model was fitted with day to return as outcome variable and initial inhibition as fixed effect. Results are reported as the predicted day to return to baseline platelet function by derived VN-PRU percent (%) inhibition at 24 hours post LD. The derived VN-PRU % inhibition is calculated as a percent decrease of PRU from baseline using the following formula: ([PRU at baseline - PRU at 24 hours post LD]/PRU at baseline) x 100%. (NCT01107899)
Timeframe: Up through 11 days
| Intervention | days (Number) | |||
|---|---|---|---|---|
| 20% Initial Inhibition | 40% Initial Inhibition | 60% Initial Inhibition | 80% Initial Inhibition | |
| All Treatments | 3.2 | 4.6 | 6.0 | 7.4 |
Initial inhibition of platelet aggregation was measured by LTA at 5 and 20 μM ADP. Maximum platelet aggregation (MPA) is reported by day. (NCT01107899)
Timeframe: Up through 11 days
| Intervention | percent platelet aggregation (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (20 μM ADP) (n=5, n=10, n=6) | Day 1 (20 μM ADP) (n=5, n=10, n=6) | Day 3 (20 μM ADP) (n=5, n=10, n=6) | Day 5 (20 μM ADP) (n=5, n=10, n=4) | Day 7 (20 μM ADP) (n=5, n=10, n=5) | Day 9 (20 μM ADP) (n=5, n=10, n=5) | Day 11 (20 μM ADP) (n=5, n=10, n=5) | Baseline (5 μM ADP) (n=5, n=10, n=6) | Day 1 (5 μM ADP) (n=5, n=10, n=6) | Day 3 (5 μM ADP) (n=5, n=10, n=6) | Day 5 (5 μM ADP) (n=5, n=10, n=4) | Day 7 (5 μM ADP) (n=5, n=10, n=5) | Day 9 (5 μM ADP) (n=5, n=10, n=5) | Day 11 (5 μM ADP) (n=5, n=10, n=5) | |
| Clopidogrel 600 mg | 68.00 | 52.60 | 56.00 | 70.40 | 71.00 | 62.40 | 72.00 | 64.40 | 39.40 | 50.20 | 64.20 | 60.40 | 58.40 | 61.80 |
| Prasugrel 30 mg | 76.33 | 31.67 | 46.33 | 58.25 | 73.20 | 68.60 | 63.80 | 70.67 | 25.50 | 48.67 | 53.25 | 65.40 | 60.00 | 56.00 |
| Prasugrel 60 mg | 72.70 | 27.30 | 42.50 | 47.00 | 58.30 | 62.00 | 65.20 | 62.60 | 22.00 | 32.80 | 39.50 | 52.40 | 56.00 | 58.90 |
Return of baseline platelet function was assessed by Multiplate® ADP test and ADP test High Sensitivity (HS). Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. The agonist ADP was added to stirred whole blood after dilution (1:2 with 0.9% NaCl solution) in a final concentration of 6.4 µM (ADP Test) or in final concentration of 6.4 µM ADP plus 9.4 nM Prostaglandin E1 (PGE1) (ADPtest HS). Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve (AUC=AU*min) of aggregation units (AU). (NCT01107899)
Timeframe: Up through 11 days
| Intervention | Aggregation Units * minutes (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ADP) (n=5, n=10, n=6) | Day 1 (ADP) (n=5, n=10, n=6) | Day 3 (ADP) (n=5, n=10, n=6) | Day 5 (ADP) (n=5, n=10, n=4) | Day 7 (ADP) (n=5, n=10, n=5) | Day 9 (ADP) (n=5, n=10, n=5) | Day 11 (ADP) (n=5, n=10, n=5) | Baseline (ADP HS) (n=5, n=10, n=6) | Day 1 (ADP HS) (n=5, n=10, n=6) | Day 3 (ADP HS) (n=5, n=10, n=6) | Day 5 (ADP HS) (n=5, n=10, n=4) | Day 7 (ADP HS) (n=5, n=10, n=5) | Day 9 (ADP HS) (n=5, n=10, n=5) | Day 11 (ADP HS) (n=5, n=10, n=5) | |
| Clopidogrel 600 mg | 536.60 | 248.80 | 347.60 | 428.40 | 478.80 | 529.40 | 555.00 | 361.00 | 166.80 | 257.60 | 256.80 | 263.60 | 388.20 | 373.20 |
| Prasugrel 30 mg | 459.33 | 118.17 | 134.67 | 296.00 | 295.40 | 484.40 | 564.00 | 344.00 | 70.17 | 90.50 | 145.00 | 170.60 | 343.60 | 404.00 |
| Prasugrel 60 mg | 601.60 | 90.00 | 140.90 | 231.30 | 316.20 | 549.00 | 500.20 | 411.70 | 34.50 | 79.30 | 114.10 | 189.50 | 344.60 | 365.40 |
Participants were classified as having platelet function return to baseline after loading dose (LD) on the first day that P2Y12 Reaction Units (PRU) was no more than 60 PRU below baseline and remained in this range. PRU was assessed by Accumetrics Verify Now™ P2Y12. PRU represents the rate and extent of adenosine diphosphate (ADP)-stimulated platelet aggregation. (NCT01107899)
Timeframe: Days 3, 5, 7, 9, and 11
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Day 3 | Day 5 | Day 7 | Day 9 | Day 11 | |
| Clopidogrel 600 mg | 60.0 | 80.0 | 100.0 | 100.0 | 100.0 |
| Prasugrel 30 mg | 0 | 0 | 100.0 | 100.0 | 100.0 |
| Prasugrel 60 mg | 0 | 10.0 | 60.0 | 100.0 | 100.0 |
MPA to 5 and 20 μM ADP were assessed by LTA. (NCT01107899)
Timeframe: 24 hours post-loading dose
| Intervention | percent aggregation (Mean) | |
|---|---|---|
| Maximum Aggregation (20 µM ADP) | Maximum Aggregation (5 µM ADP) | |
| Clopidogrel 600 mg | 52.60 | 39.40 |
| Prasugrel 30 mg | 31.67 | 25.50 |
| Prasugrel 60 mg | 27.30 | 22.00 |
The Multiplate analyzer was used to assess platelet aggregation based on impedance aggregometry in whole blood. After adding 6.4 µM ADP (ADP test) or 6.4 µM ADP plus 9.4 nM PGE1 (ADP test HS), area under the aggregation curve (AUC) were calculated. (NCT01107899)
Timeframe: 24 hours post-loading dose
| Intervention | aggregation units*minute (Mean) | |
|---|---|---|
| ADP Test AUC | ADP Test HS AUC | |
| Clopidogrel 600 mg | 248.80 | 166.80 |
| Prasugrel 30 mg | 118.17 | 70.17 |
| Prasugrel 60 mg | 90.00 | 34.50 |
The endpoint in this measure is a combination of all-cause death or MI. (NCT00910299)
Timeframe: Baseline through 6 months
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Clopidogrel | 2 |
The endpoint in this measure is a combination of cardiovascular death or MI. (NCT00910299)
Timeframe: Baseline through 6 months
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Clopidogrel | 1 |
Academic Research Consortium (ARC) criteria was used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least one of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. (NCT00910299)
Timeframe: Baseline through 6 months
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Clopidogrel | 0 |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Treatment Arm | 257 |
| Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
| Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
| Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
| Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
| Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
(NCT02914795)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Non-resuscitated Myocardial Infarction | 0 |
| Resuscitated Myocardial Infarction | 3 |
Median (Inter-Quartile Range) Collagen AUC values on Day 3 measured with optical aggregometry The more light signal is detected, the better thrombocyte function is. (NCT02914795)
Timeframe: day 3
| Intervention | AU*min (Median) |
|---|---|
| Non-resuscitated Myocardial Infarction | 109 |
| Resuscitated Myocardial Infarction | 253.8 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
"In patients treated with aspirin and clopidogrel aggregometry was performed and depending on the results the patients were either responder or low-responder of antiplatelet therapy.~The following definitions were used for clopidogrel low response (CLR: >5 ohm when stimulated with adenosine diphosphate (ADP) 5 μM) and ASA low response (ALR: >0 ohm;stimulated with arachidonic acid 10 μM) with the ChronoLog 590 aggregometer. In the case of low-response alternative antiplatelet therapy was modified according to the study plan (see protocol section)." (NCT01212302)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel Low Response | 155 |
131 reviews available for ticlopidine and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis.
Topics: Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; | 2021 |
Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.
Topics: Asian People; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Artery Disease; H | 2017 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.
Topics: Blood Platelets; Coronary Artery Disease; Drug Resistance; Genotype; Humans; Platelet Aggregation; P | 2017 |
Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mutation; Plat | 2018 |
Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; H | 2018 |
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Interv | 2013 |
Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinatio | 2013 |
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Met | 2013 |
New antiplatelet agents for cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Plate | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Dis | 2013 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro | 2014 |
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Hum | 2014 |
Combining antiplatelet and antithrombotic therapy (triple therapy): what are the risks and benefits?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibri | 2014 |
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Pla | 2014 |
Pharmacogenomics of oral antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Meta-Analysis as To | 2014 |
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Dru | 2014 |
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.
Topics: Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; Humans; Pharmacog | 2015 |
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; France | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Res | 2015 |
Dual antiplatelet therapy for coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregati | 2015 |
Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? All patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
Topics: Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneous Corona | 2015 |
Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.
Topics: Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Platelet Aggregatio | 2015 |
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Pla | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review.
Topics: Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Observat | 2015 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; H | 2016 |
Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Medication Adherence; Platelet Aggregation Inhibitors; | 2016 |
[Cholestasic toxic hepatitis due to clopidogrel in a patient with multiple conditions].
Topics: Chemical and Drug Induced Liver Injury; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggre | 2016 |
Antiplatelet Management for Coronary Heart Disease: Advances and Challenges.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary | 2016 |
Use of prasugrel in the setting of clopidogrel hypersensitivity: Case report and systematic review of the literature.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Drug Substitution; Drug-Eluting | 2016 |
Aspirin, Plavix, and Other Antiplatelet Medications: What the Oral and Maxillofacial Surgeon Needs to Know.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Medication Therapy Management; Oral Surgical | 2016 |
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; He | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Clinical implications of clopidogrel resistance.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Dru | 2008 |
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2008 |
Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disea | 2008 |
Aspirin and clopidogrel response variability: review of the published literature.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Resistance; Humans; Platelet | 2008 |
Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2009 |
Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, | 2009 |
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose- | 2008 |
Recent advances in the management of coronary artery disease: highlights from the literature.
Topics: Blood Vessels; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pump; Coronary Artery | 2009 |
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2009 |
Significant gastrointestinal bleeding in patients at risk of coronary stent thrombosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Aspirin; Clopidogrel; Coro | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery | 2009 |
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug | 2008 |
Platelet resistance to antiplatelet drugs.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug | 2009 |
Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Ag | 2009 |
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Data Collection; Female; Humans; Kinetics; Male; Middle | 2009 |
Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Humans; | 2009 |
Current controversies in the pharmacogenomics of clopidogrel.
Topics: Clopidogrel; Confidence Intervals; Coronary Artery Disease; Genotype; Humans; Myocardial Infarction; | 2009 |
Clopidogrel before elective percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; | 2010 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma | 2009 |
Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; | 2010 |
Factors associated with clopidogrel nonresponsiveness.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; | 2010 |
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Artery Dise | 2010 |
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Corona | 2011 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combinati | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coro | 2010 |
Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Corona | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; A | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogre | 2010 |
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Human | 2010 |
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Human | 2011 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clop | 2010 |
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Data Interpretation, Statistical; Dose-Res | 2011 |
Genetic variability in response to clopidogrel therapy and its clinical implications.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; DNA M | 2011 |
Platelet function variability and non-genetic causes.
Topics: Blood Platelets; Clinical Trials as Topic; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabet | 2011 |
Personalized antiplatelet therapy: review of the latest clinical evidence.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; | 2011 |
Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combina | 2011 |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genot | 2012 |
Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies.
Topics: Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Di | 2012 |
Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment.
Topics: Blood Component Transfusion; Catheters, Indwelling; Clopidogrel; Coagulants; Coronary Artery Disease | 2011 |
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; | 2011 |
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Design; Drug Interactio | 2012 |
Variability of clopidogrel response in patients with type 2 diabetes mellitus.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Monito | 2011 |
Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2011 |
Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis.
Topics: Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Proton P | 2012 |
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art | 2012 |
Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Coronary Artery Disease; Cytochrome P-45 | 2012 |
Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Biomarkers, Ph | 2012 |
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Ty | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; H | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocard | 2012 |
ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2012 |
The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis.
Topics: Adenosine; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; History, 20th Century | 2013 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; H | 2012 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon | 2002 |
[Clopidogrel: background information and use in clinical practice].
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Fibrinol | 2003 |
[Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Intera | 2003 |
[Antiplatelet drugs in prevention of complications of arteriosclerotic diseases: it is necessary to move beyond aspirin].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Drug Therapy, Combination; Hu | 2003 |
Role of antiplatelet drugs in the prevention of cardiovascular events.
Topics: Aspirin; Benzamidines; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Oximes; | 2003 |
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Corona | 2004 |
The use of clopidogrel in patients with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2004 |
Clopidogrel: how good is it and how does it work?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; | 2004 |
CD40 ligand: a novel target in the fight against cardiovascular disease.
Topics: Cardiovascular Agents; Cardiovascular Diseases; CD40 Ligand; Clinical Trials as Topic; Clopidogrel; | 2004 |
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D | 2004 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost | 2005 |
The benefits of abciximab questioned in percutaneous coronary interventions following pretreatment with high-dose clopidogrel.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Clopido | 2005 |
Clopidogrel use in coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; | 2006 |
Gastrointestinal complications of dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, | 2006 |
Clopidogrel resistance: implications for coronary stenting.
Topics: Animals; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Ag | 2006 |
Thienopyridines in percutaneous coronary interventions: standard procedures and high risk subsets.
Topics: Angioplasty, Balloon, Coronary; Biocompatible Materials; Brachytherapy; Clopidogrel; Coronary Artery | 2006 |
Antiplatelet resistance with aspirin and clopidogrel: is it real and does it matter?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibit | 2006 |
Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Diseases; Clinical | 2006 |
Variable response to clopidogrel in patients with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticl | 2007 |
Role of clopidogrel in managing atherothrombotic cardiovascular disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Dr | 2007 |
Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression.
Topics: Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Humans; Platelet Aggregation Inhibi | 2007 |
Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Economics, Pharmaceutical; Humans; Ticl | 2007 |
Contemporary use of clopidogrel in patients with coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coro | 2007 |
Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Resistance; Humans; Platelet Ag | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine; Cocaine-Related Disorders; Cor | 2007 |
Clopidogrel desensitization: case report and review of published protocols.
Topics: Cardiac Catheterization; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Desensitization, | 2008 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Diseas | 2008 |
[Blood platelet aggregation inhibitors in the treatment of heart diseases].
Topics: Angina, Unstable; Aspirin; Coronary Artery Disease; Coronary Disease; Dipyridamole; Humans; Platelet | 1993 |
Clopidogrel.
Topics: Animals; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 1997 |
Antiplatelet agents and the role of clopidogrel in the prevention of secondary atherosclerotic events.
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; | 1999 |
Prevention of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2002 |
[Modern therapy in acute coronary syndrome].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Di | 2002 |
Aspirin beyond platelet inhibition.
Topics: Abciximab; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; As | 2002 |
242 trials available for ticlopidine and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D | 2022 |
Effect of cocoa (
Topics: Aspirin; Cacao; Chocolate; Clopidogrel; Coronary Artery Disease; Humans; Pilot Projects; Platelet Ag | 2022 |
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C | 2017 |
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C | 2017 |
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C | 2017 |
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease.
Topics: Adenosine; Aged; Anticoagulants; Apoptosis; Blood Platelets; Clopidogrel; Coronary Artery Disease; C | 2017 |
Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, D | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.
Topics: Adenosine; Blood Platelets; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Coronary Circu | 2017 |
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Cause of Death; Clopidogrel; Coronary Angiograp | 2017 |
Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Genotype; Humans; Kaplan-Meier | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2018 |
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; | 2013 |
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; | 2013 |
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; | 2013 |
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; | 2013 |
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studi | 2013 |
Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Clopidogrel; Coloring Agents; Coronary Angiography; Coro | 2013 |
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coron | 2013 |
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Asian People; Clopidogrel; Coronary Artery Disease; Cytochrome | 2013 |
Comparison of antiplatelet effect and safety of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients: multi-center, randomized, double-blind, phase IV, non-inferiority clinical trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; | 2013 |
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery D | 2014 |
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transport | 2013 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Arte | 2014 |
Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Disease-Free Surviva | 2014 |
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet A | 2014 |
Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.
Topics: Blood Platelets; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over | 2013 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronar | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coro | 2014 |
Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease.
Topics: Aged; Biomarkers; Blood Vessels; Capillaries; Clopidogrel; Coronary Artery Disease; Cross-Over Studi | 2014 |
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cross-Sectiona | 2014 |
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
Topics: Adolescent; Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genetic Te | 2014 |
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; | 2014 |
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; D | 2014 |
Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb.
Topics: Adult; Chemistry, Pharmaceutical; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female | 2015 |
Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease.
Topics: Aged; Blood Coagulation; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; Humans | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage | 2014 |
Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Croatia; Dose-Response | 2014 |
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Topics: Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P- | 2014 |
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule | 2015 |
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disea | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Topics: Aged; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Ge | 2014 |
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; | 2014 |
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.
Topics: Adenosine Diphosphate; Aged; Coronary Artery Disease; Female; Follow-Up Studies; Germany; Humans; Ma | 2014 |
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 2014 |
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis | 2015 |
Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Gra | 2014 |
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Hispanic or Latino; Humans; | 2015 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu | 2015 |
Assessment of the efficacy and tolerability of clopidogrel napadisilate in Korean patients with coronary stenting: a multicenter, prospective, open-label, randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Monitoring; Drug-Eluting Stent | 2015 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug- | 2015 |
Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Glucose Tolerance Test; Humans; Insulin Resistan | 2015 |
Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug | 2015 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona | 2015 |
Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Follow-Up Studi | 2015 |
Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Germa | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug | 2015 |
Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.
Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Res | 2015 |
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Clopidogrel; Coronary Artery Disease; Cytoc | 2015 |
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2015 |
Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; D | 2015 |
Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2015 |
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Administ | 2015 |
Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Brachial Artery; Clopidogrel; Coronary Artery Disease; Cytochrome | 2015 |
Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration.
Topics: Aged; Coronary Artery Disease; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Fem | 2016 |
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
Topics: Acute Coronary Syndrome; Adult; Aftercare; Clopidogrel; Coronary Artery Disease; Drug Administration | 2016 |
Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.
Topics: Adenosine Monophosphate; Adult; Aged; Biological Availability; Blood Platelets; Clopidogrel; Coronar | 2015 |
Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thr | 2015 |
Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; Human | 2016 |
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus.
Topics: Adenosine; Administration, Oral; Aged; Chi-Square Distribution; Clopidogrel; Coronary Angiography; C | 2015 |
Antiplatelet Efficacy of Fixed-Dose Aspirin-Clopidogrel Combination in Patients with Stable Coronary Artery Disease Treated with Drug-Eluting Stent Implantation.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Dr | 2015 |
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel | 2016 |
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
Topics: Adenosine; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhib | 2016 |
Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
Topics: Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Dose-Response | 2017 |
Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female | 2016 |
Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dru | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug-Eluting Stents; Female; | 2016 |
One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study.
Topics: Adenosine; Aged; China; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Ma | 2016 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2016 |
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; | 2016 |
Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-4 | 2016 |
Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery D | 2016 |
Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus, Type 2; | 2016 |
Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Death, Sudden, Cardiac; Dose-Response Relations | 2017 |
Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hydroxymethyl | 2017 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients: A pilot study: ONSIDE TEST pilot.
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Dose-Respon | 2017 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art | 2008 |
Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administ | 2008 |
Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Ther | 2008 |
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resista | 2008 |
Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Aspirin; Cell Size; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; F | 2008 |
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Cardiac Surgical Procedures; Clopidogrel; Co | 2008 |
Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; | 2008 |
Treatment of bifurcation lesions using dedicated bifurcation stents versus classic bare-metal stents. Randomized, controlled trial with 12-month angiographic follow up.
Topics: Adult; Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Re | 2008 |
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Comorbidity; Coronary Artery Dis | 2008 |
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Diseas | 2008 |
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Coronary Arter | 2010 |
Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Collagen; Coronary Artery Disease; Drug Resistanc | 2009 |
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Fe | 2008 |
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind | 2008 |
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, C | 2009 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting | 2009 |
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; | 2009 |
Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Double- | 2009 |
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coron | 2009 |
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel | 2008 |
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Sub | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; C | 2008 |
Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Mate | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera | 2009 |
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial.
Topics: Adenosine Diphosphate; Aged; Antigens, Human Platelet; Clopidogrel; Coronary Artery Disease; Female; | 2009 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; | 2009 |
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cilostazol; Clopidogrel; Confidence I | 2009 |
Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Topics: Aspirin; Biomarkers; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule | 2009 |
Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Double-B | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2009 |
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon | 2010 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST).
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Arter | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Do | 2009 |
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thromb | 2010 |
Reasonable duration of Clopidogrel use after drug-eluting stent implantation in Korean patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Korea; Male; Middle | 2009 |
In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Topics: Adenosine; Aged; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; | 2010 |
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) st
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Proteins; Cell Adhesi | 2010 |
Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2010 |
Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; | 2010 |
The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Artery Diseas | 2010 |
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous
Topics: Administration, Oral; Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary | 2010 |
Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study.
Topics: Clopidogrel; Comorbidity; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Evide | 2011 |
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; C | 2010 |
Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy.
Topics: Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug-Elutin | 2010 |
Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2010 |
Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Clopidogrel with or without omeprazole in coronary artery disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Dru | 2010 |
Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary A | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytoc | 2010 |
Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Artery Dis | 2010 |
Pretreatment with different loading doses of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) SELECT
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Biomarkers; Chi-Square Distribution; Clo | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M | 2011 |
Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Coagulation; | 2011 |
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Di | 2011 |
Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Angiography; Coron | 2011 |
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Do | 2011 |
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Stu | 2011 |
Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study.
Topics: Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Coronary Ve | 2011 |
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Comorbidity; Coronary Artery Disease; Cytokines; Female; Genetic Predisposition to Dise | 2012 |
Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabe | 2011 |
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CY | 2011 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Mal | 2011 |
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Cor | 2012 |
Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney di
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cilostazol; Clopidogrel; Coronary Arte | 2011 |
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-B | 2012 |
Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease.
Topics: Adult; Aged; Blood Platelets; Cell Movement; Cell-Derived Microparticles; Clopidogrel; Coronary Arte | 2012 |
Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Place | 2012 |
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pipe | 2013 |
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies | 2013 |
[High maintenance dose of clopidogrel improves long-term clinical outcomes in patients with elective percutaneous coronary intervention].
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous Coronary | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery | 2012 |
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Femal | 2012 |
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; | 2012 |
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
Topics: Adenosine Monophosphate; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiogra | 2012 |
Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Topics: Administration, Cutaneous; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Arter | 2012 |
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Mi | 2012 |
Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up.
Topics: Antifibrinolytic Agents; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronar | 2013 |
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clo | 2012 |
Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Female; Follow | 2013 |
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over St | 2012 |
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; | 2013 |
Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
Topics: Adult; Aspirin; Brazil; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Co | 2012 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Rela | 2013 |
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy | 2014 |
Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninfe
Topics: Aged; Blood Platelets; Cerebrovascular Disorders; Chi-Square Distribution; Clopidogrel; Coronary Art | 2013 |
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Topics: Adult; Aged; Alleles; Chromosomes, Human, Pair 1; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2013 |
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Topics: Adult; Aged; Alleles; Chromosomes, Human, Pair 1; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2013 |
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Topics: Adult; Aged; Alleles; Chromosomes, Human, Pair 1; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2013 |
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.
Topics: Adult; Aged; Alleles; Chromosomes, Human, Pair 1; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2013 |
Effect of antioxidant probucol for preventing stent restenosis.
Topics: Aged; Antioxidants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Ar | 2002 |
Oral antiplatelet therapies have no effect on circulating levels of RANTES in patients with coronary artery disease.
Topics: Aged; Angina, Unstable; Chemokine CCL5; Chemokines; Clopidogrel; Coronary Artery Disease; Female; He | 2002 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug Ther | 2003 |
Sarpogrelate treatment reduces restenosis after coronary stenting.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cell Division; Coronary Angiography; | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Dose-Respons | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2003 |
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Cilostazol; Coronary Angiography; Coronary Artery Disease | 2004 |
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Arter | 2004 |
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost | 2005 |
Inter-individual variability in response to clopidogrel in patients with coronary artery disease.
Topics: Adult; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; | 2005 |
High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Female; Flow | 2005 |
Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Genotype; Humans; Integrin beta3; Ma | 2005 |
Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease.
Topics: Aged; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Double-Blin | 2006 |
Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
Topics: Adenosine Diphosphate; Antigens, Human Platelet; Aspirin; Blood Platelets; Clopidogrel; Collagen; Co | 2006 |
The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Body Mass Index; Clopidogrel; Coronary Artery Disease; Female; | 2006 |
Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monitori | 2007 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Human | 2006 |
Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects.
Topics: Acetylcholine; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants | 2006 |
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study.
Topics: Aged; Cells, Cultured; Chemokines; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Endoth | 2006 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; | 2006 |
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Topics: Adenosine Diphosphate; Adult; Aspirin; Bayes Theorem; Blood Platelets; Clopidogrel; Coronary Artery | 2007 |
Effects of Erigeron injection on vascular endothelium in patients after intracoronary stenting.
Topics: C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Endothelin-1; E | 2006 |
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Disease-Free Survival; Drug Re | 2006 |
The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Follow-Up | 2006 |
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
Impact of P-glycoprotein on clopidogrel absorption.
Topics: Administration, Oral; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bio | 2006 |
A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Dilatation, Pa | 2008 |
Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.
Topics: Clopidogrel; Combined Modality Therapy; Coronary Artery Disease; Drug Administration Schedule; Femal | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Diabete | 2007 |
Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Disease; Death; Drug Resistance; Female | 2007 |
Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cre | 2008 |
The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Biomarkers; Case-Control Studies; Clopidogrel; Coronary | 2007 |
The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Death; Drug-Eluting Stents; Female; | 2007 |
Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2007 |
Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vess | 2007 |
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2007 |
Clopidogrel desensitization after drug-eluting stent placement.
Topics: Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Elut | 2007 |
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Mal | 2008 |
Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand; Clopidogrel; | 2007 |
[Effects of intensive antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; D | 2008 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary A | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Chromium All | 2008 |
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Topics: Aged; Antidotes; Aptamers, Nucleotide; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind M | 2008 |
Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Coronary Artery Disea | 1996 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Double-Blind | 2000 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary | 2002 |
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary | 2002 |
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary | 2002 |
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary | 2002 |
Use of clopidogrel loading, enoxaparin, and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2002 |
509 other studies available for ticlopidine and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Influence of
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; MicroRNAs; Platelet Aggregat | 2021 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Clopidogrel Monotherapy More Effective Than Aspirin to Prevent Coronary Events After PCI With Drug-Eluting Stents.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Human | 2022 |
Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; P | 2022 |
Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.
Topics: Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Percutaneous Coronary Inter | 2022 |
Future of antithrombotic therapy for heart failure with coronary artery disease.
Topics: Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Heart Failure; Humans; Ticlopidine | 2022 |
Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy.
Topics: Adenosine; Adenosine Diphosphate; Clopidogrel; Complement C1q; Coronary Artery Disease; Humans; Perc | 2022 |
Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; MicroRNAs; | 2023 |
Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors; Ticagre | 2019 |
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndrome and Stable Coronary Artery Disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Femal | 2019 |
Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease.
Topics: Blood Platelets; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Heart Failure; Humans; Plat | 2020 |
Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; | 2022 |
Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Clopidogrel; Coronary Artery Disease; Female; Hem | 2017 |
On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Drug | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Ar | 2017 |
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Fem | 2017 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; H | 2017 |
Impact of mean platelet aggregation degree on long-term clinical outcomes among patients undergoing a complex percutaneous coronary intervention.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug | 2017 |
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2017 |
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow-Up St | 2017 |
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients.
Topics: Asian People; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Femal | 2017 |
Topics: Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Female; | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients.
Topics: Aged; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; D | 2018 |
Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angioplasty; Angioplasty, Balloon, Coro | 2017 |
Leukocyte miR-223-3p is not associated with
altered platelet responses to clopidogrel in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Leukocytes; Mi | 2018 |
[High On-Treatment Platelet Reactivity Determinants on Dual Antiplatelet Therapy in Patients With Ischemic Heart Disease Before Elective Percutaneous Coronary Intervention].
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Middle Ag | 2018 |
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy.
Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiog | 2018 |
Proton Pump Inhibitors and Dual Antiplatelet Therapy: Is the Story Over?
Topics: Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Receptors, | 2018 |
Association between high on-treatment platelet reactivity to clopidogrel and hepatosteatosis in patients undergoing elective stent implantation.
Topics: Case-Control Studies; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Fatty Liver; Femal | 2018 |
2017 ESC guidelines focus on dual antiplatelet therapy.
Topics: Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2018 |
CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
Topics: Aged; Asian People; Cell Adhesion Molecules; China; Clopidogrel; Coronary Artery Disease; Female; Hu | 2018 |
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Chest Pain; Clopidogrel; Coronary Artery Di | 2018 |
Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting St | 2019 |
Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans | 2019 |
The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary | 2013 |
Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.
Topics: Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Coronary Artery Disease; Female; Genot | 2013 |
Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".
Topics: Aryl Hydrocarbon Hydroxylases; Blood Platelets; Coronary Artery Disease; Drug Substitution; Female; | 2013 |
Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; | 2013 |
Pharmacological interactions: the next frontier?
Topics: Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Heptanoic Acids; Humans | 2013 |
Invited commentary.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Humans; Male; Ticlopidine; Tr | 2013 |
Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Hyperte | 2014 |
Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video).
Topics: Aged; Aspirin; Blood Loss, Surgical; Cholecystectomy; Coronary Artery Disease; Drug-Eluting Stents; | 2013 |
Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
Topics: Aged; Anti-Inflammatory Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; CD40 Ligand; Cell Adhesion M | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Tran | 2013 |
Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients.
Topics: Aged; Aryldialkylphosphatase; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Female; G | 2013 |
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; C | 2013 |
Aspirin desensitisation for Chinese patients with coronary artery disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2013 |
Perioperative management of a neurosurgical patient with a meningioma and recent coronary artery stent.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Coronary Artery Disease; Drug T | 2013 |
The impact of the environment on diseases and drugs.
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibi | 2013 |
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
Topics: Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Dose-Response Relati | 2013 |
Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery | 2013 |
Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; | 2013 |
[Clopidogrel resistance of patients with coronary artery disease and its correlation with platelet count and mean platelet volume].
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Mean Platelet Vol | 2013 |
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2013 |
[Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease].
Topics: Antigens, Human Platelet; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Diseas | 2013 |
Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2013 |
P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plat | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
An allele-specific PCR system for rapid detection and discrimination of the CYP2C19∗4A, ∗4B, and ∗17 alleles: implications for clopidogrel response testing.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Base Sequence; Case-Control Studies; Clopidogrel; Coronary A | 2013 |
Cilostazol--a forgotten antiplatelet agent, but does it even matter?
Topics: Cilostazol; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Percuta | 2013 |
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Fema | 2013 |
Impact of initial clinical presentation on clopidogrel low response.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Arter | 2013 |
Letter by Mangiacapra and Barbato regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".
Topics: Aspirin; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Aggregation; | 2013 |
Response to letter regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".
Topics: Aspirin; Coronary Artery Disease; Endothelium, Vascular; Female; Humans; Male; Platelet Aggregation; | 2013 |
Clopidogrel results in favourable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention.
Topics: Biomarkers; Clopidogrel; Coronary Artery Disease; Cyclic GMP; Humans; Nitrates; Nitric Oxide; Nitrit | 2014 |
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Mid | 2014 |
Antiplatelet therapy: DAPT for 3 months is sufficient.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas | 2013 |
Spontaneous chest wall hematoma with dual antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Follow-Up Studies; H | 2014 |
Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hum | 2014 |
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pilo | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Female; Fractional F | 2013 |
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; | 2014 |
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Arter | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Electrocardiography; Female; Follow-Up | 2014 |
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Topics: Adult; Aged; Amino Acid Substitution; Aspirin; Clopidogrel; Coronary Artery Disease; Factor XIII; Fe | 2014 |
Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2014 |
Triple versus dual antiplatelet therapy after percutaneous coronary intervention for coronary bifurcation lesions: results from the COBIS (COronary BIfurcation Stent) II Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 2015 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Corona | 2014 |
Increased mean platelet volume is associated with non-responsiveness to clopidogrel.
Topics: Adenosine Diphosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Drug | 2014 |
[Unexplained hypereosinophilia: too much or not enough?].
Topics: Clopidogrel; Coronary Artery Disease; Eosinophilia; Humans; Male; Middle Aged; Platelet Aggregation | 2014 |
Dual antiplatelet therapy after stent implantation.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Dual antiplatelet therapy after stent implantation--reply.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Platelet reactivity is preferred over genotyping in monitoring efficacy of antiplatelet therapy.
Topics: Aryl Hydrocarbon Hydroxylases; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; P | 2014 |
Reply: Platelet reactivity is preferred over genotyping in monitoring efficacy of antiplatelet therapy.
Topics: Aryl Hydrocarbon Hydroxylases; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; P | 2014 |
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; DNA Methylation; Drug Resistance; Female; Genetic Associ | 2014 |
Successful multidisciplinary treatment of hilar cholangiocarcinoma in a patient with complicated new-onset coronary artery disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bile Duct Neoplasms; Bile Ducts, Intr | 2014 |
Impact of CYP2C19 polymorphism on clinical outcome following coronary stenting is more important in non-diabetic than diabetic patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus; Female; Gen | 2014 |
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Factor XIIIa; Female; Humans; Male; Middle Ag | 2015 |
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregati | 2014 |
Concerning antiplatelet therapy.
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregatio | 2014 |
Concerning antiplatelet therapy. Reply.
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregatio | 2014 |
Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coron | 2014 |
[Association between clopidogrel resistance and polymorphism of platelet adenosine diphosphate receptor in patients with coronary atherosclerotic disease].
Topics: Adolescent; Adult; Aged; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male | 2014 |
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Topics: Adult; Aged; Biomarkers; Blood Platelets; Body Mass Index; Body Size; Body Surface Area; Body Weight | 2014 |
Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genot | 2014 |
The chronovariability of platelet reactivity: a hurdle in the road to personalized antiplatelet therapy?
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Ticlopidine | 2014 |
Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population.
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Resistance; Ethnicity; Humans; In | 2014 |
Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; | 2015 |
[Clinical impact of dual antiplatelet therapy on peptic ulcer disease].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Angiography; Coronary | 2014 |
Diabetes mellitus and clopidogrel response variability.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggr | 2014 |
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Association of Medicare Part D low-income cost subsidy program enrollment with increased fill adherence to clopidogrel after coronary stent placement.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Databases, Factual; Female; Humans; Insurance Benefits; | 2014 |
[Does dual antiplatelet therapy increase the risk of peptic ulcer disease?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Huma | 2014 |
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Clopidogrel; Coronary | 2014 |
Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
Topics: Aged; Aspirin; Cardiac Catheterization; Chi-Square Distribution; Clopidogrel; Cohort Studies; Corona | 2014 |
Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Ma | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Drug Therapy, | 2016 |
Impact of C34T P2Y12 genotype on endothelial function and arterial stiffness in patients after percutaneous coronary intervention receiving clopidogrel.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; Genotype; Humans; Male; M | 2014 |
Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Type | 2014 |
Letter by Sardar et al regarding article, "optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial".
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Human | 2014 |
Response to letter regarding article, "optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial".
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Human | 2014 |
High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Midd | 2014 |
Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.
Topics: Administration, Inhalation; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration | 2015 |
The arranged marriage of cangrelor and bivalirudin.
Topics: Adenosine Monophosphate; Anticoagulants; Coronary Artery Disease; Female; Humans; Male; Peptide Frag | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem | 2015 |
Stent selection and antiplatelet therapy duration: one size does not fit all.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hemorrhage; | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Ther | 2015 |
Mean platelet volume needs standardisation. Comment on Asher et al. Thromb Haemost 2014; 112: 137-141.
Topics: Blood Platelets; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Mean Platelet Volum | 2015 |
Reply to Lancé: "Mean platelet volume needs standardisation. Comment on Asher et al. Thromb Haemost 2014; 112: 137-141".
Topics: Blood Platelets; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; Mean Platelet Volum | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2015 |
Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregatio | 2015 |
Whatever will be, will be: spontaneous chest wall hematoma with regular use of low-dose acetylsalicylic Acid.
Topics: Aspirin; Coronary Artery Disease; Hematoma; Humans; Male; Platelet Aggregation Inhibitors; Thoracic | 2015 |
Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aspirin; Bisoprolol; Carbazoles; Carvedilol; Clopidog | 2016 |
Elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation; Puri | 2015 |
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Platelet Aggregation; Puri | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Dis | 2015 |
Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Drug-El | 2015 |
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
Topics: Aged; Alleles; Antigens, Human Platelet; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; | 2015 |
Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolim | 2016 |
Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Stud | 2015 |
Dual-Antiplatelet Therapy for Diabetic Patients After Stent Implantation: Lessons From an Observational Study.
Topics: Angioplasty, Balloon, Coronary; Cause of Death; Coronary Artery Disease; Diabetes Mellitus; Female; | 2015 |
Low platelet activity predicts 30 days mortality in patients undergoing heart surgery.
Topics: Adenosine Diphosphate; Aged; Aortic Valve; Arachidonic Acid; Area Under Curve; Aspirin; Blood Platel | 2016 |
Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel.
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Female | 2015 |
Clopidogrel and morphine: Aggregation disturbance?
Topics: Animals; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2015 |
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Mal | 2015 |
Duration of dual antiplatelet therapy after coronary stenting.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Plat | 2016 |
Prasugrel in Clopidogrel Nonresponders: A Way to Improve Secondary Prevention in Patients After Percutaneous Coronary Intervention?
Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous | 2015 |
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis | 2015 |
Antithrombotic therapy for stable coronary artery disease: the difficult quest for the holy balance.
Topics: Anticoagulants; Coronary Artery Disease; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitor | 2016 |
Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; D | 2016 |
Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in a Large Urban Safety-Net Hospital.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; F | 2016 |
Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Biotransformation; Chi-Square Distribution; China; | 2016 |
Personalized Antiplatelet Therapy: The Odyssey Continues.
Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous | 2016 |
Reply: Personalized Antiplatelet Therapy: The Odyssey Continues.
Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous | 2016 |
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectio | 2016 |
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platel | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; | 2016 |
Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Diseas | 2016 |
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Artery Disease; C | 2016 |
Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; F | 2016 |
Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Vessels; Drug Resistan | 2016 |
Impact of C34T P2Y12 ADP receptor polymorphism and smoking status on cardiovascular outcome in coronary artery disease patients receiving clopidogrel.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Po | 2016 |
Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Co | 2016 |
Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Dr | 2016 |
Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice.
Topics: Adenosine; Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; C | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Cl | 2016 |
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Female; Humans; Lactones; Mal | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; | 2016 |
Hospital Variation in Premature Clopidogrel Discontinuation After Drug-Eluting Stent Placement in the Veterans Affairs (VA) Healthcare System.
Topics: Aftercare; Aged; Cardiology; Cause of Death; Clopidogrel; Coronary Artery Disease; Deprescriptions; | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu | 2017 |
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C1 | 2016 |
[Comment on “Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review”].
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2016 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
[The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Clopidogrel; Coronary Artery Disease; Femal | 2016 |
The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Perc | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Predictors for Side Branch Failure During Provisional Strategy of Coronary Intervention for Bifurcation Lesions (from the Korean Bifurcation Registry).
Topics: Aged; Calcinosis; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Cor | 2016 |
Changes in response to clopidogrel therapy in patients after percutaneous coronary interventions as assessed by different platelet function tests.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Percutaneous | 2016 |
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Clopidogrel; | 2016 |
Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Clopidogrel; Confidence Intervals; Coronary A | 2016 |
Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Percutaneous Co | 2017 |
The moving target of clopidogrel response variability: new tricks of the old dog?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregati | 2016 |
Single versus double antiplatelet therapy in patients undergoing coronary artery bypass grafting with coronary endarterectomy: mid-term results and clinical implications.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combinati | 2017 |
High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; F | 2016 |
Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy.
Topics: Alleles; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; DNA; Female; Gene Frequency | 2017 |
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Topics: Anticoagulants; Antidepressive Agents; Antimetabolites, Antineoplastic; Antitubercular Agents; Aryla | 2017 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery | 2017 |
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
Topics: Alleles; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Blood Plate | 2017 |
Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease.
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clopidogrel; | 2017 |
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequenc | 2017 |
Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Humans; Nitric Oxide; Nitric Oxide S | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
The Unforgettable Cornerstone: Role of Ticlopidine in Developing Current Antithrombotic Treatment After Percutaneous Coronary Intervention.
Topics: Coronary Artery Disease; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet A | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
[Platelet Metabolism in Clopidogrel Resistant and Sensitive Patients With Ischemic Heart Disease].
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance | 2016 |
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; F | 2008 |
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
Topics: Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug-Eluting Stents; H | 2008 |
The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Evidence-Based Medicine; F | 2008 |
Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.
Topics: Adult; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Male; Middle Aged; Platelet Aggregatio | 2009 |
Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
Topics: Aged; Aspirin; Baltimore; Biomarkers; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Femal | 2008 |
Aspirin resistance an underestimated risk in patients with drug-eluting stents?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Graft Occlusion | 2008 |
Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Dr | 2008 |
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Vessel | 2008 |
Identifying clopidogrel resistance during chronic therapy: the case for a biochemical approach.
Topics: Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggrega | 2008 |
Adrenoreceptors, platelet reactivity and clopidogrel resistance.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combi | 2008 |
Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adrenergic alpha-Antagonists; Aged; Aspirin; Blood P | 2008 |
Measurement of the platelet retention rate in a column of collagen-coated beads is useful for the assessment of efficacy of antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Cell Separation; Clopidogrel; Collagen; Coronary Artery Disease; Fem | 2009 |
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; | 2008 |
Gemcitabine-induced acute coronary syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Aspirin; Bundle-Branch Block; Clopidogrel; Coronary Artery Disease; | 2009 |
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Contusions; Coronary Angiography; Coronary Artery | 2008 |
The treatment of clopidogrel resistance: triple antiplatelet therapy and future directions.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Resistance; Humans; Pla | 2010 |
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Antiplatyhelmintic Agents; Aspirin; Cell Adhesion Molecules; C | 2009 |
Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose-Response Relationsh | 2009 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; H | 2009 |
Evaluation of the platelet count drop method for assessment of platelet function in comparison with "gold standard" light transmission aggregometry.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Arter | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Electric Impedance; Electrodes; Fem | 2009 |
Point-of-care platelet function analysis ready for prime time?
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; | 2009 |
The ischaemia/bleeding balance in PCI.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Lactones; | 2009 |
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; | 2009 |
Clopidogrel pretreatment before primary percutaneous coronary stenting in patients with acute ST-segment elevation myocardial infarction: comparison of high loading dose (600 mg) versus low loading dose (300 mg).
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Sche | 2009 |
Does the Holy Grail escape us again?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Platelet Fun | 2009 |
Treatment of multilesion coronary artery disease with simultaneous drug-eluting and bare-metal stent implantation: clinical follow up and angiographic mid-term results.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; A | 2009 |
Spontaneous coronary artery dissection and severe hypothyroidism.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aspirin; Clopi | 2009 |
Clopidogrel and proton pump inhibitors: gastric protection at expense of vascular benefit?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Aspi | 2009 |
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary | 2009 |
Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Corona | 2009 |
Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: a case report.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Cardiac Catheterization; Clopido | 2009 |
Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clop | 2009 |
Combined carotid stenting and urgent coronary artery surgery in unstable angina patients with severe carotid stenosis.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Anticoagulants; Aspirin; Carotid St | 2009 |
Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Adm | 2008 |
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra | 2008 |
Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Sub | 2008 |
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Bioco | 2009 |
Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting: the SHARP study.
Topics: Aged; Angioplasty, Balloon, Coronary; Carotid Arteries; Carotid Artery Diseases; Clopidogrel; Corona | 2009 |
1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; | 2009 |
Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aspirin; Coronary Angiography; Co | 2009 |
Coronary artery disease: Platelet activity: an obstacle for successful PCI.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combina | 2009 |
Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: rationale and design of the RISK-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2009 |
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Synergism; Fe | 2009 |
Platelet reactivity and stent thrombosis: still some issues to solve.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Sten | 2009 |
Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Blood Pressure; Cerebral Arterial Diseases; Clopidogrel; Coronary Artery Disease; Dru | 2009 |
Challenge. What is your diagnosis? Answer. Primary nodal diffuse large B-cell lymphoma with secondary cutaneous involvement.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; C | 2009 |
The carina angle-new geometrical parameter associated with periprocedural side branch compromise and the long-term results in coronary bifurcation lesions with main vessel stenting only.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Clopidogrel; Confidence Intervals; Co | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chromosomes, Human, Pair | 2009 |
Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit?
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Human | 2009 |
One-year follow-up of nonrandomized comparison between coronary artery bypass grafting surgery and drug-eluting stent for the treatment of unprotected left main coronary artery disease in elderly patients (aged >or=75 years).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Confi | 2009 |
Side balloon stenting of the left main bifurcation: a three-year angiographic follow-up.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Clopidogrel; Coronary Angiography | 2009 |
Femoral artery complications after cardiac catheterization: a study of patient profile.
Topics: Aged; Anticoagulants; Cardiac Catheterization; Clopidogrel; Coronary Artery Disease; Female; Femoral | 2010 |
Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug The | 2010 |
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregati | 2009 |
[Basic examination before clinical examination. That is why it is worthwhile to return to the laboratory].
Topics: Aspirin; Biomarkers; Blood Coagulation; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Drug Ther | 2009 |
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.
Topics: Aged; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Mal | 2010 |
Clopidogrel and calcium-channel blockers: a clinically important interaction?
Topics: Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Drug Combinations; Drug Interactions | 2010 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar | 2010 |
Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
Topics: Aged; Alleles; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Coron | 2010 |
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cor | 2009 |
Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Body Mass Index; Clopidogrel; C | 2009 |
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; | 2010 |
Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; C | 2010 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar | 2009 |
Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".
Topics: Aged; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female | 2009 |
Aortic thromboembolism successfully treated with anticoagulation and antiplatelet therapy.
Topics: Anticoagulants; Aorta, Thoracic; Arm; Clopidogrel; Coronary Artery Disease; Echocardiography, Transe | 2009 |
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
Topics: Aged; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Genetic Variation; Huma | 2009 |
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Biotransformation; Blood Platelets; Cel | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto | 2010 |
Antiplatelet effect of 50-mg maintenance dose of clopidogrel compared to 200 mg ticlopidine: a preliminary study.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art | 2010 |
Highlights from Transcatheter Cardiovascular Therapeutics 2009: San Francisco, California, September 21 to 25, 2009.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Clinical Trial | 2010 |
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi | 2010 |
Very late drug-eluting stent thrombosis in the perioperative period of endoscopic choledocholithotomy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; | 2009 |
High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiog | 2010 |
In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coagula | 2010 |
Triple therapy: the future or from the past?
Topics: Administration, Oral; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinatio | 2010 |
Safety of drug eluting stents in patients on chronic anticoagulation using long-term single antiplatelet treatment with clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2010 |
Triple therapy: triple safety or triple danger?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2010 |
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Ther | 2010 |
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggr | 2010 |
Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Clopidogrel; Combi | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe | 2010 |
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Dise | 2010 |
Platelet inhibition with cangrelor.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Human | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; | 2010 |
Plasma sequestration: a good therapy to prevent the deleterious effect of clopidogrel when clopidogrel is used within one to four days of coronary bypass surgery.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Critical Care; Erythrocyte Transfusion | 2010 |
Antithrombotic management in patients undergoing coronary stent implantation requiring chronic oral anticoagulation: how to balance safety and efficacy?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Artery Disease; Drug Therapy, | 2010 |
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2010 |
Rotablation in the drug eluting era: immediate and long-term results from a single center experience.
Topics: Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assisted; Aspirin; Atherectomy, Co | 2010 |
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Coronary Artery Diseas | 2010 |
Carotid angioplasty in asymptomatic patients undergoing CABG surgery.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Carotid Stenosis; Clopidogrel; Coronary Angiography; Cor | 2010 |
Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art | 2010 |
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopid | 2010 |
Efficiency of preoperative tranexamic Acid in coronary bypass surgery: an analysis correlated with preoperative clopidogrel use.
Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Clopidogrel; Confidence Intervals; Coronary Artery | 2010 |
Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinatio | 2010 |
The H(2)-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y(12) inhibition in platelets.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Histamine H2 | 2010 |
In-laboratory high-dose clopidogrel loading: do we need a mirror of diamond for "Armida's garden"?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation; | 2010 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; C | 2010 |
Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?
Topics: Aged; Black People; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery | 2010 |
The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Biological Assay; Biomarkers; Blood Platele | 2011 |
Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease.
Topics: Anticoagulants; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Gene Expression Profi | 2010 |
Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel.
Topics: Aged; Aspirin; Blood Platelets; CD11b Antigen; Clopidogrel; Coronary Artery Disease; Coronary Stenos | 2011 |
Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Comb | 2010 |
Letter by Lozano et al regarding article, "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)".
Topics: Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Humans; Myocardial Infarction; Postoperat | 2010 |
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Body Mass Index; California; Chi-Square Distribution; Clopidogr | 2010 |
Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
Topics: Aryl Hydrocarbon Hydroxylases; Body Mass Index; Clopidogrel; Coronary Artery Disease; Cytochrome P-4 | 2010 |
Interaction of clopidogrel and omeprazole.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Comb | 2010 |
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon | 2011 |
Hybrid revascularization, comprising coronary artery bypass graft with exclusive arterial conduits followed by early drug-eluting stent implantation, in multivessel coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Chi-Square Distribution; Clopid | 2010 |
Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Di | 2010 |
Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
Topics: Aged; Cerebrovascular Disorders; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Inter | 2011 |
Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; | 2011 |
Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Chi-Square Distribution; Clopidogrel; | 2011 |
An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Biomarkers; Clopidogrel; Coronary Angiograp | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study.
Topics: Adenosine Diphosphate; Angioplasty; Clopidogrel; Coronary Artery Disease; Drug Monitoring; Humans; P | 2011 |
Functional profile of the platelet P2Y₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Diabetes Melli | 2011 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Arte
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Confidence | 2010 |
Invited commentary.
Topics: Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Drainage; Humans; Intubation | 2011 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; | 2011 |
[Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis].
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; | 2010 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cardiovascular Diseases; Chemistry, Pharmaceutical; Clopido | 2011 |
Clopidogrel with or without omeprazole in coronary disease.
Topics: Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointest | 2011 |
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Blood Vessel Prosthesis Implantation; Clopidogrel; Cohort Studies; Co | 2011 |
[Assessing clinical efficacy of the generic clopidogrel "Egutromb" in roentgenosurgical practice].
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Re | 2010 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary A | 2011 |
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clopi | 2011 |
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.
Topics: Aged; Calcium Channel Blockers; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary | 2011 |
Impact of combination of calcium-channel blockers with clopidogrel on clinical outcomes in patients with coronary artery disease.
Topics: Aged; Calcium Channel Blockers; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Therapy, | 2011 |
Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up.
Topics: Aged; Angioscopy; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Health | 2011 |
Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Surgical Procedures; Clopidogrel; Contraindications; C | 2011 |
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Aryl Hydrocarbon Hydroxyl | 2012 |
Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Female; Humans; Male; | 2011 |
Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Clopidogrel; Corona | 2011 |
Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; | 2011 |
Simultaneous drug-eluting and bare-metal stent implantation: long-term clinical outcome and findings of clinically indicated coronary angiography.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Confidence Intervals; Coronary Angiography; Co | 2011 |
Feasibility and safety of 7-Fr radial approach for complex PCI.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2011 |
High on treatment platelet reactivity and stent thrombosis.
Topics: Adult; Aged; Angioplasty; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middl | 2011 |
Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction.
Topics: Aged; Angioplasty; Bundle-Branch Block; Clopidogrel; Confidence Intervals; Coronary Artery Disease; | 2011 |
A complex case of angulated and bifurcated lesion facilitated by excimer laser coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Hu | 2011 |
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; | 2011 |
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
Topics: Adult; Angiography; Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diagno | 2011 |
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dr | 2011 |
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary | 2011 |
Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting | 2012 |
Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients).
Topics: Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug-E | 2011 |
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspir | 2011 |
Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Annexin A5; Aspirin; Baltimore; Clopido | 2012 |
Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry.
Topics: Adenosine Diphosphate; Arachidonic Acid; Area Under Curve; Arteries; Aspirin; Blood Platelets; Clopi | 2011 |
[Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting].
Topics: Abdominal Pain; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Ar | 2011 |
Optical coherence tomography findings during "evolving" stent thrombosis.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiopulmonary Resuscitation; Clopidogr | 2011 |
Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study.
Topics: Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; H | 2011 |
The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: a retrospective study.
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation; Plate | 2012 |
Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Collagen; Coronary Artery Diseas | 2012 |
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporte | 2011 |
Increased clopidogrel response is associated with ABCC3 expression: a pilot study.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2012 |
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastroi | 2012 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
Topics: Aged; Aged, 80 and over; Amplified Fragment Length Polymorphism Analysis; Angioplasty, Balloon, Coro | 2011 |
Clopidogrel use and early outcomes among older patients receiving a drug-eluting coronary artery stent.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Ar | 2012 |
Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary | 2012 |
Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
Topics: Aged; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Gast | 2012 |
Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Austria; Blood Platelets; Cardi | 2012 |
Extension of Kaplan-Meier methods in observational studies with time-varying treatment.
Topics: Age Factors; Aged; Clopidogrel; Comorbidity; Confounding Factors, Epidemiologic; Coronary Artery Dis | 2012 |
Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter?
Topics: Blood Specimen Collection; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Coronary Artery Di | 2012 |
Desensitization to prasugrel: cardiology's increased need for allergy consultation.
Topics: Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; D | 2012 |
[Aspirin response and related factors in aged patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease | 2011 |
Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Fever; Humans; Piperazin | 2012 |
Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; In Vitro Techn | 2012 |
Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Di | 2012 |
Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrilla | 2012 |
Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Asian People; Aspirin; Case-Control Studies; Clopidog | 2012 |
[Effect of clopidogrel combined with calcium-channel blocker on coronary artery disease in elderly patients: a propensity score-based retrospective cohort study].
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Clopidogrel; Cohort Studies; Coronary Artery Dise | 2012 |
High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronar | 2012 |
Blockbuster interactions: are they bad for the patient?
Topics: Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Female; Humans; Hydroxymethylglutaryl- | 2012 |
[Comparison on the effects of clopidogrel, statins combination in treating coronary artery disease among the elderly patients: a retrospective cohort study].
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Follow-Up | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
[Omega-3--clopidogrel can help!].
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Fatty | 2012 |
Fractalkine activates a signal transduction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.
Topics: Adenosine Diphosphate; Alprostadil; Chemokine CX3CL1; Clopidogrel; Coronary Artery Disease; Humans; | 2012 |
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 | 2012 |
Relationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; | 2012 |
Benefits and risks of using clopidogrel before coronary artery bypass surgery: a role of platelet function assessment.
Topics: Coronary Artery Bypass; Coronary Artery Disease; Humans; Myocardial Infarction; Platelet Aggregation | 2012 |
Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Res | 2013 |
Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice.
Topics: Aged; Analysis of Variance; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Fema | 2012 |
Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Arter | 2012 |
Complex coronary lesions and rotational atherectomy: one hospital's experience.
Topics: Aged; Angiography; Aspirin; Atherectomy, Coronary; Cardiology; Clopidogrel; Comorbidity; Coronary Ar | 2012 |
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; | 2012 |
Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients.
Topics: Aged; Asian People; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Interaction | 2013 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem | 2012 |
Less may be more: insights on dual antiplatelet therapy duration after drug-eluting stent implantation from the MATRIX registry.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hum | 2012 |
Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Chi-Square Distribution; Clopidogrel; Cor | 2013 |
Femoral pseudoaneurysm with a communicating arteriovenous fistula: a complication after percutaneous coronary intervention.
Topics: Aneurysm, False; Angioplasty, Balloon, Coronary; Arteriovenous Fistula; Aspirin; Clopidogrel; Comorb | 2012 |
Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Stenosis; Dr | 2012 |
Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response R | 2012 |
Three years ago I received a drug-coated stent and was put on aspirin and Plavix. My cardiologist recently retired, and my new cardiologist told me to stop taking Plavix. It scares me to death. I read the story you released in February about the danger
Topics: Clopidogrel; Contraindications; Coronary Artery Disease; Drug-Eluting Stents; Humans; Platelet Aggre | 2011 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
Dual antiplatelet agent-induced spontaneous liver hematoma.
Topics: Aged; Aspirin; Chemical and Drug Induced Liver Injury; Clopidogrel; Coronary Artery Disease; Drug Th | 2012 |
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-O | 2012 |
Evaluating the impact of public health notification: Duke clopidogrel experience.
Topics: Access to Information; Aged; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Dru | 2012 |
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
Topics: Carboxylic Ester Hydrolases; Clopidogrel; Coronary Artery Disease; DNA; Female; Genotype; Heterozygo | 2013 |
[Expert answer. Coronary artery patients with atrial fibrillation on anticoagulation treatment may need antithrombotic treatment. What kind is there?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2012 |
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea | 2012 |
I'm having a stent put in one of my coronary arteries soon and I wonder how long I will need to be on clopidogrel. Does it depend on the kind of stent?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; | 2010 |
Chest pain in a patient with coronary artery disease taking clopidogrel.
Topics: Chest Pain; Clopidogrel; Coronary Artery Disease; Esophageal Diseases; Esophagoscopy; Hematoma; Huma | 2013 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemo | 2013 |
Triple antiplatelet therapy with cilostazol: hitting the "sweet-spot".
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Te | 2013 |
Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cytokines; Female; Humans; Interleukins; Male; Middle | 2012 |
Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention.
Topics: Aged; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronary Artery Disease; Creatine Kinase, MB | 2013 |
Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; | 2013 |
Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Gastrointestinal Hem | 2013 |
The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 C | 2013 |
Chronic kidney disease--is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease?
Topics: Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Artery Disease; Creatinine; Female; Hemogl | 2013 |
Characterization of aspirin allergies in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cardiovascular Diseases; Clopidogrel; Coronary Artery | 2013 |
A case of in-stent thrombosis in a patient with drug eluting stents during perioperative management with glycoprotein IIb/IIIa inhibitors.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug | 2013 |
Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease.
Topics: Clopidogrel; Coronary Artery Disease; Fibrinogen; Humans; Intracranial Arteriosclerosis; Platelet Ag | 2002 |
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronar | 2003 |
[Effects of antiaggregants on concentration of plasma cytokines in patients with acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytokines; Female | 2003 |
[Sudden edema and pain in the knee].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactio | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap | 2003 |
Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Creatine Kinase | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
The effect of clopidogrel on apoptosis--an in vivo study.
Topics: Adult; Aged; Apoptosis; Cells, Cultured; Clopidogrel; Coronary Artery Disease; DNA; DNA Fragmentatio | 2004 |
Coronary spasm in a 59-yr-old woman with hyperventilation.
Topics: Alkalosis, Respiratory; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antihypertensive Ag | 2004 |
[Antiplatelet therapy in patients with peripheral arterial disease (PAD)].
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebral Infarction; Clopidogrel; Coronary Art | 2004 |
Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Follow | 2004 |
[Acute coronary syndrome, stroke, arterial occlusive disease. Bring the patients out of the danger zone!].
Topics: Arterial Occlusive Diseases; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Emboli | 2004 |
[Patients with arterial occlusive disease die of myocardial infarct or stroke. The dangerous sisters: arterial occlusive disease and coronary heart disease].
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Cause of Death; Clinical Trials as Topic; Clopidogrel; C | 2004 |
Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery B | 2004 |
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Topics: Aged; Atorvastatin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Heptanoic Acids | 2004 |
High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin | 2004 |
Concordance between clopidogrel use and prescribing guidelines.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Australia; Clopidogrel; Cohort Studies; Coronary Artery Dis | 2004 |
Why don't we practice evidence-based medicine?
Topics: Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Evidence-Based M | 2005 |
Impact of continued hospitalization in patients pre-treated with clopidogrel prior to coronary angiography and undergoing coronary artery bypass grafting.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Ho | 2005 |
Reasons for inability of clopidogrel to inhibit platelet aggregation early after coronary artery bypass surgery.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Humans; Platelet Aggregation; Platelet | 2005 |
Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Desensitization, Immu | 2005 |
Oral antiplatelet therapy.
Topics: Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; P | 2005 |
Oral antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; | 2005 |
Raising the loading dose of clopidogrel: aiming at the proper target?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidine | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Ar | 2004 |
Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; A | 2005 |
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Topics: Adenosine Diphosphate; Aged; Binding, Competitive; Blood Platelets; Clopidogrel; Coronary Artery Dis | 2005 |
Ask the doctors. My mother in her early 90s has been diagnosed with atherosclerosis, had a successful angioplasty a year ago for severe chest pain, takes clopidogrel and aspirin, and in general eats a low-fat diet, although she really likes melted ice cre
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Diet, Fat-Restricted; Exerci | 2005 |
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Membrane Proteins; Middle Aged; Pl | 2005 |
Antiplatelet therapy and the vascular tree.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Dis | 2006 |
Interpretation of clopidogrel resistance.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Platelet Aggregation | 2005 |
Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Cost-Benefit | 2006 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
[Postoperative antithrombotic treatment in diabetic patients].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mell | 2006 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin | 2006 |
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.
Topics: Adenine; Alleles; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Ar | 2006 |
Clopidogrel desensitization.
Topics: Aged; Angioplasty; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Desensitization, Immun | 2006 |
Late in-stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Disorders; Clopidogrel; Coronary Artery D | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2006 |
Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; | 2006 |
[Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T | 2006 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl | 2006 |
The CHARISMA trial and the REACH registry outcomes.
Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; Inciden | 2006 |
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F | 2007 |
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F | 2007 |
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F | 2007 |
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; F | 2007 |
Clinical trials update from the annual scientific session of the American College of Cardiology 2006.
Topics: Aspirin; Cardiac Catheterization; Cardiology; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2006 |
Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Cholesterol; Coronary Artery Disease; Diet, Atherogenic | 2007 |
Does clopidogrel each day keep stent thrombosis away?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Drug Delivery Systems; Humans; | 2007 |
Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug T | 2007 |
Severe neutropenia under clopidogrel treatment three weeks after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fem | 2007 |
Long-term outcomes in treating left main trifurcation coronary artery disease with the Paclitaxel-eluting stent.
Topics: Aged; Catheterization; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; | 2007 |
Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease.
Topics: Adult; CD40 Ligand; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocard | 2007 |
Determination of aspirin responsiveness by use of whole blood platelet aggregometry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Donors; Clopidogrel; Collagen; Coronary A | 2007 |
Selective serotonin reuptake inhibitors may interfere with the antiplatelet effect of clopidogrel.
Topics: Antidepressive Agents, Second-Generation; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disea | 2007 |
Increased incidence of stent thrombosis in patients with cocaine use.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co | 2007 |
Drug-eluting stents.
Topics: Canada; Clopidogrel; Coronary Artery Disease; Cost-Benefit Analysis; Drug Delivery Systems; Humans; | 2007 |
Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative.
Topics: Acute Disease; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Dise | 2007 |
Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Corona | 2008 |
Confined late stent thrombosis following clopidogrel withdrawal in a patient with multi-segment sirolimus-eluting stent implants.
Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary | 2007 |
Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; M | 2007 |
Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation.
Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Deliver | 2007 |
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.
Topics: Adult; Aged; Caffeine; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Drug Synergism; Fem | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudde | 2007 |
Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk.
Topics: Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Death, Sudden, Car | 2007 |
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Cohort Studies; | 2008 |
The CAPRIE-like subgroups of CHARISMA: a CAPRIEciously biased analysis of an unCHARISMAtic truth.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Ischemi | 2007 |
P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Genot | 2008 |
Coronary artery stenting in patients treated by clopidogrel without aspirin.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet Agg | 2009 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
Restrictive access to clopidogrel and mortality following coronary stent implantation.
Topics: Aged; Canada; Cause of Death; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Coronary | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Topics: Adenosine Diphosphate; Aged; Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; C | 2008 |
Rapid oral aspirin desensitization for patients with aspirin allergy requiring dual antiplatelet therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Hyperse | 2008 |
Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cor | 2008 |
Drug-eluting versus bare-metal stents: when and for whom?
Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2008 |
Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; | 2008 |
Unilateral idiopathic adrenal hematomas with a preoperative diagnosis of indeterminate adrenal tumors.
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Anemia; Aspirin; Clopidogrel; | 2008 |
Acute stent thrombosis in a patient with giant cell arteritis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2008 |
Innovations in bifurcations.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Humans; | 2008 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients.
Topics: Adult; Aged; Coronary Artery Disease; Drug Evaluation; Female; Heart Transplantation; Humans; Male; | 1993 |
Revascularization after CABG: atherectomy and stenting.
Topics: Aftercare; Aged; Algorithms; Atherectomy, Coronary; Coronary Angiography; Coronary Artery Bypass; Co | 1998 |
Preliminary experience with intravascular ultrasound guided Palmaz-Schatz coronary stenting: the acute and short-term results on a consecutive series of patients.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Evaluation Studies as Topi | 1994 |
Clopidogrel instead of ticlopidine after coronary stent placement: is the switch justified?
Topics: Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Complic | 2000 |
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coron | 2000 |
Successful management of intractable coronary spasm with a coronary stent.
Topics: Adult; Amlodipine; Aspirin; Calcium Channel Blockers; Cardiovascular Agents; Coronary Angiography; C | 2000 |
Bench to bedside: the development of rapamycin and its application to stent restenosis.
Topics: Angioplasty, Balloon, Coronary; Animals; Calcineurin Inhibitors; Carrier Proteins; Cell Cycle Protei | 2001 |
Coronary stent deployment in situs inversus.
Topics: Aged; Aspirin; Chest Pain; Clopidogrel; Coronary Artery Disease; Dextrocardia; Electrocardiography; | 2001 |
[The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].
Topics: Administration, Topical; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Anticoagulants; C | 2001 |
Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility study.
Topics: Adult; Aged; Ambulatory Surgical Procedures; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel P | 2002 |
[Two platelet inhibitors after acute coronary syndrome. Many colleagues are not aware of this].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T | 2002 |